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Abstract 
Cells integrate extracellular information via native signaling pathways to spatially 
and temporally coordinate complex tasks such as development and the immune response. 
Cellular programming holds the potential of harnessing the sophisticated and complex 
biological processes of living cells for diverse applications. In the last decade, cellular 
reprogramming has emerged as a viable therapeutic strategy. In large, reprogramming 
strategies have relied on statically programmed levels of gene expression to alter cellular 
behaviors. To construct more sophisticated programs requires dynamic control of 
expression and strategies for the facile construction of complex control architectures. 
Additionally, the application of synthetic programs to the control of native regulatory 
pathways requires the development of tools for interfacing with these pathways, as well 
as the construction of stringent controllers. Further, control systems composed of 
modular and tunable elements will facilitate the expansion of synthetic circuitry to a wide 
array of natural networks with varying system properties.  
Here we describe the development of RNA-based control systems to regulate 
signaling and dictate cell fate in a model mitogen-activated protein kinase (MAPK) 
pathway. We construct networks of RNA-based control systems that interface with the 
Saccharomyces cerevisiae mating pathway to dictate entry into one of three programmed 
alternative fates dependent on environmental stimuli. We present a readily translatable 
method for identifying control points within natural networks that enable the construction 
of a modular interface between synthetic circuitry and native networks. In building these 
networks, we demonstrate the rational tuning of circuit performance via the exchange of 
well-defined parts to compose networks capable of actuating changes in cellular behavior 
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in response to environmental cues. Further, we construct network architectures which 
facilitate reduced interference from simultaneously integrated opposing programs and 
identified sensitive parameters for engineering robust circuit performance. Finally, we 
present the development of a novel RNA-based control element for the regulation of both 
synthetic and endogenous transcripts. This work provides a model for engineering 
systems that regulate signaling and direct cell fate which may be applied to additional 
decision-making pathways to advance tissue engineering strategies, treat diseases, and 
study the behavior of natural regulatory networks.  
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Cellular differentiation, organism development, and tissue homeostasis require 
precise temporal and spatial regulation of cellular responses to external inputs. Improper 
regulation and coordination of these processes can lead to deformities, disease, and death. 
Controlling cell fate offers the potential to coordinate and redirect cellular trajectories. 
Efforts to control cell fate have primarily focused on regulating the chemical, 
biochemical, and mechanical environments in the extracellular space. Yet for a wide 
range of applications, environmental cues alone are insufficient to alter cellular 
behaviors. Further, many in vivo applications preclude precise control of the extracellular 
environment. In these instances, effective control strategies must often be performed in 
antagonistic environments. Synthetic gene regulatory networks that control the internal 
decision-making process offer an alternative approach to directing cellular fate. 
 
Synthetic gene regulatory networks to control biological systems 
The examples of synthetic gene regulatory networks encoding sophisticated 
functions have steadily increased over the last decade, aided by improved fabrication and 
sequencing methods that have reduced the cost of cloning [1-5]. Circuits capable of 
exhibiting dynamic behaviors, processing logical functions, and communicating cellular 
information have been demonstrated in synthetic gene regulatory networks [6-11]. 
Complex, multicellular behaviors such as synchronized oscillation and edge detection 
have been achieved by rational coupling of these various networks [12, 13]. Additionally, 
building genetic networks from the bottom-up has provided well-defined systems that can 
be used to study fundamental biological mechanisms [14]. Comparing the performance of 
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modeled and experimentally realized networks has informed our fundamental 
understanding of the importance of various process in biological systems, including 
degradation, cooperativity, and noise [15-17]. Despite remarkable advances in the 
realization of synthetic circuits, translation of these systems to real-world applications has 
been limited by the availability of methods to connect them to the requisite information in 
living cells [18]. There exists a need for modular interfaces that can extract specific 
information from biological systems and route this information to synthetic gene 
networks capable of programming rational responses via their interaction with native 
regulatory networks (Figure 1.1). 
 
Figure 1.1. Building synthetic circuitry that interfaces with the environment and native regulatory 
networks to control cellular behavior. Environmental signals are transduced into changes in the native 
regulatory network via synthetic circuitry. The composition of the synthetic circuitry dictates the 
environmental interface, how environmental information is input into the synthetic circuit, and the network 
interface, how the circuitry implements regulation and extracts information from the native network.   
   
Building a modular interface requires that circuitry be composed of modular parts 
such sensors, actuators, and other components that may be swapped in and out to connect 
to different environmental cues and various native networks. A synthetic circuit’s ability 
to actuate changes in a native network depends on the properties of the circuit’s parts, as 
well as, their interaction with each other (Figure 1.2A, B). An optimally placed circuit 
Synthetic circuitry
+
Network 
interface
Environmental 
interface
Environmental signals Native network
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runs quiescently until activated by the proper environmental cue to trigger a change in the 
native network (Figure 1.2C). The development of modular parts with tunable properties 
will enhance design flexibility, facilitating the optimal positioning of synthetic circuits 
for a broad range of applications.  
 
Figure 1.2. Components for interfacing with the environment and native regulatory networks. A. 
Parts used to interface with the environment and network. Function of the circuit relies on the properties of 
the elements and how they are integrated into the larger device. B. Composing circuits for optimal 
performance requires selection of the proper parts to efficiently transduce the environmental input into 
changes in the regulatory machinery. C. The latent circuit is activated by increasing environmental signal 
transduced by a sensor to imbedded synthetic circuitry. The synthetic circuit processes increasing levels of 
input by raising the profile of regulatory machinery that interfaces with the native network, mediating 
changes in the native network behavior.  
 
Building a modular interface from ncRNAs 
 The modular, tunable, and programmable nature of RNA makes it an ideal 
candidate to perform sensing, actuation, and regulatory functions within a synthetic 
circuit [19]. Over the last twenty years the scientific community has become increasingly 
Latent Circuit Active Circuit
Pathway RegulatorModulator SwitchA
B
Optimal designWeak modulatorWrong regulator Weak switch actuatorWrong switch sensor
C
Suboptimal designsIneffective designs
Switch actuator
Switch sensor
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aware of the role of non-coding RNAs (ncRNAs) in cellular control over gene 
expression. ncRNAs were thought to provide rather generic functions as ribosomal RNAs 
(rRNAs) and transfer RNAs (tRNAs) in translation and as small nuclear RNAs (snRNAs) 
in splicing. Studies of prokaryote genomes and their regulation forged the central dogma 
of biology, dictating that RNA had a relatively passive role in the transfer of genetic 
information from genes to proteins. In addition to specifying cellular state, proteins were 
thought to direct the trajectory of cellular fate by controlling gene expression networks. 
The vast tracks of ncRNA found in eukaryotes were hypothesized to be the evolutionary 
accumulation of inert sequences. However, large sets of these sequences are transcribed 
[20]. In fact, the majority of transcribed sequences in higher eukaryotes are never 
translated [21]. Additionally, the percentage of non-coding transcripts scales with 
organism complexity, while the number of coding genes does not [22]. With increasing 
discoveries of small ncRNAs that modulate gene expression [23-25] as well as with the 
discovery of the RNA interference (RNAi) pathway [26-28], ncRNAs appear to be the 
defining layer of sophisticated biological control that differentiates species with 
remarkably similar genomes [29].  
 While prokaryotes are known to use ncRNA to regulate gene expression, their 
dominant layer of control relies on protein-based regulation of transcription. Therefore, it 
is not surprising that prokaryotes have a relatively diverse genome and proteome from 
which to select elements to serve as regulators of gene expression. In contrast, eukaryotic 
organisms rely on a diversity of ncRNA to compensate for a largely stable and relatively 
small genome. As suggested by eukaryotic gene regulation strategies, control schemes for 
modulating gene expression are likely to require additional layers of control including the 
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implementation of RNA based-control systems that provide post-transcriptional control. 
To date, synthetic network engineering has largely focused on protein-based regulatory 
elements to build control systems [30]. However, there is a fundamental limitation to the 
complexity and specificity of protein-based regulatory schemes, which have a higher 
energetic cost. The burden of carrying additional genes encoding single protein regulators 
increases exponentially as complexity is introduced. Ultimately, in these accelerating 
networks, the cost of producing another protein regulator exceeds the benefit to the 
organism [31]. Regulation through alternative mechanisms such as ncRNA offers 
organisms an alternative that allows for specificity and diversity at a lower energetic cost 
[32]. 
The recurrence of ncRNA as a dominate regulatory motif in higher eukaryotes 
suggests that ncRNA-based regulators may improve the construction of complex 
regulatory architectures in synthetic circuits and facilitate connections between synthetic 
and endogenous circuitry. Additionally, the tunable properties of RNA and the potential 
to predict structure stability through existing algorithms make RNA a powerful substrate 
on which to build synthetic gene expression control systems. While post-transcriptional 
control of gene expression generally exhibits modest regulatory activities compared to 
transcriptional control, placement of post-transcriptional regulators at sensitive control 
points can mediate significant effects [33, 34]. Further, moderate activities endow these 
regulators with additive effects that provide a robust mechanism for tuning gene 
expression [35] and buffering the noise of gene expression in natural systems [36]. 
Finally, the additive nature of ncRNAs with modest activities provides a mechanism for 
synthetic circuits to logically process multiple inputs to orchestrate rational responses 
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[37]. In composing synthetic circuits, ncRNAs provide an additional degree of freedom 
for tuning circuit performance within the desired application. 
 
Selecting for RNA-based sensors 
 To construct a modular environmental interface, requires modular sensors that can 
transduce the environmental input into changes in the synthetic circuit. We propose that 
RNA aptamers demonstrate the requisite modularity as environmental sensors that can be 
wired to actuation and regulatory elements. Aptamers are a class of small nucleic acids, 
including some ncRNAs, that bind to a wide range of ligands, such as small molecules 
and peptides, with sensitivity and selectivity that can rival that of proteins [38]. Aptamers 
are thought to bind ligands through a process called adaptive recognition, in which ligand 
binding occurs as the RNA molecule transitions through relatively unstructured 
conformations until the appropriate binding pocket is formed. Upon formation of the 
binding pocket, the aptamer associates with the ligand which stabilizes the ligand-bound 
structure. Due to evolutionary pressure during selection, the three-dimensional structure 
of aptamer complexes reflects highly optimized scaffolds for ligand recognition [39].  
 The development of new aptamer sequences to cellular molecules of interest offers the 
potential to connect to endogenous networks in a rational way that can direct information into 
exogenous control systems. Synthetic RNA aptamers have been generated de novo to various 
small-molecule and protein targets through in vitro selection or SELEX strategies [40, 41]. 
Briefly, a large library of RNA molecules (~ 1014–1015) is incubated with the target of interest. 
Functional aptamers within this library space are subsequently partitioned from nonfunctional 
members and collected, typically using an affinity chromatography based separation strategy. 
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Collected sequences are then reverse transcribed and amplified to generate an enriched library 
that will serve as the input pool for the next round of selection. The Smolke laboratory has 
generated RNA aptamers that exhibit varying specificities to benzylisoquinoline alkaloids [42] 
and folinic acid derivates, and is developing high-throughput strategies for the direct selection 
and characterization of new protein- and small-molecule-responsive aptamers. Developing 
modular interfaces that facilitate information exchange between natural and engineered systems 
is critical for constructing biological control systems that program cell behavior.  
 
 Natural RNA switches as gene expression control systems 
 Naturally occurring RNA switches called riboswitches have been shown to 
regulate gene expression in response to a variety of metabolites, constructing various 
metabolic feedback control loops [43, 44]. Riboswitches are naturally occurring cis-acting 
RNA regulatory elements that modulate gene expression events in response to changes in 
intracellular metabolite concentrations [43, 44]. Riboswitches are comprised of at least two 
functional domains: a sensor or metabolite-binding domain and an actuator domain. Metabolite 
binding to the riboswitch occurs as the RNA molecule surveys equilibrium conformations. 
Once the appropriate binding pocket is formed, the ligand can bind the sensor domain. Ligand 
binding biases the equilibrium of the sensor region toward ligand-bound conformations. 
Through linker modules, conformational changes in the sensor domain induce a conformational 
change in the actuator element. In a riboswitch, the actuator is called an expression platform 
because it regulates gene expression [45]. Gene regulation occurs as metabolite binding events 
shift the equilibrium of the riboswitch toward its active or inactive conformation in which the 
expression platform adopts an active or inactive functional state. When the expression platform 
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adopts its active conformation, gene regulation occurs through an array of diverse mechanisms 
such as transcription termination, mRNA cleavage, or translation initiation [19].  
 Riboswitches are implemented by the cell as autonomous biological control systems. 
These RNA elements provide feedback control by sensing metabolites that are substrates and 
products of the riboswitch-regulated enzymes and modulating the levels of these enzymes in 
response to cellular metabolite concentrations. One such example is the glutamine-fructose-6-
phosphate (GlcN6P) amidotransferase ribozyme-based riboswitch that is located within the 5’ 
untranslated region (UTR) of the glmS gene. This enzyme metabolizes GlcN6P, which is the 
small-molecule effector of the riboswitch located upstream of glmS [46]. While some 
riboswitches have been discovered to promote gene expression [47], the majority repress the 
expression of their target gene. However, these natural RNA switches generally have 
evolved nonmodular architectures, in which the sequences of the sensor and actuator 
components interact to allow the switch to adopt different functional conformations, 
making the adaptation of these ncRNA controllers to new molecular inputs and 
regulatory mechanisms through direct component swapping unfeasible [19, 45, 47].  
 
Synthetic RNA switches that act through ribozyme-based cleavage mechanisms 
 Recent studies have demonstrated the design and implementation of synthetic 
riboswitch counterparts by pairing RNA aptamers with various ncRNA expression 
platforms [34, 48, 49]. The ncRNA regulatory element encoded in the actuation domain 
dictates the output flexibility of the controller, in terms of the genetic targets that can be 
regulated, and the organisms in which the controller functions. Therefore, regulatory 
elements that exhibit function in diverse organisms and that can be used to flexibly 
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regulate diverse genetic targets are of interest for integration into these synthetic 
controllers. A number of design strategies have been developed to functionally couple 
aptamers to small molecules and proteins to diverse ncRNA regulatory elements, from 
miRNAs [48] to ribozymes [50], such that binding of the ligand to the aptamer domain 
results in a change in the activity of the ncRNA regulatory element.  
Ribozymes are RNA molecules that catalyze a variety of reactions such as self-
cleavage or ligation [51]. Thus, ribozyme activity is independent of cell-specific 
machinery, and these RNA elements may provide a regulatory strategy that can be used 
across diverse organisms, including bacteria and eukaryotic cells. The hammerhead 
ribozyme is one of the most extensively studied ribozymes [51-54]. Previous work 
coupled aptamers to the stem-loop regions in hammerhead ribozymes, allowing for in 
vitro allosteric ribozymes [55-57]. However, the coupling strategies used in these early 
allosteric ribozyme designs inactivated the ribozyme activity at physiological salt 
conditions, not allowing these switches to be implemented as controllers inside cells. 
Through elucidation of the design rules for in vivo catalytic activity [58, 59], the stage 
was set for the design of RNA switch platforms that functionally integrate hammerhead 
ribozymes as in vivo regulatory elements.  
The Smolke laboratory recently demonstrated a modular and extensible 
framework for engineering in vivo ligand-regulated ribozyme switches. The described 
switch device contains three distinct functional domains: sensor domain, comprised of an 
aptamer sequence, a transmitter domain, and actuator domain, comprised of a 
hammerhead ribozyme sequence (Figure 1.3) [60]. When placed in the 3’ untranslated 
region (3’ UTR), the engineered ribozymes switches regulate gene expression. In the OFF 
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state, the ribozyme favors the active conformation, promoting cleavage of the transcript. 
Addition of ligand biases the ribozyme switch to the ligand-bound inactive conformation, 
resulting in increased gene expression. Small-molecule-dependent regulation of gene 
expression has been demonstrated on various heterologous genes and enabled the 
construction of RNA switches exhibiting up- and down-regulation of target expression 
levels. The design of the transmitter domain is a critical design feature that supports the 
insulation and modularity of the sensor and actuator components and allows the forward 
design and tuning of synthetic RNA switches. The resulting ability to mix-and-match 
sensing and actuation domains makes the modular RNA switch platforms powerful tools 
for developing tailored gene expression control systems.   
 
 
Figure 1.3.  RNA-based switches regulate gene expression in response to small-molecule 
concentration.  The switch device is constructed from three primary components, a sensor, a transmitter, 
and an actuator. These devices regulate the expression of a gene when placed in the 3’ untranslated region 
(3’ UTR). Shown above in the OFF state, the switch reduces gene expression in the absence of the small 
molecule by cleaving and destabilizing the transcript. Presence of the ligand alters the structure of the 
sensor which is transduced to the changes in the actuator structure via the transmitter. In the presence of 
ligand, the switch is ON and the actuator structure allows for increased gene expression. Adapted from 
Liang, J, et al.  (Submittedn). 
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The construction of ligand-responsive control elements that act in trans will 
improve our ability to study natural gene networks as well as impose exogenous control 
in biological systems. The described ribozyme switch system allows for the control of 
transgenes (in cis); however, it cannot be directly used for the regulation of endogenous 
genes (in trans). While a number of synthetic RNA switches that allow for the regulation 
of endogenous genetic targets have been described that function through miRNA-[48], 
shRNA- [61], or antisense-based [62] mechanisms, these regulatory elements are 
associated with a number of drawbacks. For example, antisense-based regulatory 
efficiency is highly variable across targets [63]. In addition, utilizing the RNAi pathway 
to process synthetic substrates has raised concerns about off-target effects and 
competition between synthetic and native substrates [64]. Cis-acting ribozymes may be 
converted into to trans-acting ribozymes by splitting the stem I loop and engineering the 
intermolecular reaction between the ribozyme and target sequence (Figure 1.4). 
Facilitating the ribozyme-target binding event in vivo is a critical hurdle to implementing 
trans-acting ribozymes as regulators of gene expression [65]. Previous attempts to control 
target expression via trans-ribozyme have been limited by poor in vivo efficiency [66, 
67].  Improvements in ribozyme designs and expression systems may increase ribozyme-
mediated knockdown of targets in vivo.  Elucidating the rules for the regulation of target 
transcripts will poise trans-acting ribozymes as unique actuators of gene expression. 
Finally, extension of the design principles elucidated for functional in vivo activity of cis-
ribozyme switches to the design of trans-ribozyme switches may provide a promising 
alternative to target the expression of endogenous proteins without modifying the natural 
context of the target gene [66, 68, 69].  
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Figure 1.4.  Converting cis-acting actuators to trans-acting requires engineering an intramolecular 
reaction into an intermolecular reaction. The cis-acting ribozyme (at left) can be converted to a trans-
acting ribozyme by opening up stem I of the ribozyme to allow binding of a target transcript (shown in 
red).  
 
 
MAPK cascades as universal signaling modules in eukaryotes 
 Mitogen-activated protein kinase (MAPK) cascades are highly conserved signaling 
pathways that control such processes as differentiation, mitosis, and apoptosis (Figure 1.5) [70]. 
Signaling through this pathway begins when extracellular signals are transduced across the cell 
membrane through receptor binding events that activate G-proteins. G-proteins relay these 
signals by facilitating phosphorylation of MAPKKKKs that continue phosphorylation through 
a three-tiered cascade until reaching the MAPK [71]. MAPKs regulate cellular behavior 
through interaction with repressors and transcription factors that determine entry into various 
cellular programs [72]. Many human cancers and other diseases are known to result from 
aberrant activation of cellular programs connected to MAPK signaling [73, 74]. Thus, 
controlling improperly activated signals has important implications in the development of 
therapeutics. Control systems that modulate MAPK pathways will provide an opportunity to 
interface with a large class of endogenous regulatory networks by which cellular fate can be 
programmed.  
Cis-acting actuator Rotated Cis-acting actuator Trans-acting actuator
Stem I
Stem I Stem I
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Figure 1.5. MAPK cascades as universal signaling modules in eukaryotes.  From yeast to mammals MAPK 
pathways preserve the transmembrane receptor and downstream three-tiered MAPK cascade that ultimately 
generates a phenotypic response to the stimuli. Adapted from [75]. 
 
 Despite an increase in our understanding of MAPK cascades, the development of 
therapeutics to intervene and redirect cellular fate through targeting components of this 
pathway has been primarily limited to kinase inhibitors [76-78]. These inhibitors act 
competitively to limit signal transduction; however, in pathways where control loops provide 
redundant verification of signaling, these inhibitors may be overwhelmed. Additionally, the 
delivery of these inhibitors is not restricted to diseased cells, which can result in unintended 
toxic side effects in healthy cells [79]. Effective therapeutics that redirect aberrant signaling 
through these pathways may need to compete with transcriptional feedback and discriminate 
between healthy and diseased cells. Implementation of control systems that regulate protein 
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levels offers the potential to rationally mediate MAPK signaling. Control systems that dictate 
MAPK signaling will provide a tool to elucidate our understanding of these pathways and 
potentially serve as a therapeutic strategy to counteract aberrant activation of cellular programs.  
The homology between MAPK cascades in single-celled organisms such as yeast and 
higher eukaryotes allows for comparison of parallel pathway responses [71]. In particular, the 
study of the Saccharomyces cerevisiae MAPK pathways has illuminated paradigms in human 
MAPK signaling such as signal insulation through scaffold proteins [80, 81]. In the model 
eukaryotic organism S. cerevisiae, multiple MAPK cascades direct cellular fate via 
divergent regulatory programs. Decisions to halt cell cycle, upregulate excretion of a 
metabolite, or change cell morphology are programmed as the rational response to 
environmental signals. S. cerevisiae responds to pheromone by activating a receptor-
coupled-G-protein three-tiered MAPK cascade (Figure 1.6A) [82]. The signal is 
transmitted from the G-proteins to the MAPK cascade of Ste11, Ste7, and Fus3.  Fus3 
translocates to the nucleus and phosphorylates the transcription factor Ste12.  Fus3 is 
deactivated by the phosphatase Msg5.  Upon pheromone stimulation, cells undergo cell 
cycle arrest, as can be seen in a halo assay, perform polarized growth to adopt the shmoo 
morphology (Figure 1.6B), and increase expression from the Fus1 promoter (pFUS1).  
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Figure 1.6. Yeast mating pathway and phenotypic response. A. Pheromone (α-factor) binding the 
transmembrane receptor initiates signaling in the internal G-proteins which is relayed to the canonical 
three-tiered MAPK cascade (Ste11, Ste7, Fus3). Phosphorylation is relayed down the cascade and 
culminates with phosphorylated Fus3 translocating to the nucleus to activate a range of transcription 
factors, transcription at mating genes, and ultimately the canonical mating response. Signaling is 
antagonized by Msg5, a phosphatase specific to Fus3. B. Phenotypic evaluation of the mating pathway can 
be performed via halo assay and by observing cell morphology. At bottom, a typical halo assay with a filter 
paper (center dark circle) saturated with pheromone establishing a gradient of pheromone. Cells within a 
particular radius corresponding to a particular concentration undergo pheromone-induced cell cycle arrest 
generating a halo in which cell density is significantly reduced relative to the plate outside of this radius. 
Above, cells stimulated with pheromone form “shmoos” by undergoing polarized cell growth.  
 
 
Combining synthetic biology and systems biology to build gene regulatory networks 
that control cellular fate 
Several modeling efforts have focused on evaluating the dynamics of MAPK 
cascades and posited that levels of signaling molecules are responsible for divergent cell 
fates [83-85]. Experimental results in the yeast pheromone-responsive MAPK pathway 
have demonstrated that particular profiles of signaling molecules are associated with 
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entry into specific fates [86-88]. Further, it has been suggested that network topology and 
the associated positive and negative feedback loops are ultimately responsible for these 
profiles and thus phenotype [87, 89]. Recent work in mammalian PC-12 cells indicates 
that the induced ERK MAPK network topology and resulting dynamics direct cell fate 
(Figure 1.7) [90]. Altering network topology routes cells to alternative fates. Questions 
still remain as to whether varying the induced network topology represents a conserved 
strategy across multiple MAPK cascades and eukaryotic organisms. Nevertheless, these 
results bode well for employing synthetic layers of positive and negative feedback loops 
as an engineering strategy to regulate cellular behavior 
 
Figure 1.7. Induced network topology shapes the dynamics in a natural regulatory pathway dictating 
cellular fate. A.  Transient stimulation with NGF and EGF leads to different Erk1/2 profiles that 
correspond to divergent cell fates. Adapted from [90]. B. Graph of network topology induced by different 
growth factors establishes feedback loops of different signs leading to divergent cell fates. Adapted from 
[91]. 
  
 Construction of synthetic biological control systems that interact with natural 
circuits has seen success in regulating pathway activity by incorporating endogenous 
promoters in feedback control schemes [81]. Additionally, construction of protein 
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scaffold chimeras has routed cells to an alternative MAPK response [92]. While this work 
has successfully modulated pathway activity and/or fate, these strategies primarily rely on 
genetic knockouts of endogenous genes. We prefer a less invasive scheme with a paucity 
of genetic manipulations to the host that may minimize difficulty in transferring these 
control strategies to higher eukaryotes. Identification of control points within the 
molecular network which are sensitive to exogenous control systems will facilitate the 
construction of noninvasive control strategies. Modulation of the expression of pathway 
components at these control points can reshape the network response and redirect cellular 
fate. Further, constructing feedback loops at these control points can fundamentally 
reshape network topology, alter dynamic signaling profiles, and enhance the robustness 
of phenotypic selection [90, 93]. Layering these exogenous control systems with RNA-
based controllers offers the potential to exogenously induce network topologies that 
redirect cell fate. We term these synthetic, exogenous control systems “molecular 
network diverters” as they conditionally divert the molecular network and consequently 
route cell fate. Molecular network diverters provide a means for orthogonally controlling 
cell fate within a genetically homogenous population via exogenously applied small-
molecule input. Orthogonal control via diverters provides an additional degree of 
freedom in specifying cell fate preserving existing mechanical, chemical, and 
biochemical channels for directing cell fate. Molecular network diverters may facilitate the 
ex vivo construction of complex tissues from progenitor cells with imbedded exogenous 
control systems. These systems may guide progenitor cells to develop normal tissues when 
seeded on designer scaffolds by supplementing the missing boundary conditions normally 
present during in vivo development and serve to complement traditional tissue engineering 
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approaches (Figure 1.8).  Such systems may be realized in the near future as researchers 
continue to unravel the systems biology governing cell-fate decisions [94, 95]. Advances 
in gene therapy delivery may allow molecular network diverters to be translated in vivo 
as cancer therapeutics targeting hyperactive MAPK pathways. Finally, the selection of 
new sensors responsive to pathway components may allow these diverters to perform 
autonomous corrective control of cell fate.   
 
Figure 1.8. Potential application of molecular network diverters to tissue engineering via small-
molecule regulated patterning of cell fate.  A scaffold with the appropriate geometry is patterned with 
two small-molecules to trigger diverter action at particular regions within the scaffold. Activated diverters 
route cells to two alternative fates. All three fates are properly distributed to compose the constructed 
tissue.   
 
 
 
Thesis organization 
This thesis is organized into two primary sections. The first section focuses on 
constructing RNA-based control systems that regulate signaling in the yeast mating 
pathway. Chapter 2 focuses on using a synthetic titration system to identify regulators of 
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pathway activity and tracing the pathway response curve that routes cells to alternative 
fates via varying regulator expression. Using this knowledge, we construct synthetic 
circuits called “molecular network diverters” composed with engineered RNA controllers 
and feedback modules that conditionally route cellular fate. Chapter 3 examines the 
construction of diverters with more complex network architectures composed of multiple 
modules with different expression modes and RNA controllers that amplify ligand-
induced phenotypic switching. We demonstrate an integrated network diverter capable of 
routing genetically identical cells to one of three fates dependent on environmental 
signals received. In the second section, chapter 4 discusses RNA-based controllers and 
efforts to develop a ligand-responsive trans-ribozyme platform that may be used to target 
both heterologous and synthetic transcript enhancing the design flexibility of synthetic 
control systems. 
As systems biology unravels the inner workings of natural molecular networks, 
synthetic biology is developing the genetic regulatory tools to implement control systems 
that guide, tune, and override endogenous network responses.  In this work, we utilize 
principles and tools from both systems biology and synthetic biology to compose a 
modular and tunable model control system by which we can conditionally direct cell fate. 
As the array of tools for controlling systems expands, proof-of-principle systems such as 
ours may be extended to applications in tissue engineering, therapeutics, and beyond.  
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Chapter 2 
 
Identifying pathway regulators and constructing RNA-based regulatory 
systems to control decision-making in the yeast mating pathway  
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Abstract 
Synthetic biology is advancing capabilities in constructing genetic circuits that 
can program biological functions. However, the application of these circuits to the 
regulation of cell fate has been limited by the means to connect synthetic circuitry to the 
pathways that govern cellular decision-making. Identifying and controlling the expression 
of key pathway regulators represents one possibility for connecting synthetic circuits to 
the processes that govern cell fate. Here, we show that in a model MAPK pathway, the 
Saccharomyces cerevisiae mating pathway, there exist titratable positive and negative 
regulators of pathway activity and a narrow range of expression of these regulators over 
which cellular fate diverges. Synthetic circuits designed to control the levels of these 
regulators were able to divert cells to alternative fates even in the face of antagonistic 
external signals. By layering these circuits with small-molecule-responsive, RNA-based 
controllers, we constructed molecular network diverters that specify alternative cell fate 
decisions in response to exogenous environmental signals. The diverters are designed to 
remain quiescent in the absence of the environmental input, but activate in the presence 
of the input signal to route cells to one of two alternative mating fates: “chaste” or 
“promiscuous”. In wild type cells, pheromone stimulates the mating pathway, inducing 
cell cycle arrest. Cells exhibiting the chaste phenotype are insensitive to mating cues and 
do not arrest, whereas promiscuous cells exhibit upregulated signaling through the mating 
pathway and arrest in the absence of the canonical mating stimulus. Diverters that 
incorporate a positive feedback architecture enhanced switching to the promiscuous fate, 
whereas diverters incorporating negative feedback exhibited reduced population 
heterogeneity. The molecular network diverters control fate decisions without modifying 
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the host’s native genetic material, obviating the need for laborious and potentially 
infeasible genetic manipulation. The modularity of this control scheme makes this 
technique broadly applicable to an extensive range of native networks such as those that 
govern stem cell fate and the establishment and proliferation of cancer. 
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Introduction 
To orchestrate complex, coordinated, multicellular tasks, organisms dynamically 
program their extracellular space with distributed molecular signals that are processed by 
individual cells into concerted responses. These extracellular signals activate signaling 
cascades that induce specific network topologies, leading cells to divergent cellular fates. 
MAPK cascades are a class of highly conserved signaling pathways that control such key 
cellular processes as differentiation, mitosis, and apoptosis [1]. Many diseases, including 
one third of human cancers, result from aberrant signaling through MAPK pathways [2, 
3]. In the model eukaryotic organism Saccharomyces cerevisiae, multiple MAPK 
cascades direct cellular fate via divergent regulatory programs. Decisions to upregulate 
gene expression, halt cell cycle, and change cell morphology are programmed through 
these pathways as the rational response to changing environmental signals. 
 The ability to dynamically modulate signaling through MAPK pathways in the 
face of antagonistic environmental stimuli represents an enormous hurdle in the 
reprogramming of cell fate decisions. Many of the current strategies for programming 
cell fate are based on strict control over the extracellular environment [4, 5], presenting 
limitations in clinical settings and necessitating the development of strategies that are 
more amenable to therapeutic contexts. Several modeling efforts have posited that levels 
of signaling molecules are responsible for divergent cell fates [6-8]. Further, 
experimental studies comparing wild-type response to overexpression and knockouts of 
signaling pathway components demonstrate that differential pathway activity and cell fate 
can be achieved via altering the expression levels of particular proteins [9-11]. However, 
these examples represent extreme perturbations to pathway response. We postulate that 
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within the continuum of regulator expression levels between wild type and high levels of 
ectopic overexpression there exists a transitory region over which cell fate diverges 
(Figure 2.1). In such a model, at subtransition levels of regulator expression, cells mirror 
the wild-type response. At expression levels above the requisite transitory range, cells 
adopt an alternative cell fate. By constructing synthetic circuits that can toggle between 
subtransition and supertransition levels of regulator expression, cellular behavior can be 
synthetically switched from wild type to programmed alternative fates.  
 
 
Figure 2.1. Regulator expression modulates pathway activity and over a narrow range of expression 
transitions to an alternative fate  
 
We present a method for identifying and interfacing with control points in the S. 
cerevisiae mating and osmolarity response pathways. Using a galactose-responsive 
titration system, we successfully identified both a positive and a negative regulator in the 
mating pathway and two coexpressed positive regulators in the osmolarity pathway. The 
regulators of the mating pathway were shown to route cells to alternative fates above a 
particular threshold of expression. By incorporating these regulators into various network 
architectures with RNA-based controllers [12], we successfully constructed several types 
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of molecular network diverters in the mating pathway which conditionally route cells to 
one of two alternative cell fates based on the presence of distinct environmental signals. 
Our results demonstrate the utility of conditionally activated control systems for 
applications modulating cell grow and/or viability as well as the rational tuning of these 
synthetic circuits via the exchange of well-characterized parts. Further, we show that 
positive feedback reshapes the pathway activity response curve, shifting the threshold at 
which cell fate diverges to lower levels of the positive regulator. Finally, we have 
elucidated design principles and methodology for constructing molecular network 
diverters that can be readily extended to new pathways and applications.  
 
Results 
Identifying key pathway regulators that allow routing of cell fate decisions to 
alternative phenotypes in the mating pathway 
S. cerevisiae activates a three-tiered MAPK cascade upon stimulation with 
pheromone that upregulates transcription of mating genes, induces cell cycle arrest, and 
initiates polarized cell growth characteristic of the mating response [8-9] (Figure 2.2). To 
identify regulators of pathway activity, we individually titrated the levels of signaling 
proteins in the pathway via an engineered galactose-inducible promoter system (pGAL1), 
which allows for linear, homogeneous regulation of a target gene [13] (Supplementary 
Figure 2.1). The engineered strain allowed us to identify key pathway regulators by 
interrogating the effect of titrating mean protein expression levels on pathway activity. 
We used these strains to determine if overexpression of the regulators was sufficient to 
cross the transitory range to mediate routing to an alternative fate. Pathway activity was 
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measured by monitoring expression from a transcriptional fusion construct (pFUS1-GFP, 
GFP fused to a mating responsive promoter), where GFP levels represent a measure of 
pathway activation, and by observing mating-associated cell cycle arrest via halo assays 
(see Materials and methods). 
 Figure 2.2. Identifying titratable regulators of pathway activity in the yeast mating pathway. A. A 
molecular view of signaling in the yeast mating pathway.  Pheromone (α-factor) binds to a transmembrane 
receptor to initiate signaling. That binding event is transduced across the cell membrane and relayed down 
to the G-proteins including,  Ste4 and Ste50, an adaptor protein, that in turn relay signaling to the Ste5 
scaffold-bound three-tiered MAPK cascade. Phosphorylation of the MAPK Fus3 results in its translocation 
to the nucleus and is antagonized by the phosphatase Msg5. Fus3 translocation activates a host of 
transcription factors which ultimately upregulate expression at various mating gene including FUS1. 
Pathway activity can be monitored via an integrated pFUS1-GFP promoter fusion. Additionally, the mating 
response is characterized by pheromone-induced cell cycle arrest and polarized cell growth called shmoo 
formation.  B. To find pathway activators, cells were monitored in the absence of stimulating pheromone. 
Ste4 increased pathway activity in a galactose-dependent manner indicating it is a titratable regulator. C. 
To find pathway inhibitors, the pathway was stimulated with pheromone. Msg5 overexpression reduced 
stimulated pathway activity. Cells were cultured in 0, 0.25 and 1% galactose for 6 hours. Pheromone was 
added 3 hours post-dilution to stimulate the pathway. Pathway activity was monitored via flow cytometry 
measurement of cellular fluorescence of GFP from the promoter fusion pFUS1-GFP.  
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 Only two of the six pathway proteins examined in this system exhibit significant 
effects as positive or negative regulators (Figure 2.2B, C). Overexpression of Msg5 from 
the engineered galactose-titratable promoter system results in a decrease in pathway 
activation, as measured from the pFUS1-GFP reporter construct, and over a threshold 
level Msg5 eliminates pheromone-induced cell cycle arrest, as demonstrated by halo 
assays (Figure 2.3A, B). Conversely, Ste4 overexpression increases pathway activation 
and reduces cell growth (Figure 2.3D, E). For both regulators, phosphorylated levels of 
the MAPK Fus3 correlated with GFP levels and cell fate, indicating that the synthetic 
circuits act through the canonical signaling pathway (Figure 2.3C, F). While previous 
work supports the role of Msg5 and Ste4 as negative and positive regulators of pathway 
activity [10, 14], respectively, we have demonstrated that these regulators modulate 
pathway activity in a dose-dependent manner and above a particular threshold of 
expression each regulator directs cell fate away from the wild-type response to an 
alternative phenotype. High levels of Msg5 inhibit pathway activation in the presence of 
pheromone, routing cells to a “chaste” fate. Above a threshold level of Ste4, cells 
constitutively activate the pathway in the absence pheromone to adopt a “promiscuous” 
fate. Our identification of only two pathway regulators from this screen supports the 
hypothesis that within many signaling pathways regulatory architectures filter out 
perturbations in the expression of signaling components [15, 16]. However, despite the 
native control schemes, we identified two control points where overexpression of the 
regulatory proteins dictates the level of pathway activity. 
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Figure 2.3. Overexpression of Msg5 and Ste4 modulates pathway activity and routes cells to an 
alternative fate. A. Increasing Msg5 overexpression results in reduced pathway activity over the galactose 
range as measure by pFUS1-GFP levels B. Halo assays at various concentrations of galactose indicate that 
as galactose concentration increases Msg5 overexpression inhibits pheromone-induced cell cycle arrest 
leading to a “chaste” phenotype. C. Phosphorylated levels of Fus3 correspondingly drop across the 
galactose range while the Cdc28 control levels remain constant. D. For Ste4 overexpression, pathway 
activity increases as galactose levels increase. E. Halo assays at various concentrations of galactose 
indicate that as galactose concentration increases Ste4 overexpression generates pheromone-independent 
cell cycle arrest or “promiscuous” fate. F. Phosphorylated levels of Fus3 correspondingly drop across the 
galactose range while the Cdc28 control levels remain constant.  
 
Identifying pathway regulators in the osmolarity pathway 
To examine the flexibility of the synthetic titration system for identifying pathway 
regulators, we applied it to a second yeast MAPK pathway, the osmolarity response 
pathway. The osmolarity response is triggered by high osmotic pressure that initiates 
signaling at two different receptors Sho1 and Sln1, which converge on a three-tiered 
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MAPK cascade (Figure 2.4A). Signaling results in phosphorylation and translocation of 
the dedicated osmo-MAPK Hog1 to the nucleus, and ultimately upregulation of osmo-
genes and production of glycerol. Activation of the osmolarity response is also known to 
repress the mating pathway. We used the engineered galactose-inducible strain to 
evaluate the potential of several signaling proteins as titratable positive pathway 
regulators. Negative regulators were not explored with this method as inhibiting the 
osmolarity pathway in yeast challenged with high osmotic pressure results in cell death 
[17].  
 
Figure 2.4. Identifying titratable regulators in the yeast osmolarity pathway. A. A molecular view of 
signaling in the yeast osmolarity pathway. High osmotic pressure initiates signaling via two transmembrane 
sensor proteins. Signaling is relayed to the Pbs2 scaffold-bound three-tiered MAPK cascade. 
Phosphorylation of the MAPK Hog1 results in its translocation to the nucleus and is antagonized by the 
phosphatase Ptc1. Hog1 translocation activates a host of transcription factors which ultimately upregulate 
expression at various osmo genes including STL1. Pathway activity can be monitored via an integrated 
pSTL1-GFP promoter fusion. Additionally, the osmolarity response is characterized by glycerol 
production. B. Increasing pathway activity in the osmolarity pathway requires overexpression of both Hog1 
and Pbs2. To find pathway activators, cells were monitored in the absence of sorbitol. Cells were cultured 
in 0, 1, and 3% galactose for 6 hours. Pathway activity was monitored via flow cytometry measurement of 
cellular fluorescence of GFP from the promoter fusion pSTL1-GFP.  
 
The impact of overexpression of three pathway proteins on osmolarity pathway 
activation was examined using the galactose-titratable expression system. Pathway 
activation was measured via a transcriptional fusion between a promoter that is activated 
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levels, the overexpression of single pathway proteins resulted in very small increases in 
pathway activation (Figure 2.4B). We hypothesized that co-overexpressing both the 
scaffold-kinase, Pbs2, and the MAPK Hog1 would lead to more substantial increases in 
pathway activity. We observed that co-overexpression of Pbs2 and Hog1 significantly 
increased pathway activation over single component expression.  
 Evaluating whether an alternative phenotypic fate can be achieved by controlling 
activation of the osmolarity pathway via regulator overexpression encountered several 
challenges. First, unlike the mating pathway (e.g., cell cycle arrest) the osmolarity 
pathway does not have a well-defined phenotypic readout. As a proxy, Hog1 
translocation to the nucleus has been used as a measure of pathway activation using a 
strain composed of a fluorescently labeled Hog1 and nuclear protein marker [18]. In the 
native pathway, Hog1 translocation occurs rapidly following hyperosmotic shock and 
pathway activity attenuates within minutes, returning nuclear Hog1 levels to pre-
stimulated levels. This timing dependence poses an issue in determining when to assay 
Hog1 translocation for our system in which the pathway is not stimulated by osmotic 
shock but instead by overexpression of protein components established over the course of 
the 6 hour assay. Similar issues are associated with evaluating phosphorylated Hog1 as a 
measure of pathway activity since the phosphorylation time scale mirrors that of 
translocation. Due to the challenges associated with determining fate from pathway 
activation, we did not perform this evaluation for the engineered systems. With 
significant method development it may be possible to evaluate fate routing in the 
osmolarity pathway. However, in light of the time scale of action for the osmolarity 
response, transcriptional feedback control may not be aptly suited to controlling the 
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osmolarity pathway. Under such time scale constraints, transcriptional control systems 
may modulate the initial conditions that guide the response, but dynamic modulation of 
signaling via feedback would be necessarily precluded.  
 
Building molecular network diverters for programming cell fate decisions 
 A molecular network has a particular topology which shapes the flow of signal in 
the pathway. Reshaping the network in decision-making pathways, such as MAPK 
pathways, offers the potential to divert the endogenous response to an alternative fate. 
Network reshaping requires identifying and plugging into a network regulatory node, a 
sensitive control point in the pathway for directing pathway activity and fate. Pathway 
regulators govern the function of their cognate regulatory nodes. Changes in the native 
network shape can be induced by raising the profile of a pathway regulator. A molecular 
network diverter conditionally routes cells to an alternative fate by transducing signals in 
the environment into changes in network shape via the modulation of the pathway 
regulator profile (Figure 2.5). A molecular network is composed of a switch which 
encodes a sensing function that recognizes the environmental signal. Increasing the input 
concentration increases the signal transduced to the actuator element within the switch 
(Figure 2.5A). The activity of the actuator combined with the strength of the modulator 
dictates the profile of the pathway regulator. As the concentration of the environmental 
input increases, the profile of the imbedded pathway regulator rises. Once the profile 
exceeds a particular threshold, the regulator docks to the network regulatory node and 
induces changes in the native molecular network, diverting the pathway response (Figure 
2.5B).  
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 Figure 2.5. Reshaping the native molecular network with molecular network diverters.  A. The latent 
diverter is activated by increasing trigger concentrations with flip the switch which raises the profile of the 
pathway regulator via the modulator. Above a certain threshold, the pathway regulator docks to the 
regulatory node to reshape the native network. B. Trigger binding to its cognate sensor flips the switch. 
Binding is transduced via the switch actuator to the modulator and finally to the imbedded pathway 
regulator, raising the profile of the regulator which plugs into its cognate regulatory node, reshaping the 
molecular network and diverting fate. The diverter function can be tuned by the properties of the switch, 
the modulator, and addition of feedback to the modulator.  
The properties of the molecular network diverter can be tuned via the genetic 
parts selected to compose the diverter. The diverter’s component functions can be 
mapped to particular genetic parts (Figure 2.6). The modulator maps to a promoter, where 
the promoter strength determines how strongly changes in the activity of the switch 
actuator are translated into changes in the profile of the pathway regulator. For the mating 
pathway, the pathway regulator is a gene cassette encoding either Ste4 or Msg5. The 
switch maps to RNA-based controllers. 
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Figure 2.6. Implementation of a molecular network diverter from various genetic parts. The 
molecular network diverter is composed with a modulator, pathway regulator, and a switch into the larger 
device. Mapping these parts to their genetic representation, the modulator is a promoter, the pathway 
regulator is a gene that regulates pathway activity, and the switch is an RNA-based controller. Assembling 
the genetic parts in the proper configuration allows the realized molecular network diverter to conditionally 
regulate pathway activity and divert cell fate. 
 Construction of a molecular network diverter requires the selection of regulatory 
elements with the appropriate strength and range for modulating the pathway regulator 
levels to conditionally route cellular fate. The selection of the promoter driving the 
expression of the regulator is a key component in setting the activity of the molecular 
network diverter. Constitutive promoters of varying strength achieve different levels of 
regulator expression (Figure 2.7). The pathway activity response curve indicates where a 
promoter-regulator pair falls on this curve, which dictates whether cells route to the wild-
type or alternative fate. Using a promoter responsive to pathway activation results in the 
construction of a feedback molecular network diverter. Feedback in molecular networks 
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can be used to change the shape of the pathway activity response curve. Negative 
feedback has been shown to antagonize ultrasensitivity, converting sigmoidal responses 
to linear responses [19]. Positive feedback architectures can be used to establish 
ultrasensitivity, reducing the threshold of expression required to trigger switching to an 
alternative fate [20]. The strength of positive feedback represents a sensitive control 
point, which dictates whether cells adopt the wild-type or alternative fate. We used four 
constitutive promoters of varying strength and a feedback promoter to construct and 
evaluate molecular network diverters (Supplementary Figure 2.2). 
Figure 2.7. Composition of a molecular network diverter from well-defined parts.  The molecular 
diverter is composed of a promoter, a pathway regulator, and a RNA-based controller, also called a switch. 
The promoter specifies the expression mode (e.g., constitutive or feedback) which determines the network 
connectivity. The promoter and switches combine to determine the expression strength and thus the activity 
of the diverter. The pathway regulator’s interaction with the native molecular network determines the 
pathway response curve. The pathway response curve can be altered by changes in network connectivity 
due to feedback expression of regulators. Switches specify which small-molecule input regulates 
expression and the range of expression across ligand concentrations.  
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RNA controllers provide a second layer of control by which to tune pathway 
regulator levels and allow the molecular network diverter to respond to environmental 
signals. Small-molecule-responsive RNA-based controllers, also called RNA switches, 
are an engineered class of noncoding RNA that allows for conditional control from any 
promoter-gene pair via a chemical trigger [12]. The RNA switches act post-
transcriptionally to destabilize transcripts in an input-dependent manner, thereby 
upregulating or downregulating target protein levels in response to increasing 
concentrations of environmental triggers. The regulated output achieved by these 
programmable RNA controllers spans a wide window of dynamic ranges and regulatory 
stringencies (Supplementary Figure 2.3). The switches used in this study respond to one 
of two chemical triggers, allowing for two independent channels through which to 
simultaneously regulate Msg5 and Ste4 expression.  The relative switch regulatory 
activity is independent of other circuit components (e.g., gene, promoter) such that the 
activity relative to the ON state control (nonswitching) is expected to be consistent across 
different promoter-gene pairs, supporting rational programming of the molecular network 
diverter properties. The ON and OFF state controls (nonswitching) demark the highest 
and lowest potential expression levels, respectively, from a promoter-gene pair coupled 
to the RNA-based controllers. Since the ON and OFF state expression levels of the RNA 
switches fall within these extrema, differential fates from the controls must be observed 
in order to construct molecular network diverters that alter cell fate decisions (Figure 
2.8).  
II-17 
 
Figure 2.8. Optimal configuration of the molecular network diverter requires tuning via the selection 
of components with the requisite metrics. A. An optimally configured diverter spans the steep linear 
range of the pathway response curve to yield a PAR value approaching PAR max. Switch S3 in the absence 
of input maintains the wild-type fate with low pathway activity (grey dashed line). With the addition of 
input (S3i), S3 switches to high pathway activity routing to the programmed alternative fate (black dashed 
line). B. Reducing the promoter strength results in a suboptimally configured diverter. C. Implementing 
feedback expression of a positive regulator introduces ultrasensitivity. As a result, a more stringent switch 
(with lower basal levels) is required to achieve optimal diverter performance. D. Substituting a negative 
regulator for a positive regulator enables construction of a negative diverter.  The negative diverter 
attenuates activity in the stimulated pathway. PAR (pathway activation ratio) is the ratio of the pathway 
activity in the presence and absence of the input for positive diverters. For negative diverters, PAR is the 
inverse of this ratio.  
 
A molecular network diverter requires that regulator expression spans the 
transitory range such that expression is above the requisite threshold in the presence of 
the input signal, while sub-transition levels are maintained in the absence of the signal. 
Optimal performance of the molecular network diverter requires tuning via the selection 
of components with the requisite metrics (Figure 2.8). In an optimally configured 
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diverter, the switch maintains wild-type behavior in the absence of environmental input 
and routes to the alternative fate in the presence of the input (Figure 2.8A). The 
efficiency of the molecular network diverter’s response to the input signal is measured by 
the pathway activation ratio (PAR), the ratio of the pathway activity in the presence and 
absence of the input for positive diverters. For negative diverters, PAR is the inverse of 
this ratio. An optimally configured diverter spans the steep linear region of the pathway 
response curve, resulting in a PAR value approaching PARmax. For positive diverters, 
PARmax is the ratio of the maximum to minima of the response curve as shown for S3 
(Figure 2.8A, inset); for negative diverters, PARmax is the inverse ratio. 
The modular components within the molecular network diverter architecture 
provide an array of tools for tuning the activities of these controllers to best interface with 
endogenous cellular networks. For example, changing the promoter in the regulator-
switch pair can significantly alter the diverter’s PAR value (Figure 2.8A, B). 
Additionally, the introduction of positive feedback into the network diverter architecture 
can result in shifts to the response curve that introduce ultrasensitivity and ultimately 
require more stringent RNA controllers to achieve optimal PAR values (Figure 2.8C). As 
another example, exchanging a positive pathway regulator in a positive network diverter 
for a negative regulator enables the construction of a negative network diverter in which 
activity is attenuated (Figure 2.8D). 
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Engineering a positive molecular network diverter that conditionally routes cells to 
a “promiscuous” phenotype 
To construct a positive molecular network diverter, we paired Ste4 with the four 
constitutive promoters of varying strength (Supplementary Figure 2.2) and the ON state 
control and evaluated the pathway response. For the three lower promoter strengths, cells 
weakly adopt a promiscuous fate characterized by diminished growth relative to cells 
harboring a control construct that lacked Ste4. Cells transformed with a construct 
harboring Ste4 under the control of the strongest promoter repeatedly failed to produce 
colonies. No phenotypic differences emerge across the range of the three lower promoter 
strengths examined (Supplementary Figure 2.4A). We paired pHIGH-Ste4 with 
tetracycline-responsive switches and nonswitch controls to determine the pathway 
response curve to regulator expression and the potential for phenotypic switching from 
this molecular network diverter architecture. Mild input-triggered phenotypic switching 
from wild-type to a promiscuous phenotype was observed from switch S4tc (Figure 
2.9A). In contrast, no phenotypic switching was observed from any of the diverters in 
which the lower strength promoter, pLOW, was paired with Ste4 (Supplementary Figure 
2.4B). We postulated that feedback expression of Ste4 might yield more robust 
phenotypic switching by introducing ultrasensitivity into the pathway response curve and 
by reinforcing pathway activation. The introduction of feedback expression of Ste4 into 
the network diverter architecture generated strong phenotypic switching from two 
tetracycline-responsive switches, S3tc and S4tc (Figure 2.9B). 
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Figure 2.9. Tetracycline-inducible positive network diverters of different architectures conditionally 
route cells to the promiscuous phenotype. A. Pairing tetracycline-inducible switches of increasing 
strength with constitutive expression of Ste4 results in increasing levels of pathway activity. Addition of 
tetracycline increases pathway activity for each switch construct. For S4tc, plate assays in the absence of 
tetracycline show a wild-type halo, while at 1 mM tetracycline cells adopt the promiscuous phenotype. B. 
Constructing a positive feedback loop amplifies ligand-induce phenotype switching. S3tc and S4tc show 
wild-type halos in the absence of tetracycline and a strong promiscuous response to tetracycline with nearly 
undetectable levels of cellular growth. 
 
A second set of diverters were composed from theophylline-responsive switches 
in both expression modes to demonstrate that routing via the molecular network diverters 
can be adapted to different target small-molecule inputs. Similar trends were observed 
between the tetracycline and theophylline-responsive switches. As expected, switches 
with similar basal levels and ranges achieve similar pathway activities and routing 
capabilities indicating the routing effect is independent of the specific identity of the 
input signal (Supplementary Figure 2.5). Further, the data support the ability to rationally 
tune molecular network diverters by the exchange of modular, well-defined parts.  
The data also suggest important tradeoffs between activity and timing in 
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for feedback expression of Ste4 exhibited significant growth despite being programmed 
for constitutive arrest. We postulated that strong Ste4 overexpression can place selective 
pressure against cells with highly active pathways, such that over time the population is 
dominated by cells resistant to pathway activation. Consequently, cells harboring these 
programs display a low pFUS1-GFP profile and exhibit growth within the expected halo 
region indicating resistance to pheromone-induced cell cycle arrest. At superthreshold 
feedback strengths, only cells resistant to activation of the mating program and/or the 
synthetic positive feedback loop are selected over time. To test this theory, we observed 
the behavior and GFP profile of cells harboring the feedback molecular network diverters 
in the presence and absence of the trigger molecule over time. The GFP profiles of cells 
harboring pFUS1-Ste4-S4tc dropped when grown in the presence of tetracycline for two 
days in contrast to cells grown in the absence of tetracycline (Supplementary Figure 
2.6A) The plasmid marker levels measured via a constitutively expressed mCherry 
cassette showed normal variation across the samples. Thus, the mCherry levels did not 
show a correlation with pathway activity, indicating the plasmid is maintained at similar 
levels in cells grown in the absence or presence of tetracycline (Supplementary Figure 
2.6B). Additionally, uniform growth across the plate in halo assays indicates that cells 
grown at superthreshold levels over an extended time are resistant to pheromone-induced 
cell cycle arrest (Supplementary Figure 2.6C). Above a threshold level of pFUS1-Ste4 
expression only cells with minimal pathway activity escape persistent cell cycle arrest. 
These data suggest that the ultrasensitivity introduced by the positive feedback 
architecture lowers the threshold to activation, capturing nearly the entire population in 
the high activity region of the curve and broadly enforcing a strong selective pressure 
II-22 
 
against pathway activation. Ultrasensitivity is not introduced into cells programmed with 
constitutive expression of Ste4, potentially explaining why similarly strong resistance to 
mating is not observed in cells harboring network diverters encoding constitutive Ste4 
expression. These results highlight the utility of programs that run quiescently until 
activated for applications in which the program necessarily modulates cellular processes 
such as growth rate and/or viability.  
By compiling the pathway activity data for Ste4, we determined the pathway 
response curve to varying Ste4 levels, identified the transitory range across which cell 
fate diverges, and examined differences between constitutive and feedback expression of 
Ste4 observed in the traces of the pathway response curve. For constitutive expression of 
Ste4, we traced pathway activity as a function of the calculated Ste4 expression and 
identified the transitory range over which cell fate diverges. The data points show a 
steady increase in pathway activity with increasing Ste4 expression up to a threshold 
followed by a precipitous drop (Figure 2.10A). Only cells induced to super-threshold 
expression levels show high pathway activity as expected from results indicating that 
over time high Ste4 expression selects for mating resistant cells. The drop in pathway 
activity coincides with the divergence of fate observed in the halo assays (Figure 2.10B). 
For feedback expression, the transitory range resides at Ste4 expression levels that are 
almost four times lower than those for constitutive expression (Figure 2.10C, D). The 
results support our hypothesis that positive feedback introduces ultrasensitivity to the 
pathway response curve, shifting the threshold to lower Ste4 expression levels.  
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Figure 2.10.  Tracing the pathway response curve of Ste4 expression to the promiscuous fate.  A. 
Tracing the pathway response to constitutive Ste4 expression shows a steady increase in pathway activity 
with increasing relative Ste4 expression up to a threshold followed by a precipitous drop. Pathway activity 
increases from 2% to 35%. Above 40% expression, pathway activity drops (for calculated Ste4 expression 
levels see Materials and Methods). B. This drop coincides with the divergence of fate shown in the halo 
assays. Plate data correspond to points with numbered circles in A selected from the pHIGH-SX data set 
(Supplementary Figure 2.4). C. Tracing the pathway response with feedback Ste4 expression shows a 
narrower transitory range shifted to lower Ste4 expression levels. Pathway activity increases from 0% to 
5%. Only samples induced with ligand show Ste4 levels above 10%. D.  Above 10% Ste4 expression 
levels, plate assays show cells adopting the promiscuous fate. Plate data correspond to points with 
numbered circles in A selected from the pFUS1-SXtc data set (Supplementary Figure 2.9B). E. Relative 
intensity values (RIV) are low at low Ste4 expression levels and high at high Ste4 levels, indicating that the 
difference between inner and outer cell growth as measure by intensity is reduced above a particular level 
of Ste4 expression (see Methods for calculation of RIV).  F. RIV values for feedback expression of Ste4 
show two regimes of behavior. At low Ste4 expression, RIV values are low, but at high Ste4 expression 
cells transition to high RIV values indicating cells undergo pheromone-independent cell cycle arrest. “T” 
indicates transitory region. 
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We have demonstrated the construction of positive network diverters that route 
cells to the promiscuous fate. Additionally, we have shown that network diverters that 
incorporate a positive feedback architecture via a pathway responsive promoter exhibit 
enhanced fate switching compared to nonfeedback network diverter architectures 
controlling the same positive regulator, Ste4. Positive feedback loops are known to be 
important in developmental decision-making processes [21]. Thus, the described 
feedback molecular network diverters may provide insight into effective strategies for 
guiding the development of tissues from progenitor cells.  
 
Building a negative molecular network diverter that conditionally routes cells to a 
“chaste” phenotype 
A negative molecular network diverter was constructed by pairing Msg5 with four 
promoters spanning a range of expression levels. We examined pathway activation in 
cells harboring these constructs under saturating pheromone conditions. Each construct 
exhibited routing to the chaste fate (Supplementary Figure 2.7). A set of negative 
network diverters of varying strength and range that are orthogonal to the positive 
diverters were constructed by pairing the strong promoter (pHIGH) and the theophylline-
responsive switches (Figure 2.11A). Having constructed both tetracycline- and 
theophylline-responsive positive diverters, negative diverters responsive either small-
molecule would provide for an orthogonal pair of diverters each responsive to its 
particular input signal. While we anticipate that tetracycline-responsive switches would 
mirror the phenotypic results observed with theophylline, we chose theophylline to 
regulate the negative diverter to mitigate any potentially confounding issues with pFUS1-
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GFP analysis associated with tetracycline autofluorescence. The low expression level of 
Msg5 associated with the OFF state control allowed pathway activation in the presence of 
pheromone, leading to high GFP levels, a low PAR value, and wild-type halo formation 
(Figure 2.11B, C, D). In contrast, the high expression level of Msg5 associated with the 
ON state control inhibited pheromone-induced pathway activation, thereby eliminating 
cell cycle arrest and resulting in low GFP levels. Between S2 and S4 cell fate diverges 
from the wild-type to chaste phenotype. The basal expression levels of Msg5 associated 
with S1 and S2 in the absence of theophylline are sufficiently low to permit elevated 
pathway activity in response to pheromone and the characteristic halo formation as is 
observed for the OFF state control. Both S1 and S2 attenuated pathway activity in the 
presence of input and showed significant phenotypic switching to the “chaste” fate as is 
observed for the ON state control.  
The molecular network diverters composed with the pHIGH-Msg5 promoter-
regulator pair highlight key design considerations associated with tuning network 
diverters to cross the associated transitory range to alternative phenotypes. The pathway 
response curve requires switches with stringent control over basal expression levels to 
maintain quiescence in the absence of the environmental trigger. While switch S4 shows 
a larger SAR value than S1 and S2 (Supplementary Figure 2.3A), the basal expression 
level from the diverter incorporating S4 inhibited pathway signaling sufficiently to 
eliminate cell cycle arrest in the presence of pheromone even in the absence of the input 
signal, yielding a low PAR value (Figure 2.11). In contrast, switches S1 and S2 exhibit a 
more stringent control profile than that of S4, and diverters incorporating these switches 
exhibit larger PAR values and achieve rerouting of cell fate in response to the input 
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signal. The results highlight the importance of tunable controllers, including those 
exhibiting stringent profiles, in targeting thresholds of key pathway components to 
achieve desired phenotypic switching.  
 
Figure 2.11. Theophylline-inducible molecular network diverters constructed with constitutive Msg5 
expression conditionally route cells to the chaste phenotype. A. and B. Pairing theophylline-inducible 
switches of increasing strength from S1 to S4 with constitutive expression of Msg5 results in decreasing 
levels of pathway activity. C. Addition of theophylline reduces pathway activity most significantly for S1 
and S2 as indicated by the higher PAR values. D. For S1 and S2, plate assays in the absence of tetracycline 
show a wild-type halo, while at 5 mM theophylline cells adopt the chaste phenotype.  
 Negative feedback loops have been shown to reduce population heterogeneity 
[22]. We examined whether improved fate routing could be achieved by integrating a 
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feedback architecture with the negative molecular network diverters. The negative 
feedback diverters were composed by pairing the pFUS1-Msg5 cassette with various 
theophylline-responsive switches (Figure 2.12). The low expression level of Msg5 
associated with the feedback diverter incorporating the OFF state control allowed 
pathway activation in the presence of the pheromone, leading to high GFP levels and 
wild-type halo formation (Figure 2.12B, D). In contrast, the high expression level of 
Msg5 associated from the feedback diverter incorporating the ON state control inhibited 
pheromone-induced pathway activation, thereby eliminating cell cycle arrest and 
resulting in low GFP levels. Cell fate diverged from the wild-type to chaste phenotype 
between S2 and S4. The entire set of feedback diverters showed low PAR values, 
indicating a weak ability to route from wild-type to chaste fate (Figure 2.12C). Weak 
phenotypic switching from the negative feedback diverters incorporating switches S1 and 
S2 was confirmed by plate assays (Figure 2.12D). Diverters incorporating negative 
feedback may linearize the pathway response curve to Msg5 expression. As a result of 
this linearization, changes in Msg5 expression may be transduced into smaller changes in 
pathway activity, thus preventing phenotypic switching. 
The feedback diverters did not inhibit pathway activation as greatly as the 
nonfeedback molecular diverters (as measured by transcriptional activation); however, 
the more active molecular diverters effectively prevented halo formation in the plate 
assays. Comparing the histograms for the ON and OFF state controls, we observe that 
while both expression modes reduce the mean of the high GFP population (and thus 
reduce the level of pathway activation), constitutive expression results in the 
establishment of a second low GFP population (Supplementary Figure 2.8A, B). GFP 
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histograms and calculated mean values of the high GFP populations are comparable 
between the two expression modes (Supplementary Figure 2.8C, D and Supplementary 
Figure 2.9). These results suggest that cell fate switching at the population level occurs 
when the mean pathway activity of the high population crosses the critical threshold. 
  
 
Figure 2.12. Theophylline-inducible molecular network diverters constructed with feedback 
expression of Msg5 route cells to the chaste phenotype. A. Pairing theophylline-inducible switches of 
increasing strength from S1 to S5. B. Constructing a negative feedback loop with Msg5 results in reduced 
pathway activity across the increasing switch range. C. PAR values are noticeably low compared to 
constitutive expression of Msg5 (Figure 2.11) D. Above S2, cells adopt the chaste phenotype. Only mild 
phenotypic switching is observed in S1 and S2.  
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Figure 2.13. Tracing pathway response to Msg5 expression to the chaste fate. A. Pathway activity 
significantly decreases over a narrow window of relative Msg5 expression (0 – 0.1). B. Above 0.08 
expression cells adopt the chaste fate. Plate data correspond to points with numbered circles in A selected 
from the pHIGH-SX data set (Figure 2.11). Relative Msg5 expression was calculated as described 
previously. C. Relative intensity values (RIV) for constitutive expression of Msg5 show two regimes of 
behavior. At low Msg5 expression (0 – 0.1 relative Msg5 expression levels), RIV values are increase in a 
graded response, but above a threshold of  Msg5 cells plateau to high RIV values (above 0.1). High RIV 
values indicate the difference between inner and outer cell growth as measure by intensity is low. Low RIV 
values indicate a large difference between inner and outer intensity values (see Methods for calculation of 
RIV). “W” indicates wild-type. “T” indicates transitory region. 
We used the calculated values of Msg5 expression to plot the pathway activation 
curve as described for the positive network diverter. At low Msg5 levels, a steady 
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decrease in pathway activity is observed with increasing Msg5 (Figure 2.13). Within a 
narrow range of expression the response curve is very sensitive to changes in Msg5 
expression, supporting the observed requirement for switches with stringent control over 
basal levels to build negative diverters that achieve conditional rerouting of cell fate. To 
facilitate comparison between both expression modes, pathway activity values were 
calculated based on the high GFP population. Inclusion of the low GFP population 
showed similar results for the transitory range and pathway response curve sensitivity 
(Supplementary Figure 2.10). While we suspect that the pathway response curve for 
diverters incorporating constitutive expression is more sensitive to changes in Msg5 than 
that for feedback diverters, the data do not provide sufficient resolution for differentiating 
features of the curves that may vary between the two expression modes.  
We have demonstrated that negative molecular network diverters can 
conditionally attenuate pathway activity in the yeast mating pathway, routing cells to the 
chaste fate. Extending the construction of negative diverters to mammalian cells offers 
the potential to intervene in the establishment and proliferation of cancers by 
counteracting aberrant pathway activation. Applying these circuits to diseases such as 
cancer may reduce or eliminate the proliferation of tumors by checking uncontrolled 
growth. Additionally, a negative molecular network diverter may be able to restrict 
pathway attenuation based on temporal and spatial distribution of the environmental 
trigger limiting the potential side-effects associated with applying such diverters as 
therapeutics.  
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Discussion 
 We have demonstrated the construction of molecular network diverters that 
positively and negatively regulate pathway activity, conditionally routing cells to 
alternative fates in response to specific molecular inputs. To construct these diverters, we 
identified titratable regulators of pathway activity and traced the pathway response curve 
to regulator levels, identifying the transitory range between the wild-type and alternative 
fates. In exploring different network architectures, we demonstrated that positive 
feedback diverters enhance ultrasensitivity in the native pathway, shifting the transitory 
range for Ste4 to lower levels and providing more robust phenotypic switching. The 
potency of the negative regulator Msg5 required stringent control of the basal levels for 
maintenance of the wild-type phenotype in the absence of the environmental trigger. Our 
studies also demonstrated that these synthetic circuits can be rationally tuned by the 
exchange of well-characterized genetic parts.  
We have demonstrated that within multiple yeast MAPK pathways there are 
titratable regulators of pathway activity. Ectopic overexpression of specific pathway 
regulators at these regulatory nodes can be used to modulate pathway activity, providing 
a readily implementable, modular interface between synthetic regulatory systems and 
these native pathways. The identification of titratable regulators in multiple pathways 
suggests that our method for identifying regulators of pathway activity may be broadly 
applicable to MAPK pathways, facilitating the construction of synthetic circuits that 
interface with and modulate the function of an important class of signaling pathways. 
While previous work supports the identified components as regulators of pathway 
activity [10, 14, 17], we demonstrate that within the mating pathway overexpression of 
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these regulators above a particular threshold can route to an alternative fate. Additionally, 
by tracing the pathway response curve in our studies, we have identified the range of 
regulator expression over which fate transitions from wild-type to the programmed 
alternative fate. Interestingly, we observed that the transition is reached at lower 
expression levels for Msg5 than for Ste4, indicating that Msg5 is a more potent regulator 
of pathway activity. Since Ste4 overexpression leads to cell-cycle arrest, weaker potency 
of this regulator may represent a control scheme to compensate for variable expression 
that might otherwise decrease population fitness by reducing overall growth rates. Since 
Msg5 does not inhibit growth, limiting its potency may be less critical to population 
fitness.  
The pathway response curve is unique to its regulator and dependent on the 
molecular details of the regulator’s interaction with other components in the native 
network. While modifying the regulator’s interaction via protein engineering can change 
these interactions to reshape the pathway response [8, 17], changing the connectivity of a 
synthetic circuit can provide a simpler method for rationally reshaping the pathway 
response curve. In our system, we demonstrated that the introduction of positive feedback 
shifts the threshold at which cell fate diverges to lower relative Ste4 expression levels, 
improving phenotypic switching and suggesting an enhancement of the pathway’s 
ultrasensitivity. Further, positive autoregulatory loops such as these have been shown to 
exhibit bistability [8, 21]. When properly tuned, positive feedback loops can thus provide 
a providing a type of memory to fate commitment by sustaining the network response 
when triggered above a particular input level [23]. While the introduction of positive 
feedback amplifies phenotypic switching from the network diverter, negative feedback 
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plays a role in reducing population heterogeneity. In our system we observed that the 
introduction of negative feedback into the network diverter reduced population 
heterogeneity, resulting in a single narrow peak of pathway activity values. Feedback 
expression provides a negative response that is proportional to pathway activity which 
may asymptote to a particular stable state. Mismatches in pathway activity and Msg5 
expression distributions are attenuated for feedback expression.  In contrast, constitutive 
expression results in a more broadly distributed response in which mismatches in 
pathway expression and regulator expression levels introduced by extrinsic noise increase 
population heterogeneity. Thus, the introduction of feedback architectures into the 
molecular network diverters result in synthetic circuits that exhibit useful properties for 
robust circuit performance, including enhanced ultrasensitivity and reduced population 
heterogeneity.  
We also demonstrate that molecular network diverters can be rationally tuned by 
the exchange of well-defined genetic parts. Specifically, the promoter and switch 
elements can be exchanged within the diverter architecture to predictably tune pathway 
activity. In addition, we showed that the ability of the switch component within the 
diverter to route cell fate is independent of the input signal the switch is programmed to 
detect and dependent on the quantitative gene-regulatory activities exhibited by the 
switch. This property allows for orthogonal sets of network diverters, which can be 
triggered by independent input channels, to be designed through the incorporation of 
RNA switches responsive to different molecular inputs. Further, independent channels of 
regulation provide for the integration of multiple network diverters that control different 
pathway nodes, allowing independent triggering of each diverter. This capability can 
II-34 
 
ultimately be used to route genetically identical cells to different cell fates dependent on 
the small-molecule trigger present in the environment. Such orthogonal control strategies 
may facilitate patterning of multiple cell fates from a genetically homogenous culture via 
the controlled distribution of small-molecule triggers.  
Our studies also highlight the design trade-offs and considerations in configuring 
network diverters to span the range of expression required for fate routing. While RNA 
switches with higher SAR values exhibit greater fold changes in regulator expression, 
regulators that exhibit high activities, such as Msg5, require more stringent switches with 
lower basal levels that can exhibit smaller dynamic ranges (SAR). In certain situations, 
the optimal diverter configuration and fate switching may not be achievable based on the 
pathway response curve and the set of available parts for composing the diverter. 
Therefore, the development of strategies to amplify input-triggered switching and an 
expanded the set of switches (and corresponding range of properties) will extend the 
number of native pathways to which molecular network diverters can be applied. In 
addition, the switch component provides a promoter-independent strategy for tuning gene 
expression, potentially providing greater flexibility to the control system, particularly in 
situations in which the application constrains the choice of promoter. For example, 
synthetic systems developed as therapies for the treatment of diabetes and gout require 
specific pathway-responsive promoters [24, 25]. In addition to facilitating tuning in these 
synthetic systems, the RNA switches will enable the construction of synthetic networks 
that provide exogenous spatial and temporal regulation, providing a strategy for limiting 
the extent of side-effects associated with such therapies. 
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The molecular network diverter architecture developed in this study offers the 
potential to independently trigger a positive and negative diverter via independent small-
molecule input channels, allowing routing to three different fates from a genetically 
identical cell population. However, the integration of both positive and negative diverters 
into a single cell poses challenges in maintaining the performance of each diverter. While 
each diverter runs quiescently with respect to fate routing in the absence of small-
molecule input, addition of the diverter measurably changes the basal activity of the 
pathway. Since the opposing diverters perform opposite functions on pathway activity 
that are processed through the native network, basal expression levels from the non-
triggered diverter may antagonize routing from the triggered diverter. The incorporation 
of RNA switches exhibiting low basal levels and large dynamic ranges may facilitate 
improved routing in such system designs. However, computational models of RNA 
switches have indicated a tradeoff in tuning the stringency of a switch and its sensitivity 
to the input ligand, ultimately impacting the dynamic range [26]. Network architectures 
that amplify small-molecule triggered routing may enhance fate switching even in the 
presence of diverter antagonization. Issues with basal expression levels impinging on 
circuit performance have observed in synthetic network construction [23, 27, 28]. 
Researchers have addressed such issues by adding layers of post-transcriptional control, 
such as through riboregulators in bacteria [29] and microRNAs in mammalian cells [30, 
31], to reduce gene expression leakage in the OFF state. Thus, RNA control elements that 
target the opposite regulator may be coexpressed with pathway regulators or imbedded 
within the opposite transcript to achieve reduced basal level leakage, diminished diverter 
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antagonization, and amplified diverter-mediated switching when positive and negative 
diverters are simultaneous implemented.  
 While our work elucidates the design principles for constructing molecular 
network diverter systems in yeast, these principles can be extended to construct similar 
systems in higher eukaryotes, offering the potential to probe native networks in 
multicellular organisms, program tissue formation, and target cancer therapies with 
synthetic molecular network diverters. Additionally, these synthetic circuits may provide 
the control tools necessary for the ex vivo construction of complex tissues when 
combined with designer scaffolds printed with small-molecule triggers. Further, our work 
highlights the utility of control systems that can be conditionally induced while 
maintaining endogenous connectivity with independent promoter selection. For genetic 
programs that decrease fitness or viability, such systems allow for conditional induction 
at the appropriate time, reducing the selection pressure to eliminate the prescribed 
program. As RNA switches are generated to sense a broader array of molecular ligands, 
diverters may be configured to respond to endogenous inputs, potentially allowing 
autonomous control within the cell. As our ability to build interfaces between synthetic 
circuits and native networks improves, synthetic biological devices that control cell fate 
will translate into therapeutic and regenerative medicine applications, as well as facilitate 
the study of natural biological systems.  
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Materials and methods 
Plasmid and strain construction 
Standard molecular biology cloning techniques were used to construct all 
plasmids [32]. DNA synthesis was performed by Integrated DNA Technologies 
(Coralville, IA). All enzymes, including restriction enzymes and ligases, were obtained 
through New England Biolabs (Ipswich, MA). Ligation products were electroporated 
with a GenePulser XCell (Bio-Rad, Hercules, CA) into an E. coli DH10B strain 
(Invitrogen, Carlsbad, CA), where cells harboring cloned plasmids were maintained in 
Luria-Bertani media containing 50 mg/ml ampicillin (EMD Chemicals). All cloned 
constructs were sequence verified by Laragen Inc (Santa Monica, CA). 
Plasmids expressing GFP were constructed from pCS321 (Supplementary Figure 
2.11A, Supplementary Table 2.1 [33]. Promoters pLOW (pADH1), pMED (pCYC1), 
pHIGH (TEF1 mutant 7) [34], pHIGHEST (pTEF1), pSTL1, and pFUS1 were PCR 
amplified and cloned into SacI (or NotI) and BamHI in pCS321 using promoter-specific 
primers (Supplementary Table 2.2).  
Plasmids for galactose-titration were constructed from pCS1128 a TRP plasmid 
which bears pGAL1-yEGFP-CYCt with an ON state control cloned in the 3’UTR 
between AvrII and XhoI (Supplementary Figure 2.11B, Supplementary Table 2.3). 
Mating genes (Ste4, Ste50, Ste11, Ste7, Fus3, Msg5) and osmo genes (Pbs2, Hog1, Ptc1) 
were cloned between AvrII and BamHI using gene-specific primers for amplification 
from plasmid and genomic templates (Supplementary Table 2.2). XhoI restriction sites in 
Fus3 and Ste4 and an AvrII restriction site in Ste7 were removed by site-directed 
mutagenesis using QuikChange II Site-directed mutagenesis kit (Agilent, Santa Clara, 
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CA) according to the manufacturer’s instruction with appropriate primers 
(Supplementary Table 2.4). Pbs2 was cloned into pCS321 using the same primers and 
restriction sites to generate a URA plasmid Pbs2 titration construct.  
To construct the negative and positive molecular network diverters, Msg5 and 
Ste4 were cloned into the GFP expressing constructs with the various promoters as 
described above for the galactose titration constructs. Ribozyme-based devices and 
appropriate controls (Supplementary Table 2.5) were inserted into the 3’ UTR via the 
unique restriction sites AvrII and XhoI, located immediately downstream of the gene stop 
codon as described previously (Supplementary Tables 3.6 and 3.7) [33]. 
Reporter strains for galactose-titration studies were constructed by knocking out 
the galactose transporter, GAL2, to construct the mating strain CSY532 and osmolarity 
strain CSY139. The pFUS1-yEGFP3-CYC1t cassette from pCS1124 was cloned into 
pCS1391, a loxP integrating vector [35], via the unique restriction sites SacI and KpnI to 
make pCS2292 (Supplementary Figure 2.12, Supplementary Table 2.8). pFUS1-yEGFP3-
CYC1t was chromosomally integrated into yeast strain CSY364 (EY1119; W303a ∆sst1 
∆kss1::HIS3) [36] via homologous recombination using the gene cassette from pCS2292 
to construct yeast strain CSY532 (W303a ∆sst1 ∆kss1::HIS3 gal2 ::FUS1p-yEGFP3-
loxP-KanR) (Supplementary Table 2.9). Briefly, the pFUS1-yEGFP3-loxP-KanR cassette 
was PCR amplified using Expand High Fidelity PCR system (Roche, Indianapolis, IN) 
from pCS2292 using forward and reverse primers (Supplementary Table 2.10), each 
carrying 60 nts of homologous sequence to the GAL2 locus. Yeast strain EY1119 was 
transformed with 12 µg of gel purified PCR product and plated on G418 plates to build 
yeast strain CSY532. CSY408 was constructed as described above using a blank 
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integration cassette. To construct a reporter for the osmolarity pathway, pSTL1-yEGFP-
CYC1t was cloned into a yeast disintegrator plasmid pCS1441 which is specific to the 
FCY1 locus via unique restriction site KpnI and SacI. CSY408 was was transformed with 
disintegrator vector bearing pSTL1-yEGFP-CYC1t linearized by digestion with AscI as 
described previously [37] to yield KGY139. For characterization of the molecular 
network diverters, yeast strain CSY840 was constructed as described for CSY532 using 
primers specific to the TRP1 locus (Supplementary Tables 3.9 and 3.10).  
 
Measuring mating pathway activity via a transcriptional reporter  
For the galactose titration studies, plasmids bearing the galactose-inducible 
promoter (pGAL1) controlling expression of various pathway regulators and appropriate 
controls were transformed into yeast strain CSY532. Cells were inoculated into the 
appropriate dropout media, grown overnight at 30°C, and back diluted into fresh media in 
the presence of varying concentrations of galactose (0, 0.25, 0.5, 1, 2 and 3%) to an 
OD600 of < 0.1. To identify negative pathway regulators, after growing for 3 hr at 30°C, 
cells were stimulated with saturating pheromone levels, to a final concentration of 100 
nM α mating factor acetate salt (Sigma-Aldrich, St. Louis, MO), to activate the mating 
pathway. The pathway was not stimulated when evaluating the potential of positive 
regulators. Following 6 hr of growth post-back-dilution, GFP fluorescence levels from 
the pFUS1-yEGFP3 reporter were evaluated via flow cytometry using a Cell Lab Quanta 
SC flow cytometer (Beckman Coulter, Fullerton, CA) with the following settings: 488-
nm laser line, 525-nm bandpass filter, and photomultiplier tube setting of 5.0 on FL1 
(GFP). Fluorescence data were collected under low flow rates for ~ 10,000 viable cells. 
II-40 
 
Normalized pathway activity is calculated as the geometric mean of three biological 
replicates of each sample normalized to the blank plasmid control not bearing a gene at 
the corresponding galactose concentration. 
The molecular diverter plasmids and appropriate controls were transformed into 
yeast strain CSY840. Cells were inoculated into the appropriate drop-out media, grown 
overnight at 30°C, and back diluted into fresh media in the presence or absence of ligand 
at the specified concentration to an OD600 of < 0.1. For negative diverters, after growing 
for 3 hr at 30°C, cells were stimulated with saturating pheromone levels, to a final 
concentration of 100 nM α mating factor acetate salt, to activate the mating pathway. 
Following 6 hr of growth post-back-dilution, GFP fluorescence levels from the pFUS1-
yEGFP3 reporter were evaluated via flow cytometry using a Cell Lab Quanta SC flow 
cytometer as described previously. Normalized pathway activity is calculated as the 
geometric mean of three biological replicates of each sample normalized to the blank 
plasmid control stimulated with saturating α mating factor in the absence of either small 
molecule.  
 
Measuring osmolarity pathway activity via a transcriptional reporter  
Galactose titration studies in the osmolarity pathway were performed as described 
previously for the mating pathway with the following exceptions. Cells were transformed 
in KGY139 to meaure the activity of the osmolarity pathway via the integrated pSTL1-
GFP reporter. Normalized pathway activity is calculated relative to the pathway 
stimulated with 1M sorbitol for 6 hr. Quanta flow cytometer photomultiplier tube setting 
of 7.5 on FL1 (GFP).  
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Measuring mating pathway activity via halo assays 
Mating associated cell-cycle arrest was evaluated via halo assays [38]. Halo 
assays were performed on cultures grown overnight in YNB with appropriate dropout 
solution, back diluted into fresh media, and grown to OD600 ~ 0.2–0.4. 200 µl of each 
replicate was plated on the appropriate drop-out plates. For galactose-titration halo 
assays, cells were plated on noninducing, nonrepressing plates with varying 
concentrations of galactose (0, 0.25, 0.5, 1, 2 and 3%).  For characterization of the 
molecular network diverters, cells were plated on plates containing no small molecule or 
5 mM theophylline or 1 mM Tetracycline as specified. After plating the cells, a gradient 
of α mating factor was established by saturating a filter disk (2 mm diameter) of 
Whatman paper with 9 µl of 0.1 mg/mL α mating factor and placing the disk on the 
center of the plate. Cells were grown for 18 hr at 30°C and imaged via epi-white 
illumination with a GelDoc XR+ System (Bio-Rad).  
Relative intensity values (RIV) were calculated to measure the difference in inner 
and outer halo cell growth. Intensity of rectangular cross-sections at r = 0.15 inches (inner 
region) and r = 0.5 inches (outer region) from the filter disc were calculated using image 
processing software from the GelDoc XR+ System. The difference between outer and 
inner intensity values were calculated for each plate to yield the plate’s intensity range. 
The difference between each plate intensity range and max intensity range was calculated 
and normalized by the max intensity range. The max intensity range was calculated by 
subtracting the minimal intensity value from the maximal intensity value for the entire set 
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of plates including both nonswitch controls and the blank plasmid control. Increasing 
RIV values indicate decreasing differences in inner and outer intensities.  
 
Measuring mating pathway activity via Western blots   
Yeast cells harboring appropriate constructs were grown as indicated above in 5 
mL cultures to ~ 1.0 OD600, pelleted via centrifugation, and resuspended in 800 ul 
modified RIPA Lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-
100, 0.5% Nonidet P-40, 0.25% sodium deoxycholate, 50 mM β-glycerophosphate (pH 
7.3), 10 mM NaPP, 30 mM NaF, 1 mM benzamidine, 2 mM EGTA, 1 mM sodium 
orthovanadate, 1 mM dithiothreitol, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 1 µg/ml 
pepstatin and 1 mM phenylmethylsulfonyl fluoride). The resuspended cell mixture was 
added to a tube containing 1 mm glass beads and shaken for 5 min at 30/sec in a 
homogenizer to generate cell lysates. Following homogenization, the lysates were boiled 
for 5 minutes in a 95 oC sand bath and subsequently centrifuged at maximum speed for 2 
min. The supernatant was recovered into a fresh tube. Cleared lysates were stored at -
80oC.  
Sample analysis was performed by adding one part 10X SDS sample buffer (50 
mM Tris–HCl (pH=6.8), 12% (vol/vol) glycerol, 2% (wt g/vol ml) SDS, 1% DTT, 0.01% 
(wt g/vol ml)bromophenol blue) to 9 parts of the cell lysate. Samples were heated at 
100oC for 5 min and subsequently loaded on a 10% acrylamide SDS-polyacrylamide gel. 
3 µL of SeeBlue Plus2 Prestained Standard (Invitrogen) was loaded into a separate lane 
as a size marker. Different volumes of lysate and loading buffer were added to each lane 
up to a total volume of 30 µL to adjust for equal protein loading. The gel was run at 50 
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mA for ~ 1 hr and transferred in transfer buffer and apparatus to nitrocellulose.  
Immunoblotting and imaging was performed as previously described using an anti-
phospho P44/42 antibody (Cell Signaling Technology to detect phosphorylated Fus3 and 
anti-Cdc28 as a loading control (Sc-53, Santa Cruz Biotechnology, Inc,  Santa Cruz, CA)  
[39].   
 
Calculating relative Ste4 and Msg5 expression levels 
For constitutive expression of Ste4 and Msg5, each construct’s promoter strength 
(Supplementary Figure 2.2) was multiplied by the switch percent expression at the 
appropriate ligand concentration. Each value was normalized to expression calculated 
from pHIGH-ON (the highest expression in these assays). For feedback expression, 
normalized pathway activity values (pFUS1-GFP) were taken as a proxy for the strength 
of pFUS1-Ste4 or pFUS1-Msg5 expression. These values were evaluated as a measure 
the promoter strength and, as for constitutive expression, multiplied by the switch percent 
expression at the appropriate ligand concentration. Each value was normalized to 
expression calculated from pHIGH-ON.   
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 Supplementary figures 
 
Supplementary Figure 2.1. Engineered strain linearly increases the mean level of expression from the 
galactose-inducible promoter in response to increasing galactose. A. Histograms for the wild-type (WT) 
strain show that the mean levels of expression do not significantly change in response to increasing levels 
of galactose. In the engineered strain (ΔGAL2), histograms demonstrate that the mean fluorescence 
increases linearly with galactose concentration.  In both strains, the percentage of cells in the high 
expression population increases as galactose levels increase. Arrows indicate direction of increasing 
galactose concentration. Cellular fluorescence was measured via flow cytometry 6 hours post-induction 
with galactose from cells harboring a construct bearing pGAL1-Fus3-GFP. Histograms are from single 
samples and are representative of three replicates. B. Mean fluorescence levels of GFP from cells bearing a 
plasmid with pGAL1-GFP. Assays were performed as described previously. Data represents mean of three 
replicates with the 0% (noninduced) control subtracted and values normalized to pHIGH-GFP expression 
levels. Standard deviation is used for the error bars.  
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Supplementary Figure 2.2. Promoter characterization. Promoter characterization is critical for placing 
the regulators at the appropriate levels of expression. Mean values of viable cells were calculated and 
normalized by the value of pHIGH.  Not shown on the graph is pHIGHEST which is more than 6 times 
higher than pHIGH (reference TEF1 library).  pLOW refers to pADH1, pMED to pCYC1, pHIGH to 
pTEF1mutant7 and pHIGHEST to pTEF1. pFUS1 is the mating-responsive promoter. GFP values were 
determined in the absence of α factor (pFUS1-) and at saturating concentration (100 nM , pFUS1+) three 
hours following stimulation.  
 
 
Supplementary Figure 2.3. Range of switch expression strengths. A. Theophylline-responsive switches’ 
basal levels, the expression levels in the absence of ligand, range from 3% to 40% of the ON control. S3 
has the highest switch activation ratio (SAR) at 5.7 . SAR is the ratio of expression levels in the presence of 
ligand to the level in the absence of ligand.  B. Tetracycline-responsive switches’ basal levels range from 
3% to 8%.  S3tc and S4tc have similar high SARs at 5.2 and 5.1, respectively.  
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Supplementary Figure 2.4. Constitutive expression with low-strength promoter shows high pFUS1-
GFP levels, yet switches fail to cross the phenotypic transitory range. A. Counterintuitively, higher 
pFUS1-GFP resulted from Ste4 expression from the LOW promoter compared to either the MED or HIGH 
promoter. Halo assays demonstrated similar phenotypic outcome across the range. B. Ste4 expression from 
the LOW promoter and paired with a range of theophylline-responsive switches shows weak routing to the 
promiscuous fate. As switch strength increases, cell growth slowly diminishes but ligand-induced routing to 
the promiscuous fate is not observed. The threshold to the promiscuous fate is postulated to be above the 
pLOW-Ste4-ON expression levels.  
Supplementary Figure 2.5. Theophylline-inducible positive network diverters mirror response of 
tetracycline-responsive diverters. A. Ste4 expression from pHIGH paired with theophylline-responsive 
switches shows that pathway activity increases across the range up to S4. Above S3 expression levels, 
pathway activity as measured by pFUS1-GFP drops. Addition of theophylline increases pathway activity 
for each switch construct up to S3. For S3, plate assays in the absence of theophylline show a wild-type 
halo, while at 5 mM theophylline cells adopt the promiscuous phenotype. B. Constructing a positive 
feedback loop amplifies ligand-induce phenotype switching. S3 shows theophylline-induced phenotype 
switching.  
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Supplementary Figure 2.6. Selection of mating-resistant cells occurs over time at superthreshold 
levels of positive feedback. A. Pathway activity drops over time for cells grown at super-threshold levels 
of positive feedback but not at low levels of positive feedback. Cells expressing the OFF state control with 
pFUS1-Ste4 show constant, low levels of pathway activity whether grown in the presence (+) or absence (-) 
of tetracycline for 2 days. S4tc shows normal increases in pathway activity when triggered with tetracycline 
on Day 1 and Day 3. However, cells triggered after 2 days growth in tetracycline, at superthreshold levels 
of positive feedback, do not significantly upregulate pathway activity. Instead, these cells adopt a low 
pFUS1-GFP profile. Cells were inoculated overnight and on Day 1 back-diluted into the indicated 
concentration of tetracycline. After 6 hours, fluorescence values for GFP were measured by flow cytometry 
as described previously. Cells were grown in the presence (+) or absence (-) of tetracycline another 18 
hours before back-dilution on Day 2. Cells were then grown 24 hours, back diluted in the presence or 
absence of tetracycline.  After 6 hours, fluorescence levels were measured. B. Constitutively expressed 
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RFP acts as a plasmid marker and indicator of expression from the plasmid. RFP plasmid marker data do 
not show a correlation between selective pressure and RFP values. Cells experiencing strong selective 
pressure do not reduce or eliminate expression from the plasmid more than at low selective pressure. These 
data suggest that mating-resistant cells evade the arrest-inducing program by a method other than 
jettisoning the plasmid. RFP fluorescence was determined by spectrophotometer plate reader with 
excitation at 587 nm and emission 610 nm. RFP values were normalized by cells density as measured by 
absorbance at 600 nm. Final values were computed by dividing by the non-RFP fluorescent control at the 
corresponding tetracycline concentration.  C. Halo assays with cells plated in the presence or absence of 1 
mM tetracycline after 3 days of growth. pFUS1-Ste4-S4tc shows that cells maintain routing ability after 3 
days when grown in the absence of tetracycline (S4tc-). Cells bearing pFUS1-Ste4-S4tc grown in the 
presence of tetracycline (S4tc+) show resistance to pheromone-induced cell cycle arrest, but still respond to 
tetracycline by modestly reducing cell growth.  The OFF state control maintains normal halo formation in 
the presence or absence of tetracycline.  
 
 
Supplementary Figure 2.7. Constitutive expression of Msg5 routes cells to for entire range of 
promoter strengths. Within the range of promoter strengths, Msg5 expression is above the threshold 
required for routing to the chaste fate.  
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Supplementary Figure 2.8. Histograms show population distribution differences for constitutive and 
feedback network diverters. A. Histogram for pHIGH Msg5 ON results in a significant increase in the 
low pFUS1-GFP population relative to OFF. B. A low pFUS1-GFP population is minimal in both ON and 
OFF controls for pFUS1-Msg5. C. Histograms evaluating only the high pFUS1-GFP population for 
pHIGH-Msg5 ON and OFF has populations that mirror pFUS1-Msg5 ON and OFF, respectively, in D.  
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Supplementary Figure 2.9. Neglecting the low pFUS1-GFP population, both feedback architectures 
show similar mean levels of pathway activity are required for diverting pathway response to the 
chaste phenotype. Mean values were calculated excluding the low pFUS1-GFP population. 
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Supplementary Figure 2.10. Tracing the pathway response curve to constitutive Msg5 expression 
including the low GFP population shows similar transitory range for fate divergence. A. Pathway 
activity significantly decreases from 1% to 10%. B. Above 8% expression cells adopt the chaste fate. Plate 
data correspond to points with numbered circles in A selected from the pHIGH-SX data set (Figure 8A). 
Mean values of pathway activity were calculated including the low pFUS1-GFP population. Relative Msg5 
expression was calculated from the relative promoter strengths (Supplementary figure 1) paired with the 
various switches (Supplementary Figure 2) relative to the pHIGH promoter paired with the ON switch 
control. 
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Supplementary Figure 2.10. Theophylline-inducible negative network diverters of different 
architectures conditionally route cells to the chaste phenotype. 
 
 
 
Supplementary Figure 2.11. Original plasmids for construction of molecular network diverter and 
reporters. A. pCS321 B. pCS1128.  
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Supplementary Figure 2.12. A. pCS1124 B. pCS1391  
  
A B
II-59 
 
 
Supplementary tables 
Supplementary Table 2.1 GFP plasmids 
 
pCS # pKG#  Cassette 3'UTR Marker
1128 pGAL1-YEGFP-CYC1t sTRSV Ctrl TRP
321 pGAL1-YEGFP-CYC1t Empty URA
1124 pFUS1 -YEGFP-CYC1t Empty URA
1585 pTEF1 -YEGFP-CYC1t Empty URA
79 pTEF7 -YEGFP-CYC1t Empty URA
80 pCYC1 -YEGFP-CYC1t Empty URA
78 pADH1 -YEGFP-CYC1t Empty URA
74 pSTL1-yEGFP-CYC1t Empty URA
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Supplementary Table 2.2 Primer sequences
 
Insert or PCR 
Product Primer Name Sequence
pTEF7-FWD  5’- AA GAGCTC ATA GCT TCA AAA TGT CTC TAC TCC TTT TT
pTEF7-REV
5’- AAA GGATCC AAC TTA GAT TAG ATT GCT ATG CTT TCT 
TTC C
pDS71.FUS1-FWD 5'-TTT GCGGCCGC CCA ATC TCA GAG GCT GAG TCT
pDS71.pFUS1-REV 5'-TTT GGATCC TTT GAT TTT CAG AAA CTT GAT GGC
pADH1-FWD 5’- AA GAGCTC AGC TCG ATA TCC TTT TGT TGT TTC C
pADH1-REV
5’- AA GGATCC ATT GTA TGC TTG GTA TAG CTT GAA ATA TTG 
TG
pCYC1-FWD  5’- AA GAGCTC CTC GGT ACC CTA TGG CAT GCA TGT
pCYC1-REV 5’- AAA GGATCCACGAATTGATCCGGTAATTTAGTGTGTG
pSTL1-FWD
5'-AA GAGCTC GAT TCT GAA ATA CTC CTT TTA CAA CCT TTG 
C
pSTL1-REV 5'-AAA GGATCC GGT CTA AAA CTT TCT ATG TTC TAT TTT TC
Ste4.k2.FWD
5’- AAA GGATCC A AT TAA TA ATG GCA GCA CAT CAG ATG 
GAC 
Ste4.REV 5'-AAA  CCTAGG CTATTGATAACCTGGAGACCATA
Ste50. k2.FWD  5’ - AAA GGATCC A AT TAA TA ATG GAG GAC GGT AAA CAG G
Ste50.REV  5- AAA CCTAGG TTA GAG TCT TCC ACC GGG G
Ste11.K2.FWD
5'-AAAAAA  GGATCC ATTAAATA ATG GAA CAG ACA CAA 
ACA GCA GAG
Ste11.Stop.REV 5'- AAAA  CCTAGG TCA AATTATGTGTGCATCCAGCCATGGA
Ste7.K2.FWD
5'-AAAAAA  GGATCC ATTAAATA ATG TTT CAA CGA AAG 
ACT TTA CAG AGA AGG
Ste7.AvrII.REV 5’-  AAAAA CCTAGG TCA ATG GGT TGA TCT TTC CGA T
Fus3.K2.FWD
5'-AAAAAA  GGATCC ATTAAATA ATG CCA AAG AGA ATT 
GTA TAC AAT ATA TCC AG
Fus3.A. STOP.REV
5'-AAAAAA  CCTAGG CTA ACTA AAT ATT TCG TTC CAA ATG 
AGT TTC TTG AGG
MSG5.K2.FWD 5'- AAA GGATCC A AT TAA TA GTGCACATGCAATTTCAC
Msg5.REV 5'-AAAA  CCTAGG TTAAGGAAGAAACATCATCTG
Hog1.FWD 5'-AAA GGATCC ATG ACC ACT AAC GAG GAA TTC ATT AGG A
Hog1.k2.FWD
5'-AAA GGATCC A AT TAA TA ATG ACC ACT AAC GAG GAA 
TTC ATT AGG A
Hog1.REV 5'-AAAA  CCTAGG TTACTGTTGGAACTCATTAGCG
Pbs2. k2.FWD
5’ - AAA GGATCC A AT TAA TA ATG GAA GAC AAG TTT GCT 
AAC CTC
Pbs2.REV  5- AAA CCTAGG CTA TAA ACC ACC CAT ATG TAA TGC CG
Pbs2. Chr.FWD  5’ - GCAGATCGAGACGTTAATTTCTC
Pbs2. Chr.REV 5- TCACGTGCCTGTTTGCTTTT
Ptc1.k2.FWD
 5’- AAA GGATCC A AT TAA TA ATG AGT AAT CAT TCT GAA 
ATC TTA GAA AGG C
Ptc1.REV  5- AAA CCTAGG TTA GAG GAA GAC AAC CAT GAC C
Ptc1.Chr.FWD  5’- GGCACTGCATTTATCTTTTAAAAATC
Ptc1. Chr.REV 5- TTGCGCGGTTTATAACGGAT
pCYC1
pSTL1
pTEF7
pADH1
pFUS1
Ste4
Ste50
Ste11
Ste7
Ptc1
Genomic Pbs2 
PCR product
Hog1
Pbs2
Fus3
Msg5
Genomic Ptc1 
PCR product
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Supplementary Table 2.3 Galactose-titration plasmids 
 
 
Supplementary Table 2.4 Primers for mutagenesis 
 
 
 
 
 
 
 
 
pCS # pKG#  Cassette 3'UTR Marker
1625 pGAL1-Ste4-CYC1t sTRSV Ctrl TRP
1483 pGAL1-Ste11-CYC1t sTRSV Ctrl TRP
1484 pGAL1-Ste7-CYC1t sTRSV Ctrl TRP
1485 pGAL1-Fus3-CYC1t sTRSV Ctrl TRP
1486 pGAL1-Msg5-CYC1t sTRSV Ctrl TRP
76 pGAL1-Ste50-CYC1t sTRSV Ctrl TRP
77 pGAL1-Pbs2-CYC1t sTRSV Ctrl TRP
158 pGAL1-Pbs2-CYC1t sTRSV Ctrl URA
157 pGAL1-Hog1-CYC1t sTRSV Ctrl TRP
pGAL1-Ptc1-CYC1t sTRSV Ctrl TRP
Primer Name Sequence Purpose
Ste4. XhoImut.FWD GTCACTGGTGTGCGATCGAGTCCAGATGG
Ste4. XhoImut.REV CCATCTGGACTCGATCGCACACCAGTGAC
Fus3-XHO.FWD GGAGAAGATGTTCCCTAGAGTCAACCCGAAAGG
Fus3-XHO.REV CCTTTCGGGTTGACTCTAGGGAACATCTTCTCC
Ste7-AvrII.FWD GTAACTGGAGAGTTTCCACTAGGTGGGCATAACGA
Ste7-AvrII.REV TCGTTATGCCCACCTAGTGGAAACTCTCCAGTTAC
pCS1441.XhoImut.FWD ATGCTGGCGGCCGCATCGAGAGATCTAAG
pCS1441.XhoImut.REV CTTAGATCTCTCGATGCGGCCGCCAGCAT
Remove XhoI 
from 
disintegrators
Remove XhoI 
in Ste4
Remove XhoI 
in Fus3
Remove 
AvrII in Ste7
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Supplementary Table 2.5 Switch sequence information 
 
 
 
Switches Alias Sequence
Basal Expression                      
(0 mM)
Standard Induced 
Expression                                 
(5 mM or 1 mM)
ON STRSV Ctrl
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTAC
GTGAGGTCCGTGAGGACAGAACAGCAAAAAGAAAAAT
AAAAACTCGAG 100.0% 100.0%
OFF sTRSV
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTG
ATGAGTCCGTGAGGACGAAACAGCAAAAAGAAAAATA
AAAACTCGAG 1.2% 1.2%
S1
L2b8-a1         
(aka L1N7-1)
AAACAAACAAAGCTGTCACCGGAATCAAGGTCCGGTCT
GATGAGTCCGTTGTCCATACCAGCATCGTCTTGATGCCCT
TGGCAGGGACGGGACGGAGGACGAAACAGCAAAAAGA
AAAATAAAAACTCGAG 3.0% 8.0%
S2
L2b8-a1-t41 
(aka L1N7-41)
AAACAAACAAAGCTGTCACCGGAATCAAGGTCCGGTCT
GATGAGTCCGTTGCGTATACCAGCATCGTCTTGATGCCCT
TGGCAGACGGTAGACGGAGGACGAAACAGCAAAAAGA
AAAATAAAAACTCGAG 3.6% 12.7%
S3
L2b8-ta47   
(aka S47)
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTG
ATGAGTCCGTTGAGTATACCAGCATCGTCTTGATGCCCT
TGGCAGACTGTATACGGAGGACGAAACAGCAAAAAGA
AAAATAAAAA 6.1% 33.6%
S4
L2b8             
(aka L2b12)
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTG
ATGAGTCCGTTGTCCATACCAGCATCGTCTTGATGCCCTT
GGCAGGGACGGGACGGAGGACGAAACAGCAAAAAGAA
AAATAAAAACTCGAG 9.1% 36.7%
S5 L2b1
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTG
ATGAGTCCGTGTCCATACCAGCATCGTCTTGATGCCCTTG
GCAGGGACGGGACGAGGACGAAACAGCAAAAAGAAAA
ATAAAAA 39.8% 75.3%
S1tc L2b12tc-11
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTG
ATGAGTCCGTTGTTGAAAACATACCAGATTTCGATCTGG
AGAGGTGAAGAATTCGACCACCTCATTTCAACGGAGGA
CGAAACAGCAAAAAGAAAAATAAAAACTCGAG 3.7% 4.8%
S2tc L2b8tc-a1 (aka 
L2b12tc-1)
AAACAAACAAAGCTGTCACCGGAATCAAGGTCCGGTCT
GATGAGTCCGTTGTCCAAAACATACCAGATTTCGATCTG
GAGAGGTGAAGAATTCGACCACCTGGACGGGACGGAGG
ACGAAACAGCAAAAAGAAAAATAAAAACTCGAGCC 3.0% 10.8%
S4tc L2b8tc (aka 
L2b12tc)
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTG
ATGAGTCCGTTGTCCAAAACATACCAGATTTCGATCTGG
AGAGGTGAAGAATTCGACCACCTGGACGGGACGGAGGA
CGAAACAGCAAAAAGAAAAATAAAAACTCGAG 8.4% 43.9%
S3tc
L2b12tc-NheI-
L2bOFF1 (aka 
Stc-OFF1)
AAACAAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTG
ATGAGTCCGTTGTCCAAAACATACCAGATTTCGATCTGG
AGAGGTGAAGAATTCGACCACCTGGACGGGACGGAGGA
CGAAACAGCAAAAAGAAAAATAAAAAGCTAGGAAAC
AAACAAAGCTGTCACCGGATGTGCTTTCCGGTCTGATGA
GTCCGTGTTGCTGATACCAGCATCGTCTTGATGCCCTTGG
CAGCAGTGGACGAGGACGAAACAGCAAAAAGAAAAAT
AAAAA    4.2% 21.2%
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Supplementary Table 2.6 Msg5 plasmids 
 
 
 
 
 
 
 
 
 
 
 
pCS # pKG# Promoter 3'UTR
88 pADH1 Empty
145 pCYC1 Empty
89 pTEF7 Empty
1487 pFUS1 Empty
200 pADH1 ON
154 pCYC1 ON
123 pTEF7 ON
121 pFUS1 ON
199 pTEF1 ON
pCS # pKG# Parent 3'UTR
121 pCS1487 ON
45 pCS1487 S5
48 pCS1487 S4
286 pCS1487 S3
220 pCS1487 S2
168 pCS1487 S1
137 pCS1487 OFF
pCS # pKG# Parent 3'UTR
123 pKG89 ON
112 pKG89 S5
122 pKG89 S4
293 pKG89 S3
219 pKG89 S2
169 pKG89 S1
136 pKG89 OFF
pX-Msg5-CYC1t
pFUS1-Msg5-CYC1t
pTEF7-Msg5-CYC1t
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Supplementary Table 2.7 Ste4 plasmids 
  
pKG# Promoter 3'UTR
90 pADH1 Empty
87 pTEF7 Empty
84 pFUS1 Empty
159 pADH1 ON
203 pCYC1 ON
144 pTEF7 ON
173 pFUS1 ON
201 pTEF1 ON
pKG# Parent 3'UTR
228 pKG227 ON
234 pKG227 S4tc
298 pKG227 S3tc
227 pCS2094 S2tc
274 pKG227 S1tc
233 pKG227 OFF
pKG# Parent 3'UTR
173 pKG84 ON
215 pKG84 S5
64 pKG84 S4
161 pKG84 S2
176 pKG84 S1
124 pKG84 OFF
95 pKG84 S5tc
189 pKG84 S4tc
179 pKG84 S2tc
180 pKG84 S1tc
pKG# Parent 3'UTR
144 pKG87 ON
272 pKG87 S4tc
296 pKG87 S3tc
177 pKG87 S2tc
178 pKG87 S1tc
152 pKG87 OFF
213 pKG87 S5tc
214 pKG87 S4tc
153 pKG87 S2tc
198 pKG87 S1tc
pKG# Parent 3'UTR
159 pKG90 ON
86 pKG90 S5
99 pKG90 S4
172 pKG90 S2
171 pKG90 S1
160 pKG90 OFF
pKG# Parent 3'UTR
321 pCS1128 S4tc
295 pCS1128 S3tc
188 pCS1128 S2tc
182 pCS1128 S1tc
181 pCS1128 OFF
pTEF7-Ste4-CYC1t
pADH1-Ste4-CYC1t
pX-Ste4-CYC1t
pTEF7-Ste4-CYC1t
pFUS1-Ste4-CYC1t
pFUS1-Ste4-CYC1t
II-65 
 
 
Supplementary Table 2.8 Plasmids for strain construction 
  
Supplementary Table 2.9 Yeast strains 
  
Supplementary Table 2.10 Primers for integration 
  
 
 
 
 
 
pCS # pKG#  Cassette Integration Loci Marker
1543 pCS1439 with XhoI removed; disintegrator [37] FCY1 URA
98 pCS1543 + pSTL1 -YEGFP-CYC1t FCY1 URA
1391 LoxP Integrating plasmid [35] Primer-specific G418
100 pCS1391+pFUS1-yEGFP-CYC1t Primer-specific G418
CSY# KGY#
364
408
532
840 144
145
139 CSY408 FCY1::pSTL1-GFP-CYC1t
CSY364  Δgal21::pFUS1-yEGFP3-CYC1t-loxP-KanR
Description
EY1119 from [36]; W303a ∆sst1 ∆kss1::HIS3 
CSY364  Δgal2::pFUS1-GFP-CYC1t-loxP-KanR
CSY364  Δtrp1::pFUS1-yEGFP3-CYC1t-loxP-KanR
CSY364  Δgal2::KanR
Loci Sequence Direction
ATGCACCTTATTCAATTATCATCAAGAATAGTAATAGTTAAGTAAACACAAGATTAACATAGATTGTACTGAGAGTGCAC FWD
ATGATAATTAAAATGAAGAAAAAACGTCAGTCATGAAAAATTAAGAGAGATGATGGAGCGCGACTCACTATAGGGAGACC REV
GTATACGTGATTAAGCACACAAAGGCAGCTTGGAGTATGTCTGTTATTAATTTCACAGGAAGATTGTACTGAGAGTGCAC FWD
TTGCTTTTCAAAAGGCCTGCAGGCAAGTGCACAAACAATACTTAAATAAATACTACTCAGCGACTCACTATAGGGAGACC REV
GAL2
TRP
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Chapter 3 
 
Constructing synthetic gene networks to control decision-making in the 
yeast mating pathway 
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Abstract 
 Cells utilize internal molecular networks to direct cell fate via the integration and 
processing of extracellular information. Control of these decision-making pathways 
offers the potential to intervene in aberrantly activated programs as well as direct 
complex, multicellular tasks such as tissue development. Programming of diverse cellular 
behaviors may be accomplished by the development of synthetic circuits capable of 
activating and attenuating the response from internal signaling pathways. Previously 
constructed positive and negative molecular network diverters encoding a single pathway 
regulator demonstrated small-molecule-dependent routing to divergent alternative fates.  
However, simultaneous integration of these previously demonstrated positive and 
negative diverters results in diverter antagonism and fails to allow dual-routing to both 
alternative fates. In this work, we demonstrate the construction of more complex diverter 
networks with integrated positive and negative routing functions that allow the 
conditional induction of alternative cell fates based on small-molecule input. By 
constructing networks with two differentially regulated expression modules composed of 
stringent RNA-based controllers we were able to limit diverter antagonism, amplify 
pathway activation, and induce pathway attenuation allowing genetically identical cells to 
be conditionally routed to one of three fates in response to environmental cues. In 
constructing these networks we identified sensitive parameters for balancing and tuning 
diverter function and demonstrate the rational tuning of both diverters to allow dual-fate 
routing. Further, we demonstrate the construction of networks that suppress subthreshold 
noise in gene expression to robustly amplify differences in environmental input and 
achieve enhanced resolution between triggered and non-triggered cell populations. 
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Expanding synthetic control to mammalian systems via the elucidated molecular network 
diverter strategies and principles will facilitate the construction of sophisticated synthetic 
programs to achieve higher-order cellular functions such as the patterning of cell fate, 
tissue homeostasis, and autonomous immune surveillance. 
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Introduction 
Biological systems process environmental signals via native regulatory networks 
directing complex processes such as development, tissue homeostasis, and the immune 
system response [1]. The temporal and spatial distribution of molecular signals enables 
responses to be coordinated in time and space via the distributed processing of these 
signals by individual cells, resulting in orchestrated system responses such as 
organogenesis, wound healing, and pathogen elimination [2-4]. Synthetic circuits that can 
interface with and redirect these processes offer the potential to orthogonally regulate 
complex cellular behaviors. However, construction of an interface that provides for 
specific pathway information to be translated via synthetic circuitry into changes in the 
native network still poses a major challenge in synthetically regulating cell fate [5, 6]. 
Further, synthetic circuits that can be tuned via their component parts as well as 
architecture will facilitate expansion of such circuits to native networks with a range of 
associated properties [7]. The development of parts that allow orthogonal tuning of 
system performance without modification of other potentially constrained regulatory 
elements (e.g., promoters, genes) will enable greater flexibility in adapting synthetic 
circuits to be regulators of cellular behavior. 
In previous work, a type of synthetic gene circuit, referred to as a molecular 
network diverter, was applied to controlling signaling and fate decisions in a model 
MAPK pathway in response to distinct environmental triggers. Specifically, we 
constructed positive and negative diverters that were used to turn the activity of the 
Saccharomyces cerevisiae mating pathway on and off, respectively. The positive network 
diverter activated the pathway in the absence of the canonical pathway input, thereby 
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routing cells to the alternative “promiscuous” fate. The negative network diverter 
inactivated the pathway even in the presence of the canonical pathway input 
(pheromone), routing cells to the “chaste” fate. The positive and negative diverters are 
programmed to respond to distinct small-molecule inputs, allowing independent channels 
by which to activate each diverter. Thus, we propose integrating positive and negative 
diverters within the same cell to achieve conditional routing of cells to three distinct cell 
fates. In the absence of either environmental trigger, cells will adopt the wild-type fate as 
the diverters run quiescently. However, when called by their respective triggers, each 
diverter is intended to route cells to the programmed alternative fates: chaste or 
promiscuous. 
Molecular network diverters are composed from expression modules containing 
three genetic parts; a promoter, a pathway regulator, and a RNA-based controller (Figure 
3.1). The properties of these parts dictate the function and performance of the diverter. 
The sign of the diverters, positive or negative, is determined by whether the pathway 
regulator activates or attenuates pathway activity in the network, respectively. The 
promoter determines the mode of expression, feedback or nonfeedback, as well as the 
strength of the diverter activity. RNA controllers provide a second layer of control by 
which to tune diverter activity and allow the molecular network diverter to respond to 
environmental signals. Small-molecule-responsive RNA-based controllers, also called 
RNA switches, are an engineered class of non-coding RNA that allows for conditional 
control from any promoter-gene pair via a chemical trigger [8]. Choice of the switch 
specifies the small-molecule trigger that activates the diverter and tunes the diverter 
activity. Combining these three parts together in various configurations generates a 
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variety of expression modules. Dependent on the context of implementation, these 
expression modules can perform independently as molecular network diverters or be 
integrated into larger networks of synthetic circuitry. Previous work has shown that 
single-module diverters, composed of one expression module, can be implemented to 
conditionally route cells to an alternative fate. However, to access both alternative fates 
the simultaneous integration of positive and negative diverters is required.  
 
Figure 3.1. Composition of an expression module from well-defined parts.  Molecular network 
diverters contain various expression modules which are composed of a promoter, a pathway regulator, and 
a RNA-based controller, also called a switch. The promoter specifies the expression mode (e.g., 
constitutive or feedback) which determines the network connectivity. The promoter and switches combine 
to determine the expression strength and thus the activity of the diverter. Additionally, switches specify 
which small-molecule input regulates expression and the range of expression across ligand concentrations. 
The pathway regulator’s interaction with the native molecular network determines the pathway response 
curve. The pathway response curve can be altered by changes in network connectivity due to feedback 
expression of regulators.  
One potential challenge that may be encountered in integrating network diverters 
encoding opposing functions is antagonization, or competition between the opposing 
activities encoded in the diverters. Antagonization may hinder the diverter’s ability to 
route cells to both alternative fates. Specifically, the positive and negative diverters 
measurably change the basal activity of the pathway in the absence of their respective 
triggers. While these sub-threshold changes in activity are insufficient to route cells to an 
Regulator
pX
Regulator
pX
+ +Parts
Pathway RegulatorPromoter RNA-based controllers
Device
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alternative fate, they may antagonize the activity and routing capability of an opposing 
diverter. Issues with basal expression levels from synthetic regulatory networks 
impinging on circuit performance have been previously reported [9-11]. One strategy 
used to increase the stringency associated with a synthetic network is to incorporate 
additional layers of post-transcriptional control via noncoding RNA control elements [5, 
12, 13]. While strategies for reducing basal expression may also reduce triggered 
expression levels, modification of the regulatory network architecture through the 
incorporation of feedback loops may supplement the reduction in triggered expression 
levels via the amplification of the pathway response to the trigger.  
Natural biological systems utilize feedback architectures to ensure proper function 
of diverse cellular processes. For example, positive and negative feedback loops are used 
to facilitate robustness in developmental processes by introducing ultrasensitivity and by 
maintaining homeostasis, respectively, [14-16]. More complex control architectures, such 
as coherent and incoherent feedfoward loops, have been shown to function as persistence 
detectors, pulse generators, and response accelerators in natural and synthetic systems 
[17-19]. The proper configuration of such regulatory architectures within developmental 
pathways is posited to contribute to the robustness of multicellular organization critical 
for higher eukaryotes [14, 20-22]. For example, modeling of cell fate determination in 
flowers has predicted that network architecture in these systems constrains pathway 
activity to a few stable states independent of the chosen initial conditions or model 
parameters [23]. In addition, synthetic circuits that reshape natural molecular pathways 
have shown that cell fate can be routed by altering the native network topology [24]. 
Thus, network topology itself can ensure robust adoption of particular cell fates.  
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 In this chapter, we show that simultaneously integrating positive and negative 
diverters in the yeast mating pathway, optimized for individual routing functions, fails to 
achieve routing to both alternative fates. In particular, routing to the promiscuous fate is 
hampered across the range of activities exhibited by the positive feedback diverters when 
paired with any negative diverter. Resistance introduced by basal level expression of 
Msg5 from the negative (resistance) diverter may prevent pathway activation above the 
requisite threshold to trigger positive feedback-induced amplification. The addition of a 
positive expression (booster) module to the positive feedback diverter effectively 
counteracts this network antagonism to construct the amplifying diverter (Figure 3.2). 
The amplifying diverter allows promiscuous routing in the presence of the resistance 
diverter. However, the resistance diverter is unable to route cells to the chaste fate when 
implemented with the amplifying diverter. The data indicate that at high levels of 
pheromone, conditions in which positive feedback is amplified, the amplifying diverter 
overwhelms pathway inhibition by the resistance module. The addition of a negative 
feedback module to the resistance diverter results in an attenuating diverter that 
effectively balanced pathway response. Utilizing this double-module strategy, we 
successfully integrated the amplifying and attenuating diverters to achieve dual-fate 
routing to both alternative programmed cell fates. Our work shows that the performance 
of the amplifying and the attenuating diverters is highly sensitive to the strengths of the 
positive feedback and resistance modules. Further, our findings have important 
implications for the construction of networks that suppress noise amplification, amplify 
differences in environmental stimuli, and trigger robust cellular phenotypic programs in 
the face of antagonistic signals. 
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Figure 3.2. Molecular network diverters are composed from single- and double-expression modules 
that allow fate-routing dependent on small-molecule input. Six different types of diverters were 
constructed. The positive feedback diverter, the booster diverter, and the amplifying diverter represent the 
three types of positive diverters. The resistance diverter, the negative feedback diverter, and the attenuating 
diverter represent the three types of negative diverters. Diverter performance is determined by the 
composition of their expression modules. Four of the diverter types are single-module diverters containing 
only one expression module. The amplifying and the attenuating diverters are double-module diverters. The 
amplifying diverter is constructed with a positive feedback module and booster module. The attenuating 
diverter contains a resistance module and a negative feedback module.   
 
Results 
Simultaneous expression of single-module positive and negative diverters fails to 
route cells to either fate 
The original molecular network diverters were optimized to independently route 
fate decisions in the yeast mating pathway and exhibited different regulatory 
architectures. The positive diverter integrated a positive network regulator (Ste4) with a 
feedback promoter (pFUS1) and a tetracycline-responsive RNA switch to compose the 
positive feedback diverter which activates pheromone-independent signaling through the 
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pathway in the presence the tetracycline, resulting in the so-called promiscuous fate. The 
negative diverter integrated a negative network regulator (Msg5) with a constitutive 
promoter (pHIGH) and a theophylline-responsive RNA switch constructing the resistance 
diverter to inhibit signaling through the pathway in the presence of theophylline even in 
the presence of pheromone, resulting in the so-called chaste fate.  
We examined an initial dual diverter architecture based on integrating the positive 
and negative diverters optimized for independent cell fate routing. To examine optimal 
pairing of diverters encoding antagonistic functions, we paired the positive feedback 
diverter (pFUS1-Ste4-S3tc) with diverse resistance diverters incorporating a set of RNA 
switches exhibiting a range of activities (pHIGH-Msg5-Sx) (Supplementary Figure 3.1). 
Pathway activity was determined by measuring GFP expression levels from a 
transcriptional fusion construct (pFUS1-GFP, GFP fused to a mating responsive 
promoter). Fate routing was determined by observing mating-associated cell cycle arrest 
via halo assays (Materials and Methods). Cells adopting the chaste fate exhibit reduced 
halo formation as cells resist pheromone-induced cell cycle arrest. Cells adopting the 
promiscuous fate demonstrate persistent, pheromone-independent cell-cycle arrest 
outside the canonical halo region as indicated by reduced cell growth across the entire 
plate. The results indicate that within the dual diverter architecture the two diverters 
antagonize one another, diminishing diverter performance and leading to less robust fate 
switching (Figure 3.3). While several dual diverter configurations preserve weak routing 
to the chaste fate, promiscuous routing was not observed from any of the dual diverter 
configurations. In addition, pathway activation was not improved by increasing the 
strength of the positive feedback module (Supplementary Figure 3.2). The data indicate 
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that switching to the promiscuous fate may be hindered by basal expression levels of 
Msg5 from the resistance module. Resistance may inhibit superthreshold pathway 
activation, which is necessary for amplification via the positive feedback loop, resulting 
in low pathway activation for a significant fraction of cells even in the presence of the 
positive molecular trigger (tetracycline).  
  
Figure 3.3. Integration of positive and negative single-module diverters fails to achieve dual-fate 
routing. A. A single-module positive feedback diverter, pFUS1-Ste4-S3tc, fails to route to the promiscuous 
fate in the presence of resistance diverters incorporating a range of switch strengths.  The Blank control 
bears a plasmid without either diverter. Increasing positive feedback strength does not improve pathway 
activation from the positive diverter (Supplementary Figure 3.1).  B. Negative diverters incorporating 
constitutive expression from pHIGH of Msg5 and switches of varying strength show significant reduction 
of pathway activity, but weak routing to the chaste fate in halo assays.  
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Building network architectures to amplify trigger-induced switching to activate the 
mating pathway in the presence of antagonistic signals 
 We explored alternate architectures for the positive diverter to support increased 
pathway activation. A number of strategies can be implemented for increasing the 
activity of the positive feedback diverter, including modifying the switch or promoter in 
the positive feedback module to exhibit increased activity, or incorporating an additional 
copy of the positive feedback module. However, such modifications are expected to raise 
the basal levels of Ste4 at high pheromone input, potentially inhibiting the performance 
of the negative diverter. As an alternative strategy, we added a second module encoding 
constitutive expression of Ste4, or a booster module, to the positive feedback diverter to 
construct the amplifying diverter. Addition of the booster module has two notable 
advantages over a second feedback module. First, the booster module is insensitive to the 
resistance imposed by the negative diverter, such that Ste4 expression from this module is 
independent of the negative diverter’s effect on pathway activity. Second, basal 
expression of Ste4 from the booster module is constant across the range of pheromone 
input, such that antagonization of the negative diverter does not increase from this 
module in the absence of its trigger molecule within the high-pheromone input regime. 
Thus, the incorporation of the booster module into the positive diverter architecture offers 
the potential to enhance the performance of the positive diverter, while imposing minimal 
effect on the performance of the negative diverter.  
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Figure 3.4. Addition of booster module to positive feedback diverter enhances fate switching in the presence of 
the resistance diverter. An amplifying diverter with S3tc regulating both expression modules is paired with resistance 
diverters incorporating pHIGH-Msg5 expression with switches of various activities.  Pathway activation via this 
amplifying diverter diminishes as the basal activity of the resistance module increases. Networks constructed with this 
amplifying diverter and low Msg5 resistance (OFF, S2) show enhanced fate switching in halo assays relative to the 
booster diverter. However, for resistance modules with switch basal levels above S2 small-molecule triggered fate 
routing is weaker. “SP” denotes strong promiscuous routing in the plate assays.  
The ability of the amplifying diverter to overcome antagonism from the negative 
diverter and achieve programmed routing to the promiscuous fate was examined. The 
amplifying diverter was composed of a tetracycline-responsive RNA switch regulating 
both expression modules (feedback: pFUS1-Ste4-S3tc; booster: pHIGH-Ste4-S3tc) and 
paired with resistance diverters incorporating a set of theophylline-responsive RNA 
switches exhibiting a range of activities (pHIGH-Msg5-Sx). Pathway activation and fate 
routing were evaluated as described previously. Results demonstrate that pathway 
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activation through the amplifying diverter diminishes as the basal activity of the 
resistance diverter increases (Figure 3.4). Network configurations with the amplifying 
diverter and low-strength resistance modules (i.e., OFF, S2) exhibit enhanced fate 
switching in halo assays relative to the booster module alone. Halo assays indicate that 
small-molecule-triggered routing to the promiscuous fate is noticeably weaker for 
resistance modules exhibiting greater activity. The data support that in the absence of the 
booster module, basal pathway activity in the presence of a resistance module is 
insufficient for amplification of pathway activity via the positive autoregulatory loop 
even in the presence of the molecular trigger (tetracycline). Thus, we postulate that 
increased expression from the booster module initiates increased pathway activity. Once 
the pathway activity crosses the requisite threshold, Ste4 expression is amplified and 
reinforced by the positive feedback module. 
 The pathway activation ratio (PAR) in the absence and presence of the 
environmental trigger provides a metric for evaluating a diverter’s ability to facilitate cell 
fate reprogramming. A large PAR value is generally desirable for regulatory networks 
that route to divergent fates as it indicates a greater difference between the pathway 
activities of triggered and non-triggered cells. However, while the PAR value offers one 
performance metric for evaluating molecular network diverters, it is not a sufficient 
metric to determine a diverter’s ability to route cells to an alternative fate. Diverters may 
achieve moderate PAR values by modifying basal pathway activity, but fail in routing if 
the triggered pathway activity does not cross the threshold for fate routing. Conversely, 
diverters exhibiting modest PAR values may effectively route fate provided they are 
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configured to cross the threshold of fate divergence. An optimal diverter configuration 
achieves both routing capability and a larger PAR value.  
   
Figure 3.5. Pathway activation ratio is enhanced for positive feedback diverters in network 
configurations including a low-strength resistance module. A. Addition of a low strength resistance 
module to the synthetic network increases the PAR value of the positive feedback diverters with and 
without the booster module by lowering basal level expression. B. Pathway activity data for tetracycline 
triggered cells over a range of network configurations indicate that only two configurations sufficiently 
increase pathway activity above the requisite fate switching threshold.  C. Halo assays demonstrate that 
only networks configured with the positive feedback modules (positive feedback diverter and amplifying 
diverter paired low resistance module) strongly route to the promiscuous fate. “SP” and “VSP” denote 
strong and very strong promiscuous routing in the plate assays, respectively.  
The PAR values for positive diverters incorporating a variety of network 
configurations were determined by measuring the ratio of pathway activity in the 
presence and absence of the environmental trigger (tetracycline). Despite activating the 
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pathway sufficiently to route cells to the promiscuous fate, positive feedback diverter 
exhibits a lower PAR value due to the increased basal activity of the pathway associated 
with this diverter (Figure 3.5A). Further, the high basal pathway activity associated with 
the positive feedback diverter provides little resolution between the triggered and non-
triggered populations (Figure 3.6A). The implementation of a positive feedback diverter 
with a low activity resistance diverter reduces the basal pathway activity, thereby 
increasing the PAR value for this network configuration and increasing population 
separation. However, the resistance module also suppresses amplification of pathway 
activity via the autoregulatory loop, thus inhibiting routing to the promiscuous fate 
(Figure 3.6B, Figure 3.5). Robust routing to the promiscuous fate is only achieved when a 
low activity resistance diverter is paired with an amplifying diverter (Figure 3.5B, C), 
resulting in enhanced separation between the triggered and non-triggered populations 
(Figure 3.6C). Altering the network configuration by incorporation of a high activity 
resistance diverter reduces the pathway activity, resulting in a diminished PAR value and 
weaker routing to the promiscuous fate. We postulate that the resistance module enhances 
differentiation between triggered and non-triggered populations by buffering the effect of 
subthreshold variations in Ste4 levels on pathway activity, reducing the amplification of 
noise in the system. Further, the strength of the resistance module modulates the triggered 
output from the amplifying diverter and thus tunes routing to the promiscuous fate. 
Therefore, the ability to rationally tune module and diverter activities is critical for 
configuring network architectures that can cross thresholds of fate divergence in the 
presence of environmental signals. Optimal diverter performance is enhanced by 
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networks that suppress noise amplification and other subthreshold variations in gene 
expression to robustly amplify the appropriate input. 
 
Figure 3.6. Structuring networks to amplify switching by layering positive feedback with a resistance 
module and a booster module.  A. A histogram of pFUS1-GFP for the positive feedback diverter pFUS1-
Ste4-S3tc shows significant overlap between the populations in the presence and in the absence of 
tetracycline, resulting in a low PAR value (1.9). Despite a low PAR value pFUS1-Ste4-S3tc effectively 
routes cells to the promiscuous fate (Figure 3.4) B. Adding the low resistance module to the network 
configuration via pHIGH-Msg5-OFF decreases overlap between the two populations, increasing the PAR 
value (4.4). Yet, this network provides insufficient pathway activation to route to the promiscuous fate 
when trigger with tetracycline (Figure 3.4). C. Addition of a booster module, pHIGH-Ste4-S3tc, to the 
positive diverter constructs the amplifying diverter.  The booster module in the amplifying diverter boosts 
pathway activity, routing cells to the promiscuous fate when triggered. Further, population separation is 
maintained in this configuration as indicated by the high PAR value (3.8) (Figure 3.4).   
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Network configurations that balance positive feedback with negative feedback 
enhance pathway attenuation 
 While addition of the booster module enhances the ability of the positive diverter 
to route cells to the promiscuous fate, the increased basal expression from this amplifying 
diverter diminishes the ability of the resistance diverter to route cells to the chaste fate. 
We postulate that high levels of pheromone leads to amplification of the positive 
feedback loop, such that the positive diverter overwhelms the attenuation provided by the 
resistance diverter. Therefore, we examined the impact of adding a negative feedback 
module to this network to balance the pathway response.  
 To counteract the amplification of pathway activity via the positive feedback 
module in the amplifying diverter, we constructed an attenuating diverter, which 
incorporates a resistance module and a negative feedback module. An amplifying diverter 
was configured with a booster module that incorporated a strong tetracycline RNA switch 
(pHIGH-Ste4-S4tc) and a positive feedback module that incorporated a moderate 
tetracycline RNA switch (pFUS1-Ste4-S3tc). This amplifying diverter was paired with 
various attenuating diverters composed of a resistance module (pHIGH-Msg5-S3) and 
negative feedback modules incorporating a set of theophylline-responsive RNA switches 
exhibiting a range of activities (pFUS1-Msg5-Sx). Pathway activation and fate routing 
were evaluated as described previously. The results indicate that pathway attenuation is 
relatively insensitive to the strength of negative feedback module (Figure 3.7A). While 
GFP levels exhibit moderate changes with increasing negative feedback strength, halo 
assays indicate that these diverters robustly route cells to the chaste fate in the presence 
of theophylline above a threshold of negative feedback strength (S3, S4). In the absence 
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of theophylline, the network maintains normal halo formation for the negative feedback 
module regulated via S3. However, the network composed with the negative feedback 
module regulated by S4 exhibits reduced halo formation even in the absence of 
theophylline. The data indicate that there exists a threshold of negative feedback strength 
residing between the basal expression levels of S3 and S4 at which wild-type and chaste 
fates diverge. 
 
Figure 3.7. Networks configured with an amplifying diverter and various attenuating diverters show 
that pathway attenuation is a weak function of the strength of the negative feedback module. A. An 
amplifying diverter composed of pFUS1-Ste4-S3tc and pHIGH-Ste4-S4tc is paired with attenuating 
diverters incorporating pHIGH-Msg5-S3 and various strength negative feedback modules. While only 
modest changes are observed across the range of strengths for the negative feedback module, the 
attenuating diverter effectively routes to the chaste fate in the presence of the theophylline input when the 
active feedback strength of the negative diverter is at or above S3 levels.  “SC” denotes strong chaste 
routing in the plate assays. B. The positive diverter weakly routes to the promiscuous fate in the presence of 
the tetracycline input when the basal feedback strength of the negative diverter is below S3. The basal 
feedback strength of S3 in the negative diverter is sufficient to inhibit the positive diverter.  
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The incorporation of an attenuating diverter, pairing both a resistance module and 
a negative feedback module, allowed chaste routing in the presence of the amplifying 
diverter. We next evaluated the ability of this dual diverter architecture to activate the 
pathway and route cells to the promiscuous fate in the presence of the positive diverter 
trigger over a range of negative feedback strengths. While GFP levels indicate that the 
amplifying diverter achieves moderate pathway activation within this network 
configuration, routing of fate to the promiscuous phenotype is weak across the range of 
negative feedback modules (Figure 3.7B). Based on these results, we chose to utilize a 
negative feedback module in the dual diverter architecture that provided strong chaste 
routing (pFUS1-Msg5-S3) as we examined tuning other components in the network to 
enhance pathway activation and routing to the promiscuous fate. 
 
The performance of the amplifying and attenuating diverters in dual diverter 
networks are sensitive to the strength of the resistance module 
 To enhance routing to the promiscuous fate in the dual diverter network, we 
examined the impact of tuning the strength of the resistance module. The amplifying 
diverter (positive feedback: pFUS1-Ste4-S3tc; booster: pHIGH-Ste4-S4tc) was paired 
with attenuating diverters composed of a negative feedback module (pFUS1-Msg5-S3) 
and resistance modules incorporating RNA switches exhibiting a range of activities 
(pHIGH-Msg5-Sx). The performance and fate routing function of the dual diverter 
networks with varying resistance modules were characterized. For this dual diverter 
configuration, the amplifying diverter significantly increases pathway activity when 
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paired with weaker resistance modules (S2 and below). Pathway activation is reduced 
and the amplifying diverter is unable to strongly route cells to the promiscuous fate when 
paired with resistance modules of greater activity (S3 and above) (Figure 3.8). The results 
demonstrate that to preserve chaste routing the basal resistance activity must be between 
S2 and S3, indicating a threshold of resistance within this configuration that permits 
promiscuous routing via the amplifying diverter. 
  
Figure 3.8. A dual-module positive diverter shows that pathway activation is sensitive to the activity 
of the resistance module.  Amplifying diverter (positive feedback: pFUS1-Ste4-S3tc; booster: pHIGH-
Ste4-S4tc) paired with various attenuating diverters (negative feedback: pFUS1-Msg5-S3; resistance: 
pHIGH-Msg5-Sx). “SP” denotes strong promiscuous routing in the plate assays. 
 We next evaluated the performance and fate routing of the attenuating diverter 
within the dual diverter network over varying resistance activities. The data demonstrate 
that pathway attenuation is sensitive to the activity of the resistance module (Figure 3.9). 
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Pathway activity drops as resistance increases from low to medium strength, above which 
the effect of resistance appears to saturate. Specifically, increasing the strength of 
resistance above that exhibited by the S3 module does not significantly reduce pathway 
activity. Strong chaste routing is observed in the presence of theophylline for resistance 
modules with activity at and above S3 levels. While no network configuration achieves 
dual-fate routing, the dual diverter network with S2 regulating the resistance module 
permits promiscuous routing while S3 enables chaste routing. These data indicate that 
dual-fate routing may be achieved by tuning the strength of the resistance module around 
the activation and attenuation thresholds that reside between S2 and S3. 
  
Figure 3.9. A dual-module negative diverter shows that pathway attenuation is a strong function of 
the activity of the resistance module. Amplifying diverter (positive feedback: pFUS1-Ste4-S3tc; booster: 
pHIGH-Ste4-S4tc) paired with various attenuating diverters (negative feedback: pFUS1-Msg5-S3; 
resistance: pHIGH-Msg5-Sx). “SC” denotes strong chaste routing in the plate assays.  
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The performance of attenuating and amplifying diverters is sensitive to the strength 
of the positive feedback module  
 We also examined the impact of tuning the strength of the positive feedback 
module on the dual-routing capability of the dual diverter network configuration. The 
attenuating diverter (resistance: pHIGH-Msg5-S3; negative feedback: pFUS1-Msg5-S3) 
was paired with amplifying diverters composed of a booster module (pHIGH-Ste4-S4tc) 
and positive feedback modules incorporating sets of RNA switches exhibiting varying 
activities (pFUS1-Ste4-Sx). We evaluated the ability of the attenuating diverter to reduce 
pathway activity and route cells to the chaste fate in this network configuration. Pathway 
attenuation increases modestly with decreasing positive feedback strength from S4tc to 
S2tc (Figure 3.10A). Across the range of positive feedback modules incorporating S2tc to 
S4tc, wild-type halo formation is mostly maintained in the absence of theophylline. For 
the network incorporating the OFF state control within the positive feedback module, 
pathway activity is low and cells are strongly routed to the chaste fate even in the absence 
of theophylline. While decreasing the strength of the positive feedback module may 
improve chaste routing, the data indicate that within this network configuration positive 
feedback above a particular threshold is required to maintain halo formation in the 
absence of either small-molecule trigger.   
 We next evaluated the ability of the amplifying diverter to increase pathway 
activation in these networks over the range of positive feedback strengths. Pathway 
activation increases with increasing positive feedback strength from OFF to S2tc. 
Increasing positive feedback strength above S2tc did not result in significant changes to 
either pathway activation or promiscuous routing within this network configuration 
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(Figure 3.10B). However, the wild-type halo was diminished in the absence of 
tetracycline over the range of feedback strengths compared to the same assay conditions 
(Figure 3.10A and B). These data indicate that the dual diverters’ ability to maintain the 
wild-type halo may be sensitive to small, unaccounted for variations in plating conditions 
such as humidity and temperature which may affect plate diffusivity and thus the 
pheromone gradient. We additionally investigated whether reducing the positive feedback 
strength from S3tc to S2tc enhanced dual-fate routing in the dual diverter network. 
Specifically, we paired the amplifying diverter (booster: pHIGH-Ste4-S4tc; positive 
feedback: pFUS1-Ste4-S2tc) with attenuating diverters composed of a negative feedback 
module (pFUS1-Msg5-S3) and resistance modules incorporating a set of RNA switches 
exhibiting a range of activities. While reducing the strength of the positive feedback 
module did enhance chaste routing for the dual diverter network, it also resulted in 
weaker promiscuous routing even when configured with low activity resistance modules 
(Supplementary Figure 3.3).  Reducing the strength of the booster module (pHIGH-Ste4-
S3tc) similarly resulted in weaker promiscuous routing in this network configuration 
without significantly improving routing to the chaste fate (Supplementary Figure 3.4). 
The results indicate that the strength of the positive feedback module represents a 
sensitive parameter in the dual diverter network that must be precisely tuned to allow 
robust function of the dual-routing activities.  
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Figure 3.10. A dual-module negative diverter shows that pathway attenuation and activation are 
sensitive to the strength of the positive feedback module. A. Attenuating diverters (negative feedback: 
pFUS1-Msg5-S3; resistance: pHIGH-Msg5-S3) paired with various amplifying diverters (positive 
feedback: pFUS1-Ste4-SXtc; booster: pHIGH-Ste4-S4tc).  “SC” and “VSC” denotes strong and very strong 
chaste routing in the plate assays, respectively. B. Pathway activation is relatively insensitive to varying 
positive feedback strength and only very weak routing is observed across the range of networks. However, 
insufficient levels of positive feedback in this network configuration inhibit normal halo formation in the 
absence of either trigger.  
  
Benchmarking network diverter performance  
 Having examined a variety of network configurations, we identified several 
configurations that achieve near-optimal performance given our set of parts and the 
architectures we had constructed. We sought to benchmark four of the best dual-routing 
configurations to networks with reduced diverter antagonism. To benchmark performance 
of the dual diverter networks, we compared the routing efficiency and efficacy of the dual 
diverters to minimally antagonistic alternative architectures (MAAAs). MAAAs 
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represent best-case scenarios for routing under conditions of reduced interference from 
the opposing diverter. Six different MAAAs, three positive and three negative, were 
composed to evaluate the performance of both the positive and negative diverters in 
various configurations.  
Positive MAAAs provide a tool for benchmarking a dual diverter’s efficiency in 
activating the pathway and efficacy in routing to the promiscuous fate. Positive MAAAs 
are constructed by reducing the strength of modules within the negative diverter, thereby 
minimizing the antagonistic impact exerted by the negative diverter on the function of the 
positive diverter. We compared the constructed dual diverters to three different positive 
MAAAs: the low-resistance, the no-negative-feedback, and the low-resistance-no-
negative-feedback MAAAs (For details of configuration see legend in Figure 3.11). We 
selected four dual diverter configurations that vary in the strength of positive feedback 
and resistance modules (positive feedback: pFUS1-pSte4-Sxtc; booster: pHIGH-Ste4-
S4tc; negative feedback: pFUS1-Msg5-S3; resistance: pHIGH-Msg5-Sx). For simplicity, 
we refer to these dual diverters as: Diverter A, B, C, and D. Diverters A and B are 
composed with S3tc regulating the positive feedback module and the resistance module is 
regulated via S2 and S3, respectively. Diverters C and D mirror Diverters A and B, 
respectively, except S2tc is incorporated into the positive feedback module. These dual 
diverters are expected to decrease in positive routing and increase in negative routing 
performance from A to D.  
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Figure 3.11. Benchmarking a dual diverters against various positive MAAAs indicates strong 
performance by Diverter A. A. Diverter A performs as well as the low resistance MAAA in activating the 
pathway, while pathway activation is notably diminished for Diverters B through D.  All four dual diverter 
networks utilize a negative feedback module regulated by S3 and a booster module regulated via S4tc.  
Diverter A and Diverter B are composed with S3tc regulating the positive feedback module and the 
resistance module is regulated via S2 and S3, respectively. Diverters C and Diverter D mirror Diverters A 
and B respectively with S2tc substituted for S3tc in the positive feedback module.  All the MAAAs 
containing the booster and negative feedback also have S4tc for the booster and S3 for negative feedback. 
Otherwise the MAAAs were composed without these elements to minimize antagonization. B. PAR values 
indicate that Diverter A performs as well as the MAAAs in differentiating the triggered and non-triggered 
populations, while performance drops for Diverter B and diminishes further across the range to Diverter D. 
The “low resistance” MAAA is composed with S3tc regulating positive feedback module, S4tc regulating 
the booster module, S3 regulating the negative feedback module and OFF regulating the resistance module. 
The low resistance MAAA represents the lowest possible level of resistance from this expression module 
given the other parameters (eg. strength of promoter, pathway regulator). The “no negative feedback” 
MAAA is composed similarly to the low resistance MAAA except it lacks a negative feedback module and 
contains S3 regulating the resistance module. The “no negative feedback, low resistance” MAAA lacks a 
negative feedback module and contains the OFF state control regulating the resistance module.  
pFUS1
pHIGH
Msg5
Msg5
SX
S3
pFUS1
pHIGH
Ste4
Ste4
SXtc
S3tc
0.0
0.1
0.2
0.3
0.4
0.5
Diverter A Diverter B Diverter C Diverter D Low resistance No negative 
feedback
No negative 
feedback and 
low  resistance
0 mM 1 mM
N
or
m
al
iz
ed
 p
at
hw
ay
 a
ct
iv
it
y
PA
R
A
B
0
2
4
6
8
10
Diverter A Diverter B Diverter C Diverter D Low resistance No negative 
feedback
Low  resistance, 
no negative 
feedback
III-28 
 
In evaluating positive routing, Diverter A performs as well as the low resistance 
MAAA in activating the pathway, while pathway activation is notably diminished for 
Diverters B through D (Figure 3.11A). As previously observed, pathway activation is 
particularly sensitive to the strength of resistance in the range between S2 and S3 when 
the positive feedback module is regulated by S3tc. Comparison of Diverters A and B with 
C and D reveals that decreasing the strength of the positive feedback module reduces this 
sensitivity by making the network less responsive to pathway activation. Interestingly, 
the positive MAAAs lacking a feedback module showed reduced pathway activity 
relative to the low-resistance MAAA. While lower pathway activity values for the 
MAAAs lacking a negative feedback module is unexpected, the differences in activity 
evaluated at a single time point may be the result of altered systems dynamics introduced 
by negative feedback. Negative autoregulation has been previously demonstrated to 
accelerate pathway response [25]. By evaluating a single time point of pathway activity, 
our assay may not capture an equally predictive measure of cellular fate when comparing 
different architectures. PAR values indicate that Diverter A performs as well as the low 
resistance MAAA in differentiating the triggered and non-triggered populations, while 
the PAR value drops for Diverter B and diminishes further in Diverters C and D (Figure 
3.11B). While the PAR value for Diverter B (PAR 3.1) is lower than that for A (PAR 6.6) 
and the low-resistance MAAA, Diverter B outperforms the booster diverter (PAR 1.4) 
and positive feedback diverter (PAR 1.9) in differentiating triggered and non-triggered 
populations (Figure 3.4). These data indicate that with further tuning the constructed 
networks may provide strong resolution between divergent cell fates. 
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Figure 3.12. Benchmarking dual diverters against various negative MAAAs indicates strong 
performance from Diverter B and D. A. Normalized pathway activity data shows that pathway 
attenuation for Diverter B and D is similar to the no activation booster control.  The data indicate that to 
further reduce pathway activity requires reducing the strength of the positive feedback module to the OFF 
state control levels. However, this configuration inhibits pathway activity even in the absence of 
theophylline. As observed previously, for these dual diverter networks a minimal level of positive feedback 
is necessary to maintain wild-type halo formation in the absence of either small molecule.  B. PAR values 
indicate that Diverter B performs as well as or better than the negative MAAAs in separating triggered and 
non-triggered populations. The negative MAAAs were composed with S3tc regulating the positive 
feedback module, S4tc regulating the booster module, S3 regulating both the negative feedback and 
resistance modules with the following changes to the positive diverter. In the “no-activation-booster” 
MAAA lacks a booster module. The “weak-positive-feedback” MAAA is composed with the OFF state 
control regulating the positive feedback module. The no-activation-booster-weak-positive-feedback” 
MAAA lacks a booster module and contains a positive feedback module regulated by the OFF state control.  
 
To benchmark the dual diverter’s efficiency in pathway attenuation and efficacy 
of routing to the chaste fate, we constructed three negative MAAAs by reducing the 
strength of the expression modules in the positive diverter. We compared the four dual 
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diverters to the three negative MAAAs: no-activation-booster, weak-positive-feedback, 
and no-activation-booster-weak-positive-feedback MAAAs (For details of configuration 
see legend in Figure 3.12). When triggered with theophylline, pathway activation data 
shows that pathway attenuation for Diverters B and D is similar to the no activation 
booster control (Figure 3.12A). The data indicate that further reduction in pathway 
activity requires reducing the strength of the positive feedback module to levels exhibited 
by the OFF state control, which results in inhibition of pathway activity even in the 
absence of theophylline. As observed previously, a minimal level of positive feedback is 
necessary to maintain wild-type halo formation in the absence of either small-molecule 
trigger. From the measured PAR values, Diverter B performs as well as or better than the 
negative MAAAs in separating triggered and non-triggered populations (Figure 3.12B) 
The data indicate that configuring the dual diverter networks for differentiating between 
triggered and non-triggered cells and conditional chaste routing requires precise 
balancing of the positive feedback strength.  
In comparing the various MAAAs and dual diverter configurations, Diverter B 
emerged as the best overall dual diverter. Diverter B achieved moderate levels of 
pathway activity and the second highest PAR value for pathway activation. Additionally, 
Diverter B attenuated pathway activity nearly as well as the no-booster MAAA and had a 
significantly higher PAR value for attenuation compared to the other dual diverters. 
While Diverter B represents the best overall dual diverter, Diverter A demonstrates that 
strong pathway activation can be achieved from the dual diverter architecture with 
amplifying and attenuating diverters simultaneously integrated. In addition, Diverter D 
demonstrates that strong pathway attenuation is possible from the same network 
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architecture tuned with different modular parts. Taken together, these results indicate that 
given the existing parts used in this study, we have optimized the dual routing system. 
Apart from modifying diverter configurations, further improvements in dual-fate routing 
may be achieved by increasing the trigger signals that activate the diverter switches 
and/or modifying growth conditions to modulate metabolic rate. 
 
Conditional routing of genetically identical cells to diverse phenotypes in response to 
distinct molecular signals  
We examined the performance of the dual diverters under conditions of elevated 
switch activation by examining dual-fate routing at elevated concentrations of the small-
molecule triggers. Initial characterization of the dual diverter configurations were 
performed at extracellular concentrations of 5 mM theophylline and 1 mM tetracycline, 
which correspond to the standard concentrations for characterization of the RNA-based 
switches. However, increasing the concentration of small molecule input has been shown 
to increase the activation and thus level of expression from the RNA switches (Liang, J, 
et al. Submitted). To determine if increased activation of the theophylline- and 
tetracycline-responsive switches improved routing to the chaste and promiscuous fates, 
respectively, we performed halo assays in the absence and presence of slightly elevated 
concentrations of the environmental triggers (2 mM tetracycline, 20 mM theophylline). 
The results show that Diverters B, C, and D robustly route to the chaste fate when 
triggered with theophylline (Figure 3.13). Additionally, all four diverters modestly route 
cells to the promiscuous fate when triggered with tetracycline. However, Diverters B, C, 
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and D do not maintain wild-type halo formation in the absence of either trigger, instead 
demonstrating significant growth in the halo region in the absence of either trigger. We 
hypothesized that the positive diverter is overwhelmed by the negative diverter even at 
basal levels of expression resulting in reduced sensitivity to pheromone even in the 
absence of theophylline.  
 
Figure 3.13. Higher small-molecule inputs improve dual-fate routing. Halo assays indicate that pushing 
the small-molecule concentration higher improves routing to both the promiscuous and chaste fate, but dual 
diverters routing to both fates (Diverters B, C, D) fail to maintain a robust wild-type halo in the absence of 
either trigger. 
  
 We attempted to restore the wild-type response in our dual diverters by altering 
growth conditions to support the positive diverter. Previous work demonstrated that the 
stability of positive feedback loops is sensitive to cellular metabolism [11]. In particular, 
reducing metabolism by exchange of sugar sources was shown to allow positive feedback 
loops to maintain memory of transient stimuli whereas under rapid growth conditions 
memory was lost. From this example, we postulated that noninducing, nonrepressing 
Blank A B C D 
Diverters
-
+
+
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(NINR) conditions, which are known to reduce metabolism compared to growth in 
dextrose, would support the positive feedback loop and restore the wild-type halo in the 
absence of either trigger. For all four diverters, the wild-type halo was restored in NINR 
conditions (Figure 3.14). Further, NINR conditions enhance promiscuous routing in the 
presence of tetracycline. 
Figure 3.14. Metabolic modulation restores wild-type halo in the absence of either trigger and 
enhances promiscuous fate routing from dual-diverters.  Halo assays performed in noninducing, 
nonrepressing (NINR) conditions demonstrate wild-type halos in the absence of either trigger. Assay 
perfomed at 0 mM (-) and 2 mM (+) tetracycline.  
 
We further evaluated Diverter B, which emerged from the benchmarking as the 
best overall performing dual diverter, for dual routing at elevated small molecule levels 
supported by metabolic cues. As expected in NINR conditions, Diverter B maintains the 
wild-type halo until triggered by tetracycline to route cells to the promiscuous fate 
(Figure 3.15). When triggered with theophylline in dextrose, Diverter B routes cells to the 
chaste fate. Taken together, these data demonstrate that a dual diverter system has been 
optimized to achieve robust dual-fate routing from genetically identical cells in response 
to small-molecule triggers when supported by the appropriate metabolic cues. 
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Figure 3.15. Routing genetically identical cells to divergent fates in response to small-molecule 
triggers supported by metabolic cues. Diverter B robustly routes cells to the promiscuous fate in response 
to tetracycline (left), preserved wild-type halo in absence of either trigger (center), and routes to the chaste 
fate in response to theophylline (right). Routing to the chaste fate is supported by dextrose, while wild-type 
and promiscuous fates are supported by NINR conditions. 
 
Discussion 
 We have shown that molecular network diverters are capable of routing 
genetically identical cells to three divergent fates in response to specific environmental 
triggers when supported by metabolic modulation. The initial network configurations 
integrated single-module molecular network diverters, which had been previously 
optimized to route cell fate in the absence of the opposing diverter. Integration of the 
positive feedback diverter with the resistance diverter failed to permit dual-fate routing, 
and the basal expression levels from the opposing diverter resulted in antagonization, 
ultimately limiting the routing ability of each diverter. Addition of a booster module to 
the positive feedback diverter resulted in an amplifying diverter, which restored 
+ +-
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promiscuous routing under low resistance conditions. In particular, the amplifying 
diverter paired with a low activity resistance module resulted in enhanced resolution 
between the triggered and non-triggered populations compared to the positive feedback 
diverter. Balancing the dual diverter networks with a negative feedback module 
facilitated routing to the chaste fate for some configurations at the sacrifice of 
promiscuous routing. By examining the network sensitivity to various parameters, our 
studies revealed that the strength of the positive feedback module and the activity of the 
resistance module represent highly sensitive control points. Our studies highlight the 
importance of architectures that allow for precise tuning of the diverter modules to allow 
dual fate routing. At lower levels of the environmental triggers none of the dual diverter 
networks achieved robust routing to both the promiscuous and chaste fates. However, 
under higher concentrations of the input triggers supported by metabolic modulation, a 
dual diverter configuration showed strong routing to both alternative fates while 
preserving the wild-type behavior in the absence of either trigger.  
While we have optimized the dual diverter networks within the limits of the 
existing set of RNA switches, there remain potential opportunities for improving dual-
fate routing performance. Given the sensitivity of the composed networks to the strength 
of the positive feedback module and the resistance module, balancing the strength of 
these modules represents an important design point for constructing networks that 
effectively route to both alternative fates. Basal level reduction from these expression 
modules represents a potential opportunity for further tuning of these networks.  
Reducing expression from the resistance module and positive feedback module 
via promoter exchange or by modifying the expression context by integration or vector 
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exchange will reduce diverter antagonism from the opposing diverter by reducing basal 
expression levels. We used the pathway activity data for the dual diverter networks and 
switch expression levels to model the effect of reducing expression of both modules by 
one third for the Diverter B configuration (Figure 3.14). The results predict that absolute 
pathway activation and attenuation as well as PAR values for positive routing are 
improved in the modeled system relative to the best overall dual diverter, Diverter B.  
Thus, reducing expression from these cassettes may represent a potential opportunity for 
optimizing the performance of this dual diverter network configuration. In addition, 
integration at various loci, including GAL2 and TRP1, has been shown to reduce 
expression by 30–35%, providing a potential mechanism for reducing expression and 
variability from these constructs (Supplementary Figure 3.5). Promoter exchange 
represents another option for reducing expression from these modules. While there exist a 
variety of constitutive promoters with strengths lower than pHIGH, replacing a specific 
feedback promoter for variants of different strength may represent more of a challenge. 
However, previous work was performed to engineer variants of the mating promoter used 
in our study, pFUS1, that exhibit varying strengths of expression [26]. Several of the 
promoters demonstrated reduced strength and may be potential candidates for replacing 
the wild-type sequence used in these studies to reduce basal expression levels and 
enhance routing. While strategies that utilize promoter exchange or different expression 
contexts to tune basal levels will also result in reductions in the triggered levels of 
expression, addition of trans-acting controller may reduce basal expression without 
significantly reducing triggered expression.  
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Figure 3.16. Reducing expression from the positive feedback and resistance modules in Diverter B 
may optimize the dual diverter network. A.  Reducing expression from the feedback module by one third 
shifts the basal promoter-switch strength from S3tc levels to S2tc levels. pFUS1-S2tc denotes the feedback 
promoter combined with S2tc, pFUS1-S3tc  denotes the feedback promoter with S3tc, and pFUS1-S3tc-
mod indicates the promoter-switch strength for pFUS1-S3tc calculated to be reduced by one third. B. 
Reducing the resistance module by one third shifts basal levels from S3 to S2 levels. pHIGH-S2tc denotes 
the pHIGH promoter combined with S2tc, pHIGH-S3tc  denotes pHIGH promoter with S3tc, and pHIGH-
S3tc-mod indicates the promoter-switch strength for pFUS1-S3tc calculated to be reduced by one third.  C.  
Pathway activity data are plotted in blue diamonds for pFUS1-S3tc (Diverter A) and pFUS1-S2tc (Diverter 
C) which both contain a resistance module regulated by S2. Diverter B contains a positive feedback module 
regulated via S3tc, a resistance module regulated via S3, a booster regulated via S4tc, and a negative 
feedback module. Pathway activity for the modified Diverter B was estimated by linearly interpolating 
between the values of pathway activity for pFUS1-S3tc (Diverter A) and pFUS1-S2tc (Diverter C) values 
of pathway activity, diamonds. D. Pathway activity data are plotted in red diamonds pHIGH-S2 (Diverter 
C) and pHIGH-S3 (Diverter D); both diverters contain S2tc regulating the positive feedback module. 
Pathway activity for the modified Diverter B was estimated by linearly interpolating between the values of 
pathway activity for pHIGH-S2 (Diverter C) and pHIGH-S3 (Diverter D), black diamonds. E. PAR values 
for pathway activation were determined from the measured and estimated values of pathway activity for the 
various configurations as previously described. F. PAR values for pathway attenuation for the various 
configurations were calculated using from measured and estimated values of pathway activity.  
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Trans-acting regulators of expression may provide a means for reducing basal 
expression levels, while being structured for minimal impact on the levels of triggered 
expression. Trans-acting RNA-based regulators, such as microRNAs or trans-acting 
ribozymes, offer a secondary layer of control by which to reduce basal level 
antagonization. Layering of trans-acting RNAs has been demonstrated to control basal 
level leakage, improving the performance of synthetic circuits [5, 12, 13]. Imbedding 
trans-acting RNA-based regulators within the transcripts of opposing regulators may 
facilitate the construction of mutually inhibitory loops between the two diverters. Such 
mutually inhibitory loops may be expected to increase the degree of divergence between 
cell fates and enhance the robustness of routing. Additionally, trans-acting RNA-based 
switches have been demonstrated to conditionally regulate target expression in 
mammalian cells [27]. Potentially, such trans-acting regulatory tools could provide a 
mechanism to conditionally reduce basal level expression with minimal effect on the 
triggered levels of expression. In addition to routing cells to three divergent fates, our 
work has demonstrated design principles for structuring networks to differentiate cells 
based on environmental cues and enhance the robustness of integrated mutually 
antagonistic programs. The dual diverter configurations incorporating the amplifying and 
attenuating diverters are structured to enhance routing while minimizing impact on 
performance of the opposing diverter. Achieving this effect required constructing 
functionally redundant genes with differential regulatory regions. Differential regulation 
of functionally redundant parts is a strategy that has been observed in natural biological 
systems, such as in the networks regulating bone formation and osteoblast differentiation 
as well as plant defense mechanisms and metabolism [28, 29]. Differential regulation of 
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functionally redundant genes may represent a common motif for amplifying pathway 
response to environmental cues that mediate changes in particular cellular behaviors and 
fate. Within our synthetic systems, we also observed that addition of a resistance module 
to the positive feedback diverter enhanced the resolution between the two populations of 
cells by reducing basal expression levels. We postulate that the resistance module 
enabled greater separation of the populations by buffering subthreshold noise of Ste4 
expression. Addition of the booster module increased the levels of pathway activity in the 
network while preserving population resolution, providing a parameter for tuning the 
network output in this system. Synthetic networks that are structured to suppress noise 
amplification while amplifying differences in exogenous input may improve the selection 
of new RNA-based controllers by enhancing the resolution between switching and 
nonswitching elements. Additionally, when applied to cellular decision-making 
pathways, these enhanced amplifying circuits may facilitate robust differentiation 
between divergent cell fates.  
 We have demonstrated a scalable, modular, and tunable method for constructing 
RNA-based control systems that interact with a native signaling pathway to direct cell 
fate that may be readily translated to new pathways. As the synthetic biology tool box 
continues to expand, an increasingly number of synthetic control systems will be 
connected to native pathways, enabling more sophisticated and complex control for a 
wide array of applications.  Many of the goals tissue engineering and molecular medicine 
such as the ex vivo construction of immunologically compatible tissues and the 
development of cell-based therapies will be advanced by synthetic control systems that 
spatially and temporally program cell fate. 
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Materials and methods 
Plasmid construction 
Standard molecular biology cloning techniques were used to construct all 
plasmids [30]. DNA synthesis was performed by Integrated DNA Technologies 
(Coralville, IA). All enzymes, including restriction enzymes and ligases, were obtained 
through New England Biolabs (Ipswich, MA). Ligation products were electroporated 
with a GenePulser XCell (Bio-Rad, Hercules, CA) into an E. coli DH10B strain 
(Invitrogen, Carlsbad, CA), where cells harboring cloned plasmids were maintained in 
Luria-Bertani media containing 50 mg/ml ampicillin (EMD Chemicals). All cloned 
constructs were sequence verified by Laragen Inc (Santa Monica, CA). 
To construct the dual expression module negative and positive molecular network 
diverters, expression modules were cloned into dual cassette plasmids pCS2094 (Liang, J, 
et al. Submitted). pCS2094 served as the expression plasmid for positive feedback 
expression modules and resistance expression modules (Supplementary Figure 3.6A, 
Supplementary Table 3.1). The positive feedback expression module (pFUS1-Ste4-S2tc) 
was amplified via PCR with primers pFUS1.ClaI.pCS2094.FWD (5’-
CCAATCTCAGAGGCTGAGTCTC) and Switch3’.XhoI.pCS2094.REV (5’-
AAAACTCGAGTTTTTATTTTTCTTTTTGCTGTTTCG) and cloned into the unique 
ClaI and XhoI sites in pCS2094 to construct pKG227 (Supplementary Figure 3.6B). 
Tetracycline-responsive switches and appropriate controls (Supplementary Table 3.5) 
were inserted into the 3’ UTR via the unique restriction sites AvrII and XhoI, located 
immediately downstream of the Ste4 stop codon as described previously [31]. Resistance 
expression modules (pTEF7-Msg5-SX) were PCR amplified from previously constructed 
III-41 
 
single-module molecule network diverter plasmids (Supplementary Table 2.6) using 
pTEF7.FWD (5’-AAGAGCTCATAGCTTCAAAATGTCTCTACTCCTTTTT) and 
CYC1t.NotI.REV (5’-AAAAGCGGCCGCTATATTACCCTGTTATCC) and cloned into 
the unique restriction sites SacI and NotI of construct harboring the positive feedback 
expression modules (Supplementary Table 3.2). To construct a complimentary expression 
system to pCS2094 (-URA) for expression of negative feedback expression modules and 
booster expression modules a secondary –TRP plasmid with dual expression cassettes 
was constructed. pKG233, a pCS2094 based-plasmid, was digested with SacI and KpnI, 
the dual-cassette fragment was gel extracted, and inserted via these same unique 
restriction sites in pCS1128 to compose pKG243 (Supplementary Figure 3.6C). Negative 
feedback expression modules (pFUS1-Msg5-SX) were constructed by PCR amplifying 
Msg5 and theophylline switches from previously constructed single-module negative 
feedback diverter plasmids (Supplementary Table 2.7) using Msg5.K2.FWD (5'- 
AAAGGATCCAATTAATAGTGCACATGCAATTTCAC) and 
Switch3’.XhoI.pCS2094.REV and cloned via the unique sites BamHI and XhoI. Booster 
expression modules (pTEF7-Ste4-SXtc) were added to the plasmids bearing the negative 
feedback expression modules via PCR of previously constructed booster diverter 
plasmids with pTEF7.FWD and CYC1t.NotI.REV and cloned into the unique restriction 
sites SacI and NotI (Supplementary Table 3.2). Single-module booster expression 
plasmids were constructed from pCS1128 for pairing with pCS2094. Previously 
constructed booster diverter plasmids were SacI and KpnI digested, the expression 
cassette was gel extracted, and cloned via these same unique restriction sites in pCS1128 
(Supplementary Table 3.3). 
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Measuring mating pathway activity via a transcriptional reporter  
The molecular diverter plasmids and appropriate controls were transformed into 
the previously constructed yeast mating reporter strain CSY840 (Supplementary Figure 
3.9). Cells were inoculated into the appropriate dropout media, grown overnight at 30°C, 
and back diluted into fresh media in the presence or absence of ligand at the specified 
concentration to an OD600 of <0.1. For negative diverters, after growing for 3 hr at 30°C, 
cells were stimulated with saturating pheromone levels, to a final concentration of 100 
nM α mating factor acetate salt (Sigma-Aldrich, St. Louis, MO), to activate the mating 
pathway. Following 6 hr of growth post-back-dilution, GFP fluorescence levels from the 
pFUS1-yEGFP3 reporter were evaluated via flow cytometry using Cell Lab Quanta SC 
flow cytometer (Beckman Coulter, Fullerton, CA) with the following settings: 488-nm 
laser line, 525-nm bandpass filter, and photomultiplier tube setting of 5.0 on FL1 (GFP). 
Fluorescence data were collected under low flow rates for ~ 10,000 viable cells. 
Normalized pathway activity is calculated as the geometric mean of three biological 
replicates of each sample normalized to the blank plasmid control stimulated with 
saturating α mating factor in the absence of either small molecule.  
 
Measuring mating pathway activity via halo assays 
Mating associated cell-cycle arrest was evaluated via halo assays [32]. Halo 
assays were performed on cultures grown overnight in YNB with 2% dextrose or in 1% 
sucrose, 2% raffinose for NINR noninducing, nonrepressing (NINR) conditions and  
appropriate dropout solution. Overnight cultures were back diluted into fresh media and 
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grown to OD 600 ~ 0.2–0.4. 200 µl of each replicate were plated on the appropriate 
dropout plates containing no small molecule, theophylline or tetracycline at the specified 
concentration on dextrose except where specifically indicated for NINR conditions. 
Standard concentrations are defined as 5 mM for theophylline and 1mM for tetracycline. 
After plating the cells, a gradient of α mating factor was established by saturating a filter 
disk (2 mm diameter) of Whatman paper with 9 µl of 0.1 mg/mL α mating factor and 
placing the disk on the center of the plate. Cells were grown for 18–24 hr at 30°C and 
imaged via epi-white illumination with a GelDoc XR+ System (Bio-Rad).  
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Supplementary figures 
  
Supplementary Figure 3.1. Range of switch expression strengths. A. Theophylline-responsive switches’ 
basal levels, the expression levels in the absence of ligand, range from 3% to 40% of the ON control. S3 
has the highest switch activation ratio (SAR) at 5.7 . SAR is the ratio of expression levels in the presence of 
ligand to the level in the absence of ligand.  B. Tetracycline-responsive switches’ basal levels range from 
3% to 8%.  S3tc and S4tc have similar high SARs at 5.2 and 5.1, respectively.  
  
Supplementary Figure 3.2. Single-module diverters fail to achieve dual-fate routing. Single-module 
positive feedback diverters, pFUS1-Ste4 with OFF, S2tc, and S4tc, fail to route to the promiscuous fate in 
the presence of negative diverters incorporating a range of switch strengths.  The Blank control bears a 
plasmid without either diverter.  
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Supplementary Figure 3.3. Reducing the strength of the feedback module from S3tc to S2tc yields 
weak promiscuous routing while modestly improving chaste routing.  
 
 
Supplementary Figure 3.4. Reducing the strength of the booster module from S4tc to S3tc yields 
weak promiscuous routing and does not significantly improve chaste routing.  
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Supplementary Figure 3.5. Loci characterization. A. Relative pFUS1-GFP expression indicates that 
integration  generally reduces expression 25–35 % for the loci, except at the FCY1 locus which increases 
expression nearly 5-fold compared to the plasmid. The loci were characterized by flow cytometry of cells 
with pFUS1-GFP integrants stimulated with 100 nM for 3 hrs.  B. Integration also reduced the coefficient 
of variation significantly.  
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Supplementary Figure 3.6. Plasmid maps: A.  pCS2094 B. pKG227 C. pKG243 
A
C
B C
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Supplementary tables 
Supplementary Table 3.1. pCS2094-based dual-expression cassette plasmids 
 
  
pCS # pKG# Downstream Cassette Upstream Cassette Marker
pCS2094 205 pTEF1-yEGFP-ON-CYC1t pTEF1-mcherry-CYC1t URA
227 pFUS1-Ste4-S2tc pTEF1-mcherry-CYC1t URA
306 pFUS1-Ste4-S2tc pTEF7 Msg5 OFF URA
231 pFUS1-Ste4-S2tc pTEF7 Msg5 S2 URA
307 pFUS1-Ste4-S2tc pTEF7 Msg5 S47 URA
232 pFUS1-Ste4-S2tc pTEF7 Msg5 S3 URA
283 pFUS1-Ste4-S2tc pTEF7 Msg5 ON URA
pKG233 pFUS1-Ste4-OFF pTEF1-mcherry-CYC1t URA
pKG238 pFUS1-Ste4-OFF pTEF7 Msg5 S2 URA
pKG300 pFUS1-Ste4-OFF pTEF7 Msg5 S47 URA
pKG239 pFUS1-Ste4-OFF pTEF7 Msg5 S3 URA
pKG271 pFUS1-Ste4-OFF pTEF7 Msg5 ON URA
pKG298 pFUS1-Ste4-Stc-OFF1 pTEF1-mcherry-CYC1t URA
pKG302 pFUS1-Ste4-Stc-OFF1 pTEF7 Msg5 OFF URA
pKG303 pFUS1-Ste4-Stc-OFF1 pTEF7 Msg5 S2 URA
pKG304 pFUS1-Ste4-Stc-OFF1 pTEF7 Msg5 S47 URA
pKG305 pFUS1-Ste4-Stc-OFF1 pTEF7 Msg5 S3 URA
pKG316 pFUS1-Ste4-Stc-OFF1 pTEF7 Msg5 ON URA
pKG234 pFUS1-Ste4-S3tc pTEF1-mcherry-CYC1t URA
pKG310 pFUS1-Ste4-S3tc pTEF7 Msg5 OFF URA
pKG236 pFUS1-Ste4-S3tc pTEF7 Msg5 S2 URA
pKG313 pFUS1-Ste4-S3tc pTEF7 Msg5 S47 URA
pKG237 pFUS1-Ste4-S3tc pTEF7 Msg5 S3 URA
pKG280 pFUS1-Ste4-S3tc pTEF7 Msg5 ON URA
pKG228 pFUS1-Ste4-ON pTEF1-mcherry-CYC1t URA
pKG311 pFUS1-Ste4-ON pTEF7 Msg5 OFF URA
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Supplementary Table 3.2. pCS1128-based dual-expression cassette plasmids 
 
  
pCS # pKG# Downstream Cassette Upstream Cassette Marker
pCS1128 - None pGAL1-yEGFP-CYC1t TRP
pKG243 pFUS1-Ste4-OFF pTEF1-mcherry-CYC1t TRP
pKG251 pFUS1-Msg5-OFF pTEF1-mcherry-CYC1t TRP
pKG265 pFUS1-Msg5-OFF pTEF7 Ste4 S2tc TRP
pKG308 pFUS1-Msg5-OFF pTEF7 Ste4 Stc-OFF1 TRP
pKG317 pFUS1-Msg5-OFF pTEF7 Ste4 S3tc TRP
pKG267 pFUS1-Msg5-OFF pTEF7 Ste4 ON TRP
pKG248 pFUS1-Msg5-S2 pTEF1-mcherry-CYC1t TRP
pKG273 pFUS1-Msg5-S2 pTEF7 Ste4 OFF TRP
pKG258 pFUS1-Msg5-S2 pTEF7 Ste4 S2tc TRP
pKG299 pFUS1-Msg5-S2 pTEF7 Ste4 Stc-OFF1 TRP
pKG318 pFUS1-Msg5-S2 pTEF7 Ste4 S3tc TRP
pKG260 pFUS1-Msg5-S2 pTEF7 Ste4 ON TRP
pKG287 pFUS1-Msg5-S47 pTEF1-mcherry-CYC1t TRP
pkG288 pFUS1-Msg5-S47 pTEF7 Ste4 OFF TRP
pKG301 pFUS1-Msg5-S47 pTEF7 Ste4 S2tc TRP
pKG309 pFUS1-Msg5-S47 pTEF7 Ste4 Stc-OFF1 TRP
pKG319 pFUS1-Msg5-S47 pTEF7 Ste4 S3tc TRP
pKG290 pFUS1-Msg5-S47 pTEF7 Ste4 ON TRP
pKG249 pFUS1-Msg5-S3 pTEF1-mcherry-CYC1t TRP
pKG291 pFUS1-Msg5-S3 pTEF7 Ste4 OFF TRP
pKG268 pFUS1-Msg5-S3 pTEF7 Ste4 S2tc TRP
pKG314 pFUS1-Msg5-S3 pTEF7 Ste4 Stc-OFF1 TRP
pKG320 pFUS1-Msg5-S3 pTEF7 Ste4 S3tc TRP
pKG267 pFUS1-Msg5-S3 pTEF7 Ste4 ON TRP
pKG250 pFUS1-Msg5-ON pTEF1-mcherry-CYC1t TRP
pKG261 pFUS1-Msg5-ON pTEF7 Ste4 OFF TRP
pKG262 pFUS1-Msg5-ON pTEF7 Ste4 S2tc TRP
pKG315 pFUS1-Msg5-ON pTEF7 Ste4 Stc-OFF1 TRP
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Supplementary Table 3.3. pCS1128-based single-module booster plasmids 
 
 
pCS # pKG# Parent 3'UTR
pKG321 pCS1128 S4tc
pKG295 pCS1128 S3tc
pKG188 pCS1128 S2tc
pKG182 pCS1128 S1tc
pKG181 pCS1128 OFF
pTEF7-Ste4-CYC1t
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Chapter 4 
 
Development of trans-ribozymes as actuators controlling gene 
expression 
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Abstract 
The modular and tunable nature of RNA makes it ideal to perform both sensing and 
actuation functions within an synthetic control system [1]. RNA regulates gene 
expression through a variety of mechanisms at the transcriptional, post-transcriptional, 
and translational levels. Ribozymes are RNA molecules that regulate gene expression 
through post-transcriptional cleavage of target RNA. While their ability to cleave 
transcripts in a sequence-specific manner makes trans-ribozymes attractive candidates for 
targeting therapeutically relevant transcripts, applications have been limited by poor in 
vivo efficiency. However, through the recent elucidation of the design rules for in vivo 
catalytic activity, hammerhead ribozymes are now poised to be effective regulators of 
gene expression. In this work, we apply the rules for in vivo activity established for cis-
ribozymes to the development of more effective trans-ribozymes. We demonstrate that 
precise engineering of the intramolecular reaction between the ribozyme and target 
transcript is required for efficient cleavage at physiological Mg2+ concentrations. To 
improve the correlation between our in vitro and in vivo assays of ribozyme cleavage 
efficiency, we employed a dual cis-hammerhead ribozyme cassette to excise our trans-
ribozyme designs from the ribonucleoprotein (RNP) in vivo. Finally, we varied the levels 
of target sequence to examine how the concentration of target transcript, and 
consequently, the ratio of ribozyme to target affect target knockdown levels. These 
experiments demonstrated that knockdown efficiency has a biphasic relationship to target 
transcript levels. Our results suggest that one of the key limitations to trans-ribozyme-
mediated knockdown may be facilitating the intermolecular binding event between the 
trans-acting ribozymes and the target transcript. While this limits the potential application 
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space of trans-acting ribozymes, it may position these devices as uniquely targeted regulators of 
endogenous transcripts associated with cell proliferation whose expression must be precisely 
balanced to maintain normal cellular growth while preventing serious pathologies that result 
from overexpression. Finally, trans-ribozymes maybe aptly suited to regulating expression 
within synthetic gene networks where transcript colocalization can be mediated via expression 
of the trans-ribozyme and target transcript from the same vector.  
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Introduction 
 Novel cellular behaviors can be generated by coupling engineered control systems 
to the cell’s natural regulatory network [2]. However, the ability to run preprogrammed 
control algorithms depends on the facile construction of modular input / output interfaces 
between endogenous and synthetic systems. Currently, engineering gene circuits relies 
heavily on engineering protein-DNA interactions to control transcription. The rational 
design of protein-based control systems has been impeded by our limited understanding 
of how to engineer precise tertiary structures into proteins. Until it is possible to 
efficiently construct de novo connections between native and synthetic circuitry, the 
application of cellular programming strategies will be limited to a small set of input and 
output interfaces. As a result of these limitations, widespread application of exogenous 
control to cellular engineering applications remains unfeasible.  
 The modular and tunable nature of RNA makes it an ideal candidate to perform 
both sensing and actuation functions within an exogenous control system. Already 
researchers have demonstrated that RNA is capable of targeted gene knockdown through 
RNAi, trans-acting ribozymes, and antisense mechanisms [3-5]. However, the current 
technologies are limited in their ability to be integrated into robust, modular control 
systems. Off-target effects and poor efficiency hinder the effective application of 
antisense regulation of gene expression [5]. Hijacking the RNAi pathway has raised 
concerns that saturating the cellular machinery with heterologous substrates competes 
with the processing of endogenous RNAi substrates and can result in off-target or other 
undesired effects [6]. Additionally, RNAi is not universal throughout eukaryotic 
organisms such as Saccharomyces cerevisiae, a model organism for studying the 
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activation of various cancer pathways [7-9]. Ribozymes may offer an alternative gene 
regulatory mechanism upon which to build flexible, modular control systems. 
Ribozymes are RNA molecules that catalyze a variety of chemical reactions such 
as self-cleavage or ligation [10]. The hammerhead ribozyme is comprised of three helical 
regions that converge on a highly conserved catalytic core of eleven nucleotides (nts) 
(Figure 4.1A) [11]. Cleavage is sequence-specific and targets a 5’-NUX-3’ triplet, where 
N is any base, U is uracil, and X is any base except guanine. The optimal NUX for 
efficient and fast cleavage is GUC. Ribozyme cleavage is catalyzed when the 2’ hydroxyl 
group from X directly 3’ of the cleavage site is deprotonated. This nucleophile then 
attacks the scissile phosphate and, through a penta-coordinated trigonal bi-pyramidal 
transition state, produces a 5’ and 3’ product (Figure 4.1B) [12].  
 
 
Figure 4.1. The hammerhead ribozyme. A) The catalytic core is shown in pink with the NUX sequence 
in black. The flanking helical regions are shown in yellow. Stem II is shown in blue. Black circles represent 
stem loops. Figure adapted from [13]. B) Ribozyme cleavage mechanism at the NUX triplet. Figure 
adapted from [12]. C) Folding of the ribozyme is thought to proceed through two magnesium binding 
events. Figure adapted from [14]. D) The “Y”-shaped ribozyme is thought to be stabilized by loop 
interactions between unpaired bases in the stem loops. Figure adapted from [11].  
 
A B 
C D 
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Folding of the ribozymes into an active conformation is postulated to proceed 
through dual divalent ion binding events (Figure 4.1C). A high affinity binding event 
occurs at 500 μM and orders the first set of tertiary interactions. The second low affinity 
addition of ion occurs at 10 mM and restructures the ribozyme stem orientations such that 
helix I folds away from helix III and interacts with helix II [14]. Ribozymes with a 
conserved catalytic core that do not maintain specific helical regions are called minimal 
ribozymes (mRzs). While at high divalent ion concentrations (10 mM) mRzs are active, 
at lower concentrations mRzs are effectively inert [11, 15]. Crystal structures of natural 
ribozymes depict a “Y”-shaped molecule that has two of the helical regions interacting as 
“kissing loops” (Figure 4.1D) [16]. Given the “kissing loop” interaction between the two 
helical regions, tertiary interactions between unpaired bases in the stem loops are 
proposed to stabilize the catalytically active conformation and obviate high divalent ion 
conditions. Researchers have demonstrated restored in vitro catalytic activity at 
biologically relevant divalent ion concentrations, between 100 and 300 μM, by 
reincorporating the loops into minimal ribozyme designs [11, 15, 17-20].  
While the list of naturally occurring ribozymes is limited to cis-acting elements 
that perform intramolecular cleavage, synthetic trans-acting hammerhead ribozymes 
(thRzs) have been demonstrated that cleave intermolecular target sequences [4, 21, 22]. 
With their potential ability to target endogenously expressed transcripts, thRzs offer a 
significant advantage over their cis-acting counterparts, chRZs (Figure 4.2). Further, 
unlike cis regulatory elements, trans-acting elements like thRzs allow decoupling of 
ribozyme and target expression levels, offering the potential to tune knockdown via the 
independent modulation of thRz levels.  While in vitro cleavage assays confirm that 
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trans-ribozymes cleave target transcripts specifically [23, 24], in vivo demonstrations of 
targeted gene regulation with trans-ribozymes are limited and restricted to higher 
eukaryotes [22, 25]. In addition, in vivo knockdown of gene expression remains 
hampered by low trans-ribozyme activity in the intracellular environment [20]. However, 
in vivo design rules have recently been specified and applied toward the construction of 
ribozymes that effectively regulate gene expression in cis through self-cleavage when 
placed in the 3’ untranslated region (UTR) of target transcripts [26]. The application of 
the in vivo design rules that have been successfully implemented to convert cis-ribozymes 
into effective regulators of gene expression may be applied to trans-ribozymes to increase 
their efficacy as gene regulatory elements. Finally, while the simple knockdown of target 
genes is scientifically and clinically important, conditional regulation of gene products 
through integrated molecular control systems offers the potential to temporally and 
spatially tune therapies to restore proper function in diseased cells. Designing robust 
RNA-based control systems necessitates well-defined, modular actuators. By delineating 
the requirements for in vitro and in vivo activity we intend to examine the plasticity of the 
ribozyme domains requisite for targeting novel endogenous transcripts. Further, given the 
rules for constructing ligand-responsive chRz switches have recently been established 
[26], we evaluate the potential for constructing ligand-responsive RNA switches from the 
trans-acting ribozyme platform.  
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Figure 4.2. The anatomy of a cis-acting hammerhead ribozyme and trans-acting hammerhead 
ribozyme with target transcript. A. Canonical representation of cis-acting hammerhead ribozyme (chRz) 
with PLMVd loops incorporated into transcript via stem III. Stem I and stem II branch off catalytic core to 
give the eponymous hammerhead shape. B. A cis-acting hammerhead ribozyme with stem III rotated 
counter-clockwise 90o with stem I fixed for simple comparison with trans-acting counterpart. C.  Trans-
acting hammerhead ribozyme (thRz) hybridized with target transcript. For all representations the catalytic 
core is shown in red and NUX triplet shown in green. Converting cis-acting ribozymes to trans-acting 
opens stem I from a closed loop. Preserving the loop (shown in blue) from the chRz require these 
nucleotides to be unpaired as a bulge. At low Mg+2 concentrations, the bulge in stem I and stem loop II 
(shown in blue), interact to stabilize the active conformation (Figure 1D). These interactions are found in 
natural chRzs and have been adapted for engineered thRzs.  
  
 In this work, we have taken the rules established for effective in vivo activity of 
chRzs and applied them to the development of thRzs. We demonstrate additional design 
constraints for efficient thRz cleavage in engineering the intramolecular binding event 
between the ribozyme and target transcript. In particular, we demonstrate that 
engineering the stem loops and the length of the targeting arms of the thRz is necessary to 
achieve efficient cleavage of the target transcript in vitro. Finally, we observe that thRz 
knockdown varies biphasically with target expression levels. Taken together these data 
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suggest that thRz knockdown is highly context-dependent and limited by system 
constraints that govern the intermolecular binding event.  
 
Results 
Initial thRz designs demonstrate in vivo limitations 
 The initial thRz designs were adapted from previous in vitro studies [20] to target 
a region in the transcript encoding yEGFP (yeast enhanced green fluorescent protein). 
We focused on developing thRzs that specifically target a fluorescent reporter protein 
(yEGFP) as an initial design goal as it allows us to quantify gene knockdown activity 
through fluorescence-based assays. In addition, yEGFP can be used to monitor various 
endogenous proteins via protein fusions, such that a trans-acting yEGFP ribozyme can be 
directly applied to regulate the expression of any coding sequence tagged with the target 
sequence from the yEGFP fluorescent protein. While the plasticity of the targeting arms 
is yet to be fully explored, we anticipate that the targeting arms will prove to be amenable 
to targeting a variety of sequences. Therefore, by modifying the targeting arms of the 
developed thRz construct we expect that we can adapt the system to target a wide array of 
cellular transcript. 
The initial trans-ribozyme designs conformed to the following composition rules. 
First, the catalytic core was conserved to maintain activity (Figure 4.2C). Second, the 
target transcript contains a NUX triplet, where N is any base, U is uracil, and X is any 
base but guanine. Finally, for in vivo activity, the catalytically active “Y” shaped 
conformation must be formed. To achieve this requirement at physiological Mg2+ 
concentrations, the nucleotides in the bulges in stem I and stem II, are designed to 
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interact to stabilize the active conformation. These stem loop sequences are derived from 
those found in the peach latent mosaic viroid (PLMVd) ribozyme, a natural chRz [11]. 
Adopting these loops requires careful design considerations when selecting a target 
sequence. The bulge region must maintain unpaired nucleotides such that the targeted 
region in the target transcript does not have sequence complementarity to this region of 
the thRz. Additionally, canonical PLMVd ribozymes exhibit particular stem lengths 
between the stem I loop, the stem II loop, and the catalytic core, which were maintained 
in our designs. In stem I, 5 base pairs separate the bulge sequence from the catalytic core. 
In stem II, 4 base pairs separate the catalytic core and the stem loop sequence. Thus, 
canonical ribozymes will adopt the following nomenclature “X54” where X denotes the 
number of base pairs formed between the targeting arm sequence and the transcript 5’ of 
the bulge (Figure 4.3).  
 
 
Figure 4.3. Various thRz designs.  A. Previous in vitro  studies focused on incorporating the PLMVd-
derived stem loops into thRz targeted a segment of HIV1 mRNA, PLMVd-L1 thRz adapted from [20]. B. 
By redesigning the targeting arms, we created a series of PLMVd-derived thRzs targeting a sequence in 
yEGFP.  
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 The initial thRz designs were characterized through in vitro cleavage assays in 
which separately transcribed ribozymes and radiolabeled target sequences were purified, 
combined, annealed, and incubated. Annealing was performed to allow transcripts to 
escape nonminimal free-energy structures potentially adopted during column purification. 
Endpoint cleavage efficiency was determined by comparing the amount of full-length to 
cleaved target sequence when visualized via PAGE gel and phosphorimaging analysis 
(see Methods). We modified our cleavage assay from previously reported methods to 
facilitate a more accurate correlation between in vitro results and in vivo activity. 
Specifically, we extended the length of the target transcript beyond the region that binds 
to the targeting arms. By including the peripheral transcript regions, we were attempting 
to more closely recapitulate the folding microenvironment of the full-length transcript for 
the region of interest. For example, the flanking sequences might interact with the target 
region to form secondary structures that might impede hybridization of the trans-
ribozyme to the target region and thus cleavage. Accessibility of the target sequence is 
known to control the efficacy of thRz knockdown in vivo [27]. By targeting a RNA strand 
that more closely resembles in vivo transcripts, the in vitro cleavage assays are expected 
to reflect in vivo cleavage efficiencies more accurately. Following incubation, cleaved 
and noncleaved products were quantified through PAGE gel analysis. At 10 mM MgCl2, 
the canonical trans-ribozymes, 554 and 654, cleave ~ 90% of the target (Figure 4.4A). 
The mRz with no loop structures cleaves ~ 50% of target. At Mg2+ concentrations 
comparable to physiological levels the activity of the mRz is completely abolished, 
whereas the canonical ribozymes maintain significant activity. 
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Figure 4.4. Initial ribozyme designs with pCS933. A. In vitro cleavage assays after 1 hr at various Mg+2 
concentrations and ratios of ribozyme to target. B. In vivo fluorescence levels of yEGFP in various controls 
and constructs. Relative fluorescence levels were calculated by normalizing mean GFP levels of cells by 
the mean GFP level of the no ribozyme control. All fluorescence data are reported as the mean ± SD from 
at least three independent experiments.  
 
 We next investigated whether the cleavage activity observed in vitro translates to 
in vivo knockdown of target gene expression. In our system, thRzs were expressed from 
the strong constitutive TEF1 promoter on a high-copy plasmid, pCS933. The yEGFP 
target sequence fused to a PEST destabilization tag and placed under the control of the 
TEF1 promoter was integrated into the yeast chromosome. Cellular fluorescence of 
samples harboring trans-ribozyme expression plasmids and controls was analyzed by 
flow cytometry and the geometric means of gated cells were calculated (see Methods). 
Relative expression was calculated by subtracting the mean of the nonfluorescent control 
and normalizing by the no ribozyme control. The results indicate that despite exhibiting 
promising in vitro activities, these ribozymes did not yield observable knockdown of the 
target gene when expressed in vivo (Figure 4.4B). In vitro activity may not translate to in 
vivo knockdown for several reasons. First, our assays capture endpoint cleavage 
efficiency not kinetic rates of cleavage. Slow cleavage rates may prevent an observable 
change in gene expression. Alternatively, ribozyme colocalization and hybridization with 
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the target transcript in vivo may be limiting. Given that in the in vitro assay we anneal 
both strands together, the in vitro assay may not capture rate limitations with ribozyme-
target hybridization and/or nonminimal global free energy states that inhibit the 
efficiency of hybridization. 
Despite the limitations of the assay, the in vitro results from the canonical thRzs 
suggest that cleavage efficiency is limited by the ribozyme-target hybridization. At high 
Mg2+ concentrations the loop interactions should have little effect on the rate of cleavage 
since sufficient Mg2+ is present to stabilize the catalytically active conformation. Thus, 
observed differences between the mhRz’s and the canonical thRzs’ cleavage efficiencies 
at high Mg2+ may be a result of differing binding affinities. Increasing the length of the 
targeting arm is expected to increase the affinity of the ribozyme for its target, facilitating 
ribozyme-target hybridization.  The targeting arms of the mRz are 4 nts and 5 nts shorter 
than 554 and 654, respectively. At 10 mM, this difference in targeting arm length yields a 
40% difference in cleavage efficiency between the mRz and the canonical ribozymes 
(Figure 4.4A). At 500 µM, the difference in the length of the targeting arms is magnified. 
Ribozyme 654, which only differs from 554 by a single nucleotide in the targeting arms, 
is ~ 25% more efficient. These results led us to speculate that increasing the length of the 
targeting arms may significantly increase the in vivo gene-regulatory efficiency of a 
trans-ribozyme element. In addition to increasing ribozyme affinity for target, increasing 
the targeting arm length should favor proper ribozyme binding to the target.  
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Optimization of thRz targeting arms leads to fast, efficient cleavage at physiological 
MgCl2 concentrations 
 To test whether increasing the targeting arms improves ribozyme cleavage 
efficiency, we constructed three new thRz designs that incorporated longer targeting arms 
(Figure 4.3B). One design (1154) increased the length of the 5’ arm by 5 nts. The second 
(1154+5) and third (1654) designs built on the first by adding 5 nts to the 3’ and 5 nts to 
the 5’ end, respectively (Figure 4.3B). When the resulting ribozyme sequences were 
folded in RNAstructure 4.3 with the 137 nt target sequence, the proper ribozyme-binding-
to-target structure dominated the energy landscape as the minimum free energy (MFE) 
structure and was the only structure found in the 20 lowest free energy structures 
(Supplementary Figures 4.1-3). When tested in the in vitro ribozyme cleavage end point 
assays the canonical trans-ribozymes with increased targeting arm length, resulted in 
greater than 90% cleavage of the target transcript at physiological Mg2+ concentrations 
(Figure 4.5A). Furthermore, the thRzs with increased targeting arm length (1154, 
1154+5, 1654) exhibit greater cleavage efficiencies at low Mg2+ concentrations than the 
previous canonical thRz design (554, 654) at higher Mg2+ concentrations. These results 
support that the limiting step in the cleavage reaction is the intramolecular binding event 
between the thRz and target sequences. Formation of the catalytically active 
conformation appears to occur readily once the target is found as indicated by the 
difference between 654 and 1154. However, increased targeting arm lengths may also 
contribute to increased cleavage efficiency by increasing the stability of the active tertiary 
conformation as well as the formation of the correct secondary structure. Additionally, 
the in vitro cleavage assays demonstrate that lengthening the targeting arms facilitates 
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very rapid cleavage of target transcript (Figure 4.5A). Within 10 minutes, all of the 
redesigned thRzs reach 97% cleavage efficiency or higher, while even after an hour thRzs 
with shorter arms showed 90% or less cleavage efficiency. For in vivo application it is 
important that the ribozymes act on biologically relevant time scales (~several minutes). 
While previous in vitro studies have demonstrated fast and efficient thRz cleavage at 
higher Mg2+ concentrations (1 mM), these results suggest that full-kinetic evaluation will 
prove these thRzs to be highly efficient at 500 μM (on the order of minutes).  
Figure 4.5. Initial ribozyme designs with extended targeting arms show improved in vitro efficiency 
but fail to knockdown expression in vivo. A. In vitro cleavage assay after 10 minutes at 500 uM Mg+2. B. 
In vivo fluorescence levels of yEGFP in various controls and constructs. Relative fluorescence levels were 
calculated by normalizing mean GFP levels of cells by the mean GFP level of the no ribozyme control. All 
fluorescence data are reported as the mean ± SD from at least three independent experiments.  
  
The gene-regulatory activities of the thRzs with lengthened targeting arms were 
assayed in vivo as described previously from the pCS933 expression system. However, 
despite very promising in vitro results, these optimized trans-ribozymes did not yield 
observable knockdown of the target gene when assayed in the in vivo expression system 
(Figure 4.5B). We suspect that topological constraints on the ribozyme transcript may 
hinder ribozyme-target binding, potentially explaining the lack of observable cleavage 
activity of these ribozymes in vivo. The ribozymes are expressed from a Pol II promoter, 
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such that during transcription, a modified nucleotide called the 5’ cap is added to the 5’ 
end of the ribozyme-encoding mRNAs. As protein factors accumulate on the transcript, 
the cap binds to the poly-A tail and circularizes the transcript. We postulated that in the 
ribonucleoprotein particle (RNP) ribozymes may be inhibited from binding to the target 
transcript by the topological constraints imposed by circularization of the transcript and 
binding of proteins to the transcript. For example, ribosome loading onto the transcript 
through the 5’ cap structure may occlude the targeting arms from being free to interact 
with the target transcript. 
 
Implementation of a novel expression system improves the knockdown efficiency of 
the trans-ribozyme elements 
 To test whether knockdown could be improved by preventing topological 
constraints imposed during transcript circularization, we designed and constructed an 
expression cassette that would allow the thRz to be separated from the RNP. Specifically, 
two cis-acting hammerhead ribozymes (chRzs) were placed on either side of the thRz 
element (into pCS933 at AvrII and SacII restriction sites) (Figure 4.5). This new thRz 
expression cassette contains two chRz, previously shown to be highly efficient at self-
cleaving in vivo [11, 15], separated by two unique restriction sites, SacI and SphI, for the 
rapid cloning of the thRz between these two elements (pCS975). The chRzs are expected 
to excise the thRz from the RNP through self-cleavage, resulting in removal of the 
transcript tails containing the 5’ cap and the poly-A tail. Removal of the 5’ cap and poly-
A tail will also prevent ribosomes from loading onto the transcript. Additionally, by 
isolating the liberated transcript from promoter- and terminator-specific transcript tails, 
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the chRz processing cassette is expected to facilitate thRz portability across a range of 
expression systems. 
  
Figure 4.6.  Redesigned expression system. The chRz processing cassette was cloned into pCS933 at 
AvrII and SacII sites to create pCS975. thRz were subsequently cloned between SphI and SacI. pCS975 
expresses the trans-ribozyme with flanking cis-hRz (boxes in green) on either side of the thRz transcript 
designed. Following transcription the chRZs trim the transcript tails, removing the 5’ cap and poly-A tail  
to yield the chRz-processed RNA. Remaining chRz tails shown in blue boxes.  
  
 To test in vitro activity of the ribozymes in the context of the new expression 
system, the ribozymes were transcribed from pCS975 containing the chRz cassette along 
with promoter- and terminator-tails as described previously. In vitro cleavage assays 
confirmed that the chRzs cleave with near-perfect efficiency during transcription as 
expected given the high Mg2+ concentration of the T7 transcription buffer (data not 
shown). The resulting thRzs with chRz tails were incubated with target at various Mg2+ 
concentrations. At physiological Mg2+ concentrations, the thRzs in the context of the 
chRz-processing cassette show significant sensitivity to targeting arm length. Activity is 
completely abolished for the thRz with shorter targeting arms (554, 654), but restored for 
the thRzs with longer targeting arms (Supplementary Figure 4.4A and Figure 4.7A). 
Overall, the thRzs flanked by the chRzs demonstrated lower cleavage activity compared 
to the original expression system while maintaining similar trends in cleavage 
efficiencies. These data suggest that the chRz tails that remain on the trans-ribozyme 
transcript following cis-cleavage may interfere with thRz activity especially when the 
targeting arms are shorter. By investigating the predicted structures of ribozymes folded 
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with target transcripts in RNAstructure 4.3, we determined that the chRzs’ tails are 
predicted to interfere with thRz binding to the target by preferentially promoting 
formation of Watson-Crick bonds between the target sequence and the catalytic core 
(Supplementary Figures 4.5–4.7). The resulting competition between the core region and 
targeting arms for binding to the target sequence may result in the observed decrease in 
the activity of the trans-ribozyme elements. This effect may be magnified at low Mg2+ 
concentrations, where proper folding of the ribozyme is not aided by increased levels of 
this ion.  
 
 
Figure 4.7. Improved ribozymes with chRz-processing expression cassette show only modest in vivo 
knockdown despite significant improvement in vitro. A. In vitro cleavage assays after 1 hr at 500 uM 
Mg+2. B. In vivo fluorescence levels of yEGFP in various controls and constructs. Relative fluorescence 
levels were calculated by normalizing mean GFP levels of cells by the mean GFP level of the no ribozyme 
control. All fluorescence data are reported as the mean ± SD from at least three independent experiments. 
  
In vivo assays of ribozyme gene-regulatory activity were performed as described 
previously to determine if the chRz-processing cassette improved ribozyme-mediated 
knockdown. In vivo expression of the ribozymes from the redesigned plasmid system 
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demonstrated minimal knockdown of gene expression (~ 10%) (Figure 4.7B). Given that 
we had established efficient catalytic activity of our designs at low Mg2+ concentrations 
(through the in vitro cleavage assays) and modified the design of the expression construct 
to eliminate potential interference from the RNP and ribosome loading via the chRz 
processing cassette, we suspected that the in vivo gene-regulatory activity of the trans-
ribozyme system may be limited by efficient localization and thus hybridization of the 
trans-ribozyme element to the target transcript in the dense cellular milieu. Additionally, 
it is possible that by excising the thRzs from the RNP stability of the ribozyme transcript 
was compromised. Destabilized transcripts would be expected to have short residence 
times, potentially shorter than the time necessary to locate and hybridize to a target 
transcript.  
 
Varying target expression levels indicates a biphasic relationship between target 
concentration and in vivo knockdown activity of the trans-ribozyme elements  
To determine whether in vivo knockdown could be improved by modulating the 
expression of the target, we modified the in vivo assay system such that the level of target 
transcript could be tuned relative to the level of ribozyme being expressed. It is expected 
that increasing the level of target transcript will increase the probability of trans-ribozyme 
binding to the target, thereby potentially increasing ribozyme-mediated knockdown 
within a particular range of target transcript. Above this range, as ribozymes become 
saturated by target, knockdown would be expected to taper off and ultimately become 
unobservable as the rate of binding and cleaving the target transcript is dwarfed by the 
rate of target expression. Due to these competing effects of target transcript levels, there 
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may be an optimal level of target expression at which to observe knockdown. Given that 
we anticipated that ribozyme saturation could be an issue, the original and improved thRz 
expression systems were constructed on a high-copy plasmid with a strong TEF1 
promoter to maximize thRz expression. To further increase the ratio of ribozyme to target 
we modified the target expression system to allow titration of the target transcript over a 
lower range of expression levels. An expression construct encoding the yEGFP gene 
regulated from a galactose-inducible promoter, pGAL1, was integrated into the yeast 
chromosome to make strain CSY341. Integrating the yEGFP cassette at the GAL2 locus, 
converted the all-or-none response of the galactose-inducible promoter to a linear, 
homogenous response to galactose as was previously shown [28]. With this modified 
expression system the target transcript levels increase as a function of increasing 
galactose concentrations. The previous target expression strain CSY132 has yEGFP 
integrated with pTEF1 and a PEST destabilization tag. The TEF1 promoter is more than 
10 times stronger than the pGAL1 promoter induced with 2% galactose for 6 hours 
(Supplementary Figure 4.8). 
 
Figure 4.8. Controlling target expression via the galactose-inducible promoter demonstrates  that 
knockdown increases at higher expression levels of target transcript. A. In vivo  fluorescence levels of 
yEGFP in various controls and constructs for thRz in chRz-processing expression cassette (pCS975) at  1% 
galactose and  B. 2% galactose.  Target transcript levels increase with increasing galactose levels. Relative 
fluorescence levels were calculated by normalizing mean GFP levels of cells by the mean GFP level of the 
1% galactose 2% galactose
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no ribozyme control. All fluorescence data are reported as the mean ± SD from at least three independent 
experiments.  
 
 
We tested the thRz with and without the chRz processing cassette expression 
system, pCS933 and pCS975, respectively, for in vivo knockdown of different levels of 
target expression. Cells were grown overnight in noninducing, nonrepressing conditions 
and induced at 1% or 2% galactose for 6 hours before assaying yEGFP via flow 
cytometry (Materials and Methods). Relative expression was calculated by normalizing 
to the mean fluorescence of the no ribozyme control at the corresponding galactose 
concentration. Raw fluorescence means increase on average 3-fold from 1% to 2% 
galactose. At 1% galactose, ribozyme-mediated knockdown activity is not observed for 
the thRzs expressed with or without the chRz processing cassette (Figure 4.8A and 
Supplementary Figure 4.9A, respectively). However, both trans-ribozyme expression 
systems exhibit improved knockdown ranging from 16%–35% when target gene 
expression is increased by adding 2% galactose to the cells (Figure 4.8B and 
Supplementary Figure 4.9B). This data supports the hypothesis that mediating the 
ribozyme-target binding event is the limiting step in vivo. 
In evaluating the efficacy of the thRzs across a range of target expression levels, 
the results indicate that increasing expression levels by ~ 3-fold (from 1% to 2% 
galactose) increases knockdown from 0% to 35%. However, in the pTEF1-yEGFP-PEST 
target expression system where expression levels are estimated to be an order of 
magnitude higher than in the galactose-titratable CYS341 system at 2% galactose, very 
minimal knockdown is observed (Figure 4.7B). Taken together, these data suggest that 
ribozyme-mediated knockdown may exhibit a biphasic response to target transcript 
levels.  
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Discussion 
 We have shown that thRzs can be engineered for improved catalytic activity in 
vitro that translates to in vivo knockdown dependent on target transcript expression. 
Through the rational design of the targeting arms aided by computational models of RNA 
secondary structure, in vitro thRz activity at physiologically relevant Mg2+ concentrations 
was significantly increased. Additionally, by modifying our in vitro cleavage assay such 
that the target sequence more accurately reflects the sequence and associated structure 
targeted in vivo, we developed a more instructive in vitro cleavage assay for evaluating 
the potential of thRz designs to efficiently cleave target transcripts at physiologically 
relevant Mg2+ concentrations. Results from the improved in vitro assays indicate that 
increasing targeting arm length improves thRz cleavage efficiency. Further, at these 
lower Mg2+ concentrations, our in vitro results support that the designed thRzs efficiently 
cleave the target on biologically relevant timescales. We observed that implementation of 
a chRz processing cassette that releases the thRz from the RNP facilitates modest 
knockdown of the target in vivo, an improvement over our initial expression system. 
Finally, varying target expression levels suggests that ribozyme-mediated knockdown in 
vivo is highly sensitive to target expression levels and responds biphasically to increasing 
target expression.  
To capture binding constraints imposed by the structures formed by the sequences 
flanking the target sequence on the target transcript, we modified our in vitro assay to 
analyze cleavage of a longer target sequence. Previous in vitro analysis of trans-ribozyme 
efficiency evaluated ribozymes targeting transcripts that were 18 nts in length, such that 
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the targeting arms hybridized to all but one nt of the sequence [20]. In our modified assay 
we transcribed 137 nts of the target sequence with 86 and 51 nts on either side of the 
cleavage site. We anticipated that a target of this length would capture local interactions 
of the target sequence with the flanking sequence, thus providing us with an assay that 
captures potential limitations to ribozyme hybridization and cleavage that may exist in 
the in vivo conditions. While previous assays utilizing short target sequences showed that 
canonical ribozymes with short targeting arms rapidly achieve high cleavage efficiencies 
(> 90% in 5 minutes) at low Mg2+ concentrations [20], our results with the longer target 
transcript demonstrate that increased targeting arm length was required for similarly 
efficient cleavage. Further, only thRzs with elongated arms achieved observable 
knockdown in vivo, suggesting that assaying thRz with longer target transcripts improves 
the translation of cleavage efficiency observed in vitro to knockdown observed in vivo 
Despite improving the ability of the in vitro assay to capture the impact of longer 
target transcripts on cleavage efficiency, the assay could be further improved to mimic 
the additional constraints imposed by the in vivo environment on thRz binding and 
cleavage. Assays were performed at 50 mM Tris-Cl pH 7.0, 100 mM NaCl at different 
MgCl2 concentrations as described in previous work [20]. This reaction buffer is unlikely 
to model the crowded cellular environment. Supplementing the buffer with PEG and/or 
BSA could potential provide a closer model of the dense cellular milieu in which 
ribozymes and target transcripts must hybridize. Additionally, since we performed our 
assays by annealing the ribozyme and target sequences together following purification, 
the assay could be improved by separately annealing the sequences. In vivo ribozymes 
and target transcripts are transcribed and folded independently, which is likely to result in 
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important intramolecular structures that can influence ribozyme-target binding. To more 
accurately represent potential limitations to hybridization of the thRz and target transcript 
that arise in the intracellular folding environment, individual annealing steps to remove 
entrapped, nonminimal energy structures induced during the purification step can be 
performed prior to combining the transcripts or potentially dispensed with all together. 
While it is desirable to cotranscribe ribozymes with the target, the composition of T7 
transcription buffer precludes assessing cleavage efficiency at low Mg2+ concentrations, 
an important requirement for accurately modeling the effect of the intracellular 
environment on cleavage efficiency.     
We demonstrated that the chRz-processing expression system modestly improves 
knockdown over the original system at high target expression levels. However, no 
significant difference is observed at low target expression between the two ribozyme 
expression systems examined in this study. Because the chRz-processing cassette 
removes the 5’ cap and poly-A tail that acts to stabilize transcripts, this expression system 
may reduce the half-life of expressed thRzs in vivo. One explanation for the observed 
behavior is that at high target expression levels, removing the topological constraints 
imposed by the RNP may improve ribozyme hybridization rates such that a reduced half-
life is less consequential. However, at lower target expression levels, where the average 
time to bind to a target sequence is expected to increase, thRz half-life may more 
significantly impact knockdown efficiency and erase efficiencies gained from removing 
topological constraints associated with the RNP. The expression system might be further 
improved by the addition of strong hairpin elements at the 5’ and 3’ ends of the thRz. 
Such hairpins can increase the residence time of transcripts by protecting against 
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exonuclease degradation [29, 30]. In addition, spacer regions can be designed to separate 
the hairpins from the thRz, which may allow for greater insulation of the thRz targeting 
arms from any bound nucleases or other proteins. Expression systems that can prevent 
proteins from occluding the thRz targeting arms and increase thRz half-life may result in 
improved knockdown efficiency. 
Varying the levels of the target indicated that ribozyme-mediated knockdown 
exhibits a biphasic dependence on target expression levels. Specifically, at very low 
expression levels, no knockdown is observed. Increased expression (3-fold) above this 
low level results in an increase in the observed knockdown, suggesting that in vivo the 
intramolecular binding event may be limiting knockdown at low target concentrations. 
However, increasing expression by an order of magnitude reduces observable knockdown 
potentially due to the target transcript saturating the available ribozyme pool. Probing the 
range and threshold of target expression for which knockdown is observed could provide 
a better understanding of the optimal range of target expression levels for thRzs. 
Delineating this response curve to target expression levels would be useful in identifying 
potential systems in which trans-acting ribozymes may be effectively applied as 
regulators of gene expression. The range and threshold of target expression permitting 
thRz-mediated knockdown are likely to be sequence-specific, thus it would be important 
to identify a high impact set of targets for ribozyme-mediated knockdown. We did not 
further probe the threshold and range in our system due to a few system limitations. One 
drawback of the galactose-titratable system is the inherent noisiness of the galactose 
promoter. For some samples such as pCS975 1654 (Figure 4.8B), the replicate variability 
did not allow for significant differentiation from the controls given the error associated 
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with the assay and system. A more comprehensive and precise study of the relationship 
between knockdown and target expression levels could be performed by assaying thRz 
gene-regulatory activities in strains in which the target is expressed from constitutive 
promoters of varying strength and integrated into the chromosome.  
While we have addressed several potential limitations to ribozyme-mediated 
knockdown, there remain several additional avenues that should be explored to further 
improve knockdown efficiency. Previous in vivo work with thRzs has shown success in 
targeting the HIV-1 transcript, which is localized to the nucleolus [4]. Researchers used 
an expression system that localizes thRzs to the nucleolus in order to achieve substantial 
knockdown of HIV-1 transcripts. Thus, developing a mechanism to localize ribozymes to 
the target transcript may broadly improve knockdown across a range of target transcript 
levels. While for many endogenous genetic targets it is not possible to colocalize 
sequences to cellular substructures, this strategy may be effective for particular systems 
in which transcripts localize to specific parts of the cell. Additionally, the localization 
constraints for transcripts may position trans-ribozymes as effective regulators within the 
context of synthetic gene networks where transcript colocalization can be mediated via 
expression of the trans-ribozyme and target transcript from the same vector. One final 
consideration in developing ribozymes as effective regulators of gene expression is the 
accessibility of the target sequence. Several studies have examined the accessibility of 
sequences within transcripts for binding to nucleic acids and developed algorithms that 
predict sequences that exhibit enhanced binding accessibility [31-33]. The utilization of 
such algorithms may improve the design of trans-acting ribozymes by identifying 
accessible target sequences. 
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 While the development of a trans-ribozyme platform represents an opportunity to 
regulate the expression of target transcripts without the need to modify existing, 
endogenous cellular components, such as binding sites, promoters, repressors, and other 
cis-acting regulatory elements, or saturating the natural regulatory RNAi pathway, the 
limited activity observed from these systems in vivo constrain the potential applications 
of this system. Based on these studies, systems with moderately high levels of target 
transcript that require only modest levels of knockdown are potential candidates for thRz 
regulation. For example, diseases such as cancer and Alzheimer’s are characterized by 
aberrantly high mRNA levels of particular genes [7, 34, 35]. In Her2 positive cancer 
cells, overexpression of the Her2 receptor leads to increased cellular growth via 
upregulation of the signaling pathway [35]. High Her2 expression negatively correlates 
with survival rates in endometrial cancer [34]. Monoclonal antibodies that target the Her2 
receptor reduce tumor proliferation and increase survival rates presumably by binding to 
Her2 and blocking signaling. Further, siRNA knockdown of Her2 sensitizes cells to 
monoclonal antibody therapy [34]. However, the systemic administration of these 
antibodies has resulted in lethal side-effects such as cardiac dysfunction [36]. Broad 
distribution of these antibodies particularly to cardiac tissue is suspected to reduce 
signaling critical to preventing cardiac myopathy [35]. To improve therapies for Her2 
positive cancers, a thRz targeting the overexpressed Her2 transcripts could provide a 
therapy targeted to diseased cells. At high Her2 levels, a modest yet potentially 
significant knockdown of the target transcript could reduce aberrant signaling and 
additionally sensitize cells to monoclonal therapy. Further, such thRz therapies could 
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prevent lethal side effects by remaining inert in the case of lower expression levels 
characteristic of healthy cells.   
There remain several challenges in developing such a therapy. First, the 
expression levels of target transcripts in healthy and diseased cells would need to be 
determined and evaluated. To reduce expression in diseased cells, expression must be 
above the requisite threshold for trans-ribozyme-mediated knockdown, but not so high as 
to saturate the ribozymes present in the cell. Additionally, to optimally differentiate 
healthy and diseased cells and limit side-effects, expression levels for each cell type 
should fall below and above the minimum threshold, respectively. Second, utilizing the 
principles elucidated above, various thRzs would need to be designed to the target 
transcripts. Utilizing previously mentioned algorithms may aid in the identification of 
accessible target sites within the transcript. Thirdly, the threshold for knockdown would 
need to be evaluated to determine if significant knockdown of the targets can be achieved 
in the diseased cells and if there are any potential effects on healthy cells. It would be 
useful to determine if the threshold of target transcript knockdown can be tuned via the 
design of the targeting arm lengths, such that transcripts across a broad range of 
concentrations can be targeted, increasing the range of potential systems to which these 
thRzs could be applied. Additionally, differences in metabolism, particularly those 
affecting transcript degradation and translation rates, may alter the in vivo efficiency of 
thRzs between organisms. This consideration may explain why previous examples of 
thRzs in vivo knockdown have been mostly limited to higher eukaryotes [22, 25].  
Finally, ligand-mediated control of ribozyme activity would be a useful tool in directing 
thRzs as a therapeutic agent. However, the limited efficiency observed in our in vivo test 
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system implies that the current designs would not be amenable to switch construction. 
While the rules for construction of ligand-responsive switches from chRzs are expected 
to be readily transferable to thRzs, constructing switches requires appending sequences to 
the thRz stem II loops. In chRzs, appending sequences to the stem II loops has been 
shown to reduce cleavage efficiency compared to the nonswitch control [26]. For the 
successful construction of ligand-responsive thRz switches, ribozymes are anticipated to 
require higher in vivo activity than those developed in this study to target yEGFP. 
 While significant progress has been made in understanding the catalytic behavior of 
trans-acting ribozymes in vitro in this work and others [17, 18, 20], this progress has not yet 
been translated beyond modest in vivo gene regulation. Given the success of cis-acting 
ribozymes in vivo, the key limitation to efficacy of trans-acting ribozymes appears to be 
facilitating the intermolecular hybridization interaction between the trans-ribozyme and target 
mRNA sequences. While this limits the potential application space of trans-acting ribozymes, it 
may position these devices as uniquely targeted regulators of gene expression for systems 
requiring modest knockdown of targets that are overexpressed and near quiescence at normal 
low levels. Additionally, trans-ribozymes may be useful control tools within synthetic circuits 
where there exists greater design flexibility for mediating transcript colocalization. Future work 
on these devices should focus on identifying potential systems for application and designing 
thRz to function in these systems as biochemical controllers of gene expression.  
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Materials and methods 
Plasmid and ribozyme construction 
Standard molecular biology cloning techniques were used to construct all 
plasmids [37]. DNA synthesis was performed by Integrated DNA Technologies 
(Coralville, IA). All enzymes, including restriction enzymes and ligases, were obtained 
through New England Biolabs (Ipswich, MA). Ligation products were electroporated 
with a GenePulser XCell (Bio-Rad, Hercules, CA) into an E. coli DH10B strain 
(Invitrogen, Carlsbad, CA), where cells harboring cloned plasmids were maintained in 
Luria-Bertani media containing 50 mg/ml ampicillin (EMD Chemicals). All cloned 
constructs were sequence verified by Laragen Inc (Santa Monica, CA). 
The thRz expression constructs, pCS933 and pCS975, were constructed from 
pCS346 (Supplementary Figure 4.10). pCS346 bears two sets of TEF1 promoters and 
CYC1 terminators with intervening unique restriction sites.  Briefly, pCS933 was 
constructed by cloning a version of RFP (tdimer2), which served as a transformation 
control signal, into the SalI and NotI restriction sites downstream of the second TEF1 
promoter in pCS346. Site-directed PCR mutagenesis was performed to remove the two 
SacII sites from tdimer2, preserving SacII as a unique restriction site using the 
QuikChange II Site-directed mutagenesis kit (Agilent, Santa Clara, CA) according to 
manufacturer instructions. The pCS933 engineered ribozyme constructs were generated 
by cloning the appropriate thRz constructs into the unique restriction sites, AvrII and 
SacII, downstream of the first TEF1 promoter (see Supplementary Table 4.1 and 
Supplementary Table 4.2). The thRz with flanking chRzs plasmid, pCS975, was 
constructed by cloning a cassette containing two chRz with two intervening unique 
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restriction sites, SphI and SacI, into AvrII and SacII using the primers Cis-
Cis.sTRSV.FWD and Cis-Cis.sTRSV.REV. The pCS975 engineered ribozyme constructs 
were generated by cloning the appropriate thRz constructs into the SphI and SacI sites. 
All oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA). 
Cloned plasmids were transformed via electroporation into an electrocompetent 
Escherichia coli strain, DH10B (Invitrogen, Carlsbad, CA), and all cloned ribozyme 
constructs were confirmed by sequencing (Laragen, Los Angeles, CA).  
Confirmed plasmid constructs were transformed into CSY132, a S. cerevisiae 
W303 strain harboring a chromosomally integrated pTEF1-yEGFP-PEST target construct 
(MATα his3-11,15 trp1-1 leu2-3 ura3-1 ade2-1, pTEF1-yEGFP-PEST) or CSY341, a S. 
cerevisiae W303 strain harboring a chromosomally integrated pGAL1-yEGFP target 
construct (MATα his3-11,15 trp1-1 leu2-3 ura3-1 ade2-1, ∆gal2, pGAL1-yEGFP) using a 
standard lithium acetate procedure (Supplementary Table 4.3) [38].  To construct 
CSY341, the pGAL1-yEGFP cassette was PCR amplified from pCS1340 (Supplementary 
Figure 4.11) using primers GAL2ko.fwd and GAL2ko.rev to integrate the cassette at the 
GAL2 locus (Supplementary Table 4.4). Yeast strain CSY3 was transformed as described 
previously with 12 µg of gel purified PCR product and plated on G418 plates to build 
yeast strain CSY341.  
 
In vitro endpoint cleavage assays 
All ribozymes were PCR amplified from their plasmids beginning at 23 nts 
upstream from the TEF1 promoter using primers T7Rbz 5'-23.FWD and T7Rbz 3’.REV 
(Supplementary Table 4.5). A 137 nt region of the target yEGFP sequence was amplified 
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by PCR using Target.yEGFP.FWD and Target.yEGFP.REV, where the forward primer in 
each of these amplification reactions harbors the T7 polymerase sequence at its 5’ end. 
PCR products were transcribed using an Ampliscribe T7 kit (Epicentre Technologies, 
Madison, WI) according to manufacturer’s instructions. Transcription reactions were 
DNaseI treated for 15 min. at 37oC and purified into reaction buffer (50 mM Tris-Cl pH 
7.0, 100 mM NaCl, and the specified MgCl2 concentration) through a NucAway column 
(Ambion, Foster City, CA) following the manufacturer’s instructions. The target 
transcript was radiolabeled by modifying the reaction solution to include 2 μl of [α-32P]-
GTP and 1 μl GTP. Cleavage reactions were performed in a 20 μl total volume at 50 mM 
Tris-Cl pH 7.0, 100 mM NaCl, and the specified MgCl2 concentration. The ratio of 
ribozyme to target was 10:1 and 7:1 was specified by varying the volume of purified 
ribozyme and target RNA added to reactions. The ribozyme and target sequence were 
annealed in reaction buffer by incubating at 95°C for 5 min and cooling at room 
temperature for 15 minutes. Reactions were run at 37°C for either 10 or 60 minutes and 
quenched with the addition of RNA loading buffer II (Ambion). Prior to loading on the 
gel, reaction products were heated at 65°C for 5 minutes and chilled at 4°C for 5 minutes. 
The reaction products were separated on a 6% denaturing PAGE gel, dried, and 
visualized on a FX phosphorimager (Bio-Rad, Hercules, CA). The RNA decade ladder 
(Ambion Foster City, CA) was used as a size marker. The background-subtracted 
intensity of full-length target (137 nt) and cleaved products (~50 and 85 nts) were 
quantified for each sample using the Quantity One software package (Bio-Rad). The 
fraction of RNA uncleaved was determined by dividing the intensity of full-length target 
by total intensity. 
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In vivo ribozyme characterization assays 
S. cerevisiae cells (W303) harboring the appropriate plasmids were grown in 
synthetic complete medium supplemented with an appropriate dropout solution and sugar 
[2% (wt/vol) dextrose] overnight at 30°C. For galactose titration, 2% raffinose and 1% 
sucrose were substituted for dextrose. Overnight cultures were back-diluted into fresh 
medium to an optical density at 600 nm (OD600) of ∼ 0.1 and grown at 30°C. For 
galactose titration experiments, cells were back-diluted into fresh medium containing the 
specified galactose concentration. Cells were grown for 6 hours (~ OD600 of 0.8−1.0) 
before measuring GFP levels on a Cell Lab Quanta SC flow cytometer (Beckman 
Coulter, Fullerton, CA). 
 
Fluorescence quantification 
Population averaged fluorescence values were measured on a Quanta flow 
cytometer with the following settings: 488 nm laser line, 525 nm bandpass filter, and 
photomultiplier tube setting of 7.53 on FL1 (GFP) and 6.53 on FL3 (RFP). Fluorescence 
data were collected under low flow rates for ∼ 20,000 viable cells. Cells bearing plasmids 
not expressing RFP were used to set a “RFP negative” gate. Viable cells bearing the 
plasmid were selected by gating for cells with fluorescence values on FL3 greater than 
the RFP negative gate. GFP fluorescence levels were determined from 10,000 counts in 
this selected population. Since the pTEF1-yEGFP cassette is integrated into the 
chromosome, the mean FL1 values from the entire population of viable, RFP positive 
cells was determined as the sample’s GFP expression level. Relative fluorescence levels 
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were calculated by normalizing mean GFP levels by the mean GFP level of the no 
ribozyme control. All fluorescence data are reported as the mean ± SD from at least three 
independent experiments. 
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Supplementary figures 
 
Supplementary Figure 4.1. Comparison of minimal ribozyme folded with truncated and extended 
target sequence in RNAstructure. A. The minimal ribozyme, SS1, folded without promoter and 
terminator transcript tails to truncated target sequence shows proper ribozyme-target binding and formation 
of the catalytic core. B. The minimal ribozyme, SS1, folded with promoter and terminator transcript tails 
from pCS933 to the extended 137 nucleotide (nt) yEGFP sequence shows nucleotides in the catalytic core 
preferentially binding to target sequence, preventing core formation. Stem II boxed in blue to provide 
orientation and comparison between figures.  
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Supplementary Figure 4.2. Control ribozyme sequences from pCS933 folded with extended 137 
nucleotide yEGFP target sequence. A. SSCR1, a ribozyme with scrambled core sequence folded with 
target shows mutated core binding to target sequence. B. SSACR, a ribozyme with scrambled targeting 
arms shows that targeting arms do not properly fold with target. C. SS1, a minimal ribozyme without 
canonical loops, shows nucleotides in the catalytic core binding to target sequence. Stem II boxed in blue to 
provide orientation and comparison between figures.  
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Supplementary Figure 4.3. Canonical ribozyme sequences from pCS933 folded with extended 137 
nucleotide yEGFP target sequence. A. 554, a ribozyme with canonical PLMVd stem loops folded with 
target shows core binding to target sequence. B. 654, a ribozyme with canonical PLMVd stem loops folded 
with target shows 5’ targeting arm preferentially binding as a hairpin instead of to target sequence. C-E. 
1154, 1154+5, and 1654 folded with target show ribozyme binding to target sequence and proper catalytic 
core formation. Stem II boxed in blue to provide orientation and comparison between figures.  
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Supplementary Figure 4.4. Initial ribozyme designs with chRZ processing expression cassette 
(pCS975). A. In vitro cleavage assays after 1 hr at various Mg+2 concentrations demonstrate the chRz-
processing cassette thRzs are highly sensitive to Mg+2 concentrations.  B. In vivo fluorescence levels of 
yEGFP in various controls and constructs. The initial ribozyme designs are insufficient to knockdown 
expression in vivo as expected from the in vitro data. Relative fluorescence levels were calculated by 
normalizing mean GFP levels of cells by the mean GFP level of the no ribozyme control. All fluorescence 
data are reported as the mean ± SD from at least three independent experiments.  
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Supplementary Figure 4.5. Control ribozyme sequences from pCS975 folded with extended 137 
nucleotide yEGFP target sequence. A. SSCR1, a ribozyme with scrambled core sequence folded with 
target shows arms correctly binding target sequence. Mutated core also binds “X” in NUX triplet of target 
sequence. B. SSACR, a ribozyme with scrambled targeting arms shows that targeting arms do not properly 
fold with target. C. SS1, a minimal ribozyme without canonical loops, shows nucleotides in the catalytic 
core binding to target sequence. Stem II boxed in blue to provide orientation and comparison between 
figures.  
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Supplementary Figure 4.6. Canonical ribozyme sequences from pCS975 folded with extended 137 
nucleotide yEGFP target sequence. A. 554, a ribozyme with canonical PLMVd stem loops folded with 
target shows core highlighted in red binding to target sequence. B. 654, a ribozyme with canonical PLMVd 
stem loops folded with target shows core highlighted in red binding to target sequence. Stem II boxed in 
blue to provide orientation and comparison between figures.  
 
Supplementary Figure 4.7. Canonical ribozyme sequences from pCS975 folded with extended 137 
nucleotide yEGFP target sequence. A-C. 1154, 1154+5, and 1654, respectively folded with target show 
ribozyme binding to target sequence and proper catalytic core formation highlighted in red. Stem II boxed 
in blue to provide orientation and comparison between figures.  
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Supplementary Figure 4.8. Promoter characterization. pGAL1 induced at shown percentage of 
galactose for 6 hours. GFP expression is calculated from the fluorescent geometric mean of viable cells 
gated above the nonfluorescent control. Expression is shown relative to pTEF7. pTEF1 data from reference 
for TEF1 library showing pTEF7 is 16% of pTEF1 strength. 
 
 
Supplementary Figure 4.9. Ribozyme designs with extended arms in pCS933. A. In vitro cleavage 
assays after 1 hr at various Mg+2 concentrations. B. In vivo fluorescence levels of yEGFP in various 
controls and constructs. Relative fluorescence levels were calculated by normalizing mean GFP levels of 
cells by the mean GFP level of the no ribozyme control. All fluorescence data are reported as the mean ± 
SD from at least three independent experiments, except where a single sample is indicated by * and no 
error bars. 
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Supplementary Figure 4.10. Plasmid maps for ribozyme expression vectors. A. pCS346 was previously 
constructed by K. Hawkins with two expression cassettes with promoter (pTEF1) and terminator (CYC1t) 
controlling two enzymes NCSdelta19 and 6OMT.  B. pCS933 was constructed from by cloning a version of 
RFP, tdimer2, into the SalI and NotI restriction sites downstream of the second TEF1 promoter in pCS346 
and served as a transformation control signal. C. pCS975 was constructed from pCS933 by cloning a 
cassette containing two chRz with two intervening unique restriction sites, SphI and SacI, into AvrII and 
SacII using the primers Cis-Cis.sTRSV.FWD and Cis-Cis.sTRSV.REV to create the cis-processing cassette 
shown as Cis-Cis module.  
 
Supplementary Figure 4.11. Plasmid maps for construction of CSY341 expression vectors. A. 
pCS687. B. pCS1340 was constructed from pCS687 adding yEGFP between BamHI and AvrII and 
B_PLMVd Barcode between AvrII and XhoI.  
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Supplementary tables 
Supplementary Table 4.1. Plasmids 
 
 
 
 
 
 
 
 
 
 
pCS# Description Yeast Marker E.coli Marker
pCS687
LoxP integrating vector, no yeast origin of 
replication, derived from pCS270, a pUC 
vector.
KanMX AMP
pCS1340
pCS687+ yEGFP cloned between BamHI 
and AvrII and  B_PLMVD (5'-) cloned in 
3'UTR between AvrII and XhoI
KanMX AMP
pCS346
Previously constructed by K. Hawkins with 
two expression cassettes with  promoter 
(pTEF1) and terminator (CYC1t )
URA AMP
pCS933
pCS346 + tdimer2 between SalI and NotI
URA AMP
pCS975
pCS933 + cis-cis.STRSV Cassette 
between SacII and AvrII URA AMP
pCS933 SSCR1 (aka "Rz core mut") URA AMP
pCS933 SSACR  (aka "Rz arms mut") URA AMP
pCS933 SS1-(aka "mRz" or "Rz no loops") URA AMP
pCS933 554 URA AMP
pCS933 654 URA AMP
pCS933 1154 URA AMP
pCS933 1154+5 URA AMP
pCS933 1654 URA AMP
pCS975 SSCR1 (aka "Rz core mut") URA AMP
pCS975 SSACR  (aka "Rz arms mut") URA AMP
pCS975 SS1-(aka "mRz" or "Rz no loops") URA AMP
pCS975 554 URA AMP
pCS975 654 URA AMP
pCS975 1154 URA AMP
pCS975 1154+5 URA AMP
pCS975 1654 URA AMP
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Ribozyme Type Sequence Cloning notes
GGAAAGCATGCTAACAAGTACTGTGAGGTGAAAACC
TCCTCACCATGTGGGAGCTCAAAC
GGAAAGCATGCGATGTCCTGATGAGAGGTGAAAACC
TCGAACACGTGAATGAGCTCAAAC
GGAAAGCATGCTAACAACTGATGAGAGGTGAAAACC
TCGAAACCATGTGGGAGCTCAAAC
GGAAAGCATGCATTCTTAAAACAACTGATGAGTCGCT
GAAATGCGACGAAACCATGTGGGAGCTCAAAC
GGAAAGCATGCAATTCTTAAAACAACTGATGAGTCGC
TGAAATGCGACGAAACCATGTGGGAGCTCAAAC
GGTAACAAATTCTTAAAACAACTGATGAGTCGCTGAA
ATGCGACGAAACCATGTGGC
GGTAACAAATTCTTAAAACAACTGATGAGTCGCTGAA
ATGCGACGAAACCATGTGGTCTCTC
GGAGCAGTAACAAATTCTTAAAACAACTGATGAGTCG
CTGAAATGCGACGAAACCATGTGGC
CTAACAAATTCTTAAAACAACTGATGAGTCGCTGAAA
TGCGACGAAACCATGTGGGAGCT
CTAACAAATTCTTAAAACAACTGATGAGTCGCTGAAA
TGCGACGAAACCATGTGGTCTCTGAGCT
CAGCAGTAACAAATTCTTAAAACAACTGATGAGTCGC
TGAAATGCGACGAAACCATGTGGGAGCT
Canonical 
PLMVd Rz
1654 Canonical 
PLMVd Rz
1154+5 Canonical 
PLMVd Rz
1654 Canonical 
PLMVd Rz
1154 Canonical 
PLMVd Rz
Annealed for 
insert into 
pCS933;                                                                           
Annealed and 
SacI and SphI 
double-
digested for 
insertion into 
pCS975
Annealed for 
insert into 
pCS933
Annealed for 
insert into 
pCS975
SSCR1 Rz core mut
SSACR Rz arms mut
Rz no loopsSS1       
(aka mRz)
554 Canonical 
PLMVd Rz
654 Canonical 
PLMVd Rz
1154 Canonical 
PLMVd Rz
1154+5
CSY# Description
132 MATa his3 -11 ,15 trp1 -1 leu2 -3 ura3 -1 ade2 -1, pTEF1-yEGFP-PEST
341 MATa his3 -11 ,15 trp1 -1 leu2 -3 ura3 -1 ade2 -1,  ∆gal2, pGAL1-yEGFP
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Name Sequence
tdimer2.K2.fwd AAAAAAGTCGACATTAAATAATGGTGGCCTCCTCCG
AGGA
tdimer2.rev AAAAAAGCGGCCGCGAAATTCGCTTATTTAGAAGT
Cis-Cis. sTRSV.FWD
GGCTGTCACCGGATGTGCTTTCCGGTCTGATGAGTCC
GTGAGGACGAAACAGGCATGCAAAAAGAGCTCCTGT
CACCGGATGTGCTTTCCGGTCTGATGAGTCCGTGAGG
ACGAAACAGC
Cis-Cis. sTRSV.REV
CTAGGCTGTTTCGTCCTCACGGACTCATCAGACCGGA
AAGCACATCCGGTGACAGGAGCTCTTTTTGCATGCCT
GTTTCGTCCTCACGGACTCATCAGACCGGAAAGCAC
ATCCGGTGACAGCCGC
tdimer2.SacII.mut.Fwd CTACAAGGTGAAGTTCAGAGGCACCAACTTCCCCC
tdimer2.SacII.mut.Rev GGGGGAAGTTGGTGCCTCTGAACTTCACCTTGTAG
GAL2ko.fwd
ATGCACCTTATTCAATTATCATCAAGAATAGTAATAG
TTAAGTAAACACAAGATTAACATAATAGTGCGGGCCT
CTTCGCTATTACGCCA
GAL2ko.rev: 
ATGATAATTAAAATGAAGAAAAAACGTCAGTCATGA
AAAATTAAGAGAGATGATGGAGCGTCTCACTTCACTA
TAGGGAGACCGGCAGAT
Notes
Primers to mutate Sac II 
sites in tdimer2 
Primers amplifying pCS687 
for integration of pGAL1-
yEGFP into GAL2 locus
SalI, NotI restriction sites;
PCR of tdimer2 for insert 
into pCS346
AvrII and SacII restriction 
sites; 
Annealed for insert into 
pCS933
Name Sequence
T7Rbz 5'-23.FWD GAAATTAATACGACTCACTATAGGCATAGCAATCTA
ATCTAAGTTTTGC
T7Rbz 3’.REV AATTACATGATGCGGCCCTCTCAACCTA
Target.yEGFP.FWD GAAATTAATACGACTCACTATATCCAGTCTTGTTAC
CAGACAAC
Target.yEGFP.REV CAATTCATCCATACCATGGGTAATACC
137nt target sequence
TCCAGTCTTGTTACCAGACAACCATTACTTATCCACT
CAATCTGCCTTATCCAAAGATCCAAACGAAAAGAGA
GACCACATGGTCTTGTTAGAATTTGTTACTGCTGCTG
GTATTACCCATGGTATGGATGAATTGT
T7 sequence in bold;                          
137nt target transcript 
yEGFP (573-708) 86bp 5’ 
and 51bp 3’
Actual sequence transcribed
Notes
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Robustly engineering cell fate via synthetic circuits offers the potential to direct 
developmental programs and intervene in aberrantly activated cell processes. Controlling 
cell fate will advance regenerative medicine by facilitating the ex vivo construction of 
replacement tissues. Further, synthetic circuits may be configured to recognize 
hyperactive programs that lead to disease and reinstitute the proper behavior or eliminate 
misbehaving cells on a cell-by-cell basis limiting side-effects of such therapies [1, 2].  
However, the engineering of systems to regulate cell fate requires precise control over 
circuit performance as well as the ability to interface with decision-making pathways [3]. 
To facilitate the construction of synthetic circuits that regulate cellular behavior for a 
wide range of potential applications, we developed RNA-based controllers and systems 
that were applied to regulate signaling in a model MAPK pathway and direct cell fate. 
Utilizing modular and tunable RNA-based controllers and network architectures, 
we constructed networks of RNA-based control systems that interface with the 
Saccharomyces cerevisiae mating pathway to dictate entry into one of three alternative 
fates dependent on environmental stimuli. In building these networks, we developed a 
readily translatable method for identifying control points within natural networks that 
enable the construction of a modular interface between synthetic circuitry and native 
networks. Additionally, we demonstrated the rational tuning of circuit performance via 
the exchange of well-defined parts to compose networks capable of actuating changes in 
cellular behavior in response to environmental cues. Further, we constructed network 
architectures which facilitate reduced interference from simultaneously integrated 
opposing programs and identified sensitive parameters for engineering robust circuit 
performance. This work provides a model for engineering systems that regulate signaling 
V-3 
 
and direct cells fate which may be applied to additional decision-making pathways to 
advance tissue engineering strategies, treat diseases, and study the behavior of natural 
regulatory networks.  
Immediate challenges for the development of RNA-based control systems that 
regulate signaling and dictate cell fate 
The constructed molecular network diverters robustly program fate in response to 
small-molecule input when integrated into cells independent of the opposing diverter. 
However, due to diverter antagonization, dual-fate routing is only permitted at elevated 
levels of small-molecule input supported by metabolic modulation.. Diverter 
antagonization occurs through subthreshold basal levels of expression from the opposing 
diverter reducing the actuated change in pathway activity induced by the triggered 
diverter, leading to weaker routing. There exist several potential avenues by which to 
reduce the basal expression levels from the diverters and minimize diverter 
antagonization. Reducing the strength of expression by exchanging the promoters that 
regulate the most antagonistic expression modules will reduce basal expression levels. 
However, this strategy necessarily reduces the expression induced from the module, 
potentially hindering diverter performance. Reducing module expression by modification 
of the plasmid system or integration of the expression modules offer the same limitations 
as promoter exchange. Nevertheless, integration of the expression modules may provide 
an advantage over promoter exchange, as integration has been demonstrated to reduce the 
variance of gene expression compared to plasmid-based systems [4]. While broadly 
reducing expression from the various modules may reduce the triggered levels of 
expression from the diverters, the reduction in diverter antagonism may more than 
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compensate for the reductions, potentially enhancing dual-fate routing performance in 
these systems. 
Secondary layers of control provide an alternative to broadly reducing expression 
from the diverters. Trans-acting RNA elements have been demonstrated to reduce basal 
level leakage from circuits in the OFF state, enhancing circuit performance [5-7]. While 
these particular elements are not amenable to the regulation gene expression in yeast, 
trans-acting ribozymes offer a control tool for limiting the basal levels of expression in 
our system. We developed trans-acting ribozymes that target a sequence in the GFP 
transcript. Appending this GFP target sequence to the genes of pathway regulators may 
reduce basal expression when trans-ribozymes are coexpressed with the diverters.  The 
development of additional trans-acting ribozymes and cognate target sequences could 
allow independent regulation of various genes. However, our results indicate that the 
developed trans-acting ribozymes efficiently regulate expression within a relatively 
narrow window of transcript expression, presenting limitations in the effective 
incorporation of these elements to our system. Further work is required to determine if 
the limited window of efficacy is specific to trans-acting ribozymes in general or to the 
particular target sequence to which the ribozyme was developed. Additionally, our results 
suggest that one of the key limitations to trans-ribozyme-mediated knockdown may be 
facilitating the intermolecular binding event between the trans-acting ribozymes and the 
target transcript.  Co-expression of trans-ribozymes with target from the same locus or 
vector may overcome these limitations and improve the range of expression levels over 
which knockdown is observed by facilitating transcript colocalization.   
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Given the success of their cis-acting counter parts as switches, the development of 
more potent trans-acting ribozymes would poise these elements as expression platforms 
by which to construct ligand-responsive trans-acting RNA-based controllers. Trans-
acting RNA-based controllers that regulate gene expression in response to small molecule 
concentrations have been demonstrated in mammalian systems [8, 9] With these trans-
acting switches, basal expression levels could be regulated in response to small-molecule 
concentrations by appending the target sequence to the desired genes. Conditionally 
reducing target expression via the presence or absence of the small molecule offers a 
mechanism for reducing basal expression levels from the various modules without a 
similar reduction in the triggered levels. Reduced diverter antagonism and greater fold 
changes in expression from the diverters may be achieved by the development and 
incorporation of ligand-responsive trans-acting RNA controllers.  
In addition to layers of trans-acting controllers, the introduction of mutual 
inhibitory modules between the dual diverters may facilitate enhanced dual-routing 
performance by reducing diverter antagonization. Mutually inhibitory loops have been 
demonstrated to allow cells to toggle between two distinct phenotypes [10, 11] and may 
be constructed from transcriptional or post-transcriptional elements. Construction of 
transcriptional mutually inhibitory modules requires two orthogonal repressible 
promoters each regulating the expression of the other’s repressor protein. Transcriptional 
mutual inhibitory modules are simply connected to the diverters by promoter exchange in 
the expression modules containing constitutive promoters. While the system is readily 
constructed, identifying repressible promoters of the requisite strength and tuning the 
mutual inhibitory module present a critical hurdle for enhancing diverter function via 
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transcriptional mutually inhibitory modules. Construction of repressible promoter 
libraries will increase the feasibility of constructing and connecting transcriptional mutual 
inhibitory modules to synthetic circuits. Alternatively, post-transcriptional controllers 
provide a promoter-independent mechanism for introducing mutual inhibitory loops into 
the diverter networks, providing greater design flexibility. Post-transcriptional mutually 
inhibitory loops may be constructed by directly modifying the constructed expression 
modules with target sites specific for a trans-acting RNA regulatory element. Imbedding 
cognate trans-acting RNA regulators in the expression modules of the opposing diverter 
establishes an inhibitory regulatory loop from one diverter to another. Addition of a 
secondary inhibitory loop with a different trans-acting RNA regulator and cognate target 
site results in a mutually inhibitory architecture. Further, mutual inhibition via trans-
acting RNA regulators can be made ligand-dependent by the use of small molecule-
responsive trans-acting RNA switches. The continued development of ligand-responsive 
switches from potent trans-acting ribozymes, microRNAs, and other trans-acting RNA-
based regulators of gene expression will enable the construction of more complex control 
schemes within synthetic networks. While regulation via post-transcriptional control may 
be limited in stringency compared to transcriptional control, the added flexibility, 
tunability, and potential for ligand-dependent regulation position post-transcriptional 
mutually inhibitory loops to be important tools for the construction of synthetic circuits. 
The addition of mutually inhibitory modules that enhance differentiation between 
synthetic circuits’ ON and OFF state outputs will enable robust control of cell fate, 
expanding the range of systems and applications to which synthetic circuits may be 
applied.  
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Future directions for the development of RNA-based control systems to regulate 
signaling and dictate cell fate 
The ex vivo construction of tissues, the implementation of autonomous immune 
surveillance, and the development of ‘smart’ therapeutics will require flexible, tunable, 
and scalable synthetic networks that can interface with a range of native pathway via 
circuitry capable of extracting cellular information and actuating changes in cellular 
behavior. Our work presents a method for identifying control points in native pathways 
that is amenable across a wide array of systems. Further, the development of the 
molecular network diverters provides a framework for constructing and tuning synthetic 
networks that control cellular behavior that is readily transportable across pathways, 
organisms, and applications. Yet there remain several challenges to extending these 
systems to applications in health and medicine.  
Application of the molecular diverter strategy for biomedical purposes will 
require the identification of titratable pathway regulators in the decision-making 
pathways in mammalian cells. While our results with the yeast MAPK pathways 
illuminate potential candidates within the homologous mammalian pathways, titration 
studies must be performed in these systems to validate potential pathway regulators’ 
ability to route cells to alternative fates. Further, examination of the pathway response 
curve to varying regulator expression will facilitate identification of the transitory range 
over  which fate diverges and enable rational design of molecule network diverters. 
Titration studies to identify pathway regulators may be performed in mammalian cells 
using the well-documented tetracycline-inducible promoter [12]. Already similar work 
has been performed using the tetracycline-inducible system to facilitate the programming 
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of induced pluripotent stem cells (iPSCs) via the control of key transcription factors [13]. 
In addition to the requisite pathway regulators, our work highlights the utility of pathway-
responsive promoters for the construction of feedback loops that amplify and attenuate 
pathway activity. Identification of relevant pathway-responsive promoters will facilitate 
the construction of molecular network diverters within new pathways. In the ERK 
signaling pathway which is homologous to the yeast mating pathway and responsible for 
controlling cell growth, several pathway-responsive promoters have been characterized 
and reporter constructs with these elements and a host of other signaling pathway are 
commercially available [14]. Tuning promoter expression to achieve the desired strength 
may be accomplished by the construction of promoter libraries or by rational design [15, 
16]. 
Beyond pathway regulators and promoters, improvements in the stringency and 
regulatory range of RNA-based switches as well as the development of new switch 
sensor domains will expand the applicability of molecular network diverters. The 
incorporation of RNA switches exhibiting low basal levels and large dynamic ranges may 
increase between the range of circuit output, enhancing differentiation between triggered 
and non-triggered cells. However, computational models of RNA switches have indicated 
a tradeoff in tuning the stringency of a switch and its sensitivity to the input ligand, 
ultimately impacting the dynamic range [17]. Nevertheless, selection of switches with 
high stringency and large dynamic ranges is important particularly for the development of 
switches responsive to new ligands, an important step in translating these systems to 
clinical applications. In this study, we incorporated switches responsive to theophylline 
and tetracycline in our designs. While these molecules are suitable for the regulation of 
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yeast gene expression, cytotoxicity restricts the concentrations that may be safely 
administered in mammalian systems thus reducing the range of expression from these 
elements in a therapeutically relevant context [2]. The selection of new aptamer 
sequences to FDA-approved molecules will facilitate the construction of switches that 
may be applied as therapies. Additionally, the development of new aptamer sequences to 
cellular molecules of interest offers the potential to connect information from endogenous 
networks to synthetic control systems. The construction of circuits responsive to endogenous 
molecules will facilitate autonomous cell-based therapies. Synthetic RNA aptamers have been 
generated de novo to various small-molecule and protein targets through in vitro selection or 
SELEX strategies [18, 19]. The Smolke laboratory has generated RNA aptamers that exhibit 
varying specificities to benzylisoquinoline alkaloids [20] and folinic acid derivates, and is 
developing high-throughput strategies for the direct selection and characterization of new 
protein- and small-molecule-responsive aptamers. The development of switches responsive to 
new molecules will provide additional independent channels of regulation by which to 
construct orthogonal control of multiple genes within complex networks.  
Finally, connecting additional synthetic circuitry to the molecular network 
diverters may facilitate more complex and sophisticated cellular programming [3]. 
Complex functions such as the synchronization of genetic clocks and edge detection have 
been demonstrated via the rational coupling of communication circuits to oscillators and 
light-responsive logical circuits, respectively, [21, 22]. Coupling synthetic circuits that 
control cellular signaling to communication circuits may facilitate robust spatial 
patterning of cell fate, enable tissue homeostasis, and allow the coordination of 
distributed tasks, requisite achievements for the construction, maintenance, and function 
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of complex tissues [23-25]. Further, advances in iPSC technology may enable the 
construction of immunologically compatible tissues from cells synthetically programmed 
for precise spatial and temporal differentiation on designer cell scaffolds [26-28].  
In this work we have demonstrated the construction of RNA-based control 
systems that route cells to divergent cell fates in response to exogenously applied 
triggers. These systems highlight the potential to develop synthetic networks that 
spatially and temporally program cell fate advancing the fields of tissue engineering and 
molecular medicine. As the systems biology and synthetic biology tool box expands, the 
future development of these systems promises the construction of larger, more complex 
networks engineered to control a range of systems from cells to organs to whole 
organisms for a wide array of biotechnological and medical applications. 
  
V-11 
 
 
References 
1. Culler SJ, Hoff KG, Smolke CD: Reprogramming cellular behavior with RNA 
controllers responsive to endogenous proteins. Science 2010, 330:1251 – 1255. 
2. Chen YY, Jensen MC, Smolke CD: Genetic control of mammalian T-cell 
proliferation with synthetic RNA regulatory systems. Proc Natl Acad Sci U S 
A 2010, 107:8531 – 8536. 
3. Chen YY, Galloway KE, Smolke CD: Synthetic biology: advancing biological 
frontiers by building synthetic systems. Genome Biol 2012, 13:240. 
4. Michener JK, Thodey K, Liang JC, Smolke CD: Applications of genetically-
encoded biosensors for the construction and control of biosynthetic 
pathways. Metab Eng 2012, 14:212 – 222. 
5. Deans TL, Cantor CR, Collins JJ: A tunable genetic switch based on RNAi and 
repressor proteins for regulating gene expression in mammalian cells. Cell 
2007, 130:363 – 372. 
6. Xie Z, Wroblewska L, Prochazka L, Weiss R, Benenson Y: Multi-input RNAi-
based logic circuit for identification of specific cancer cells. Science 2011, 
333:1307 – 1311. 
7. Callura JM, Dwyer DJ, Isaacs FJ, Cantor CR, Collins JJ: Tracking, tuning, and 
terminating microbial physiology using synthetic riboregulators. Proc Natl 
Acad Sci U S A 2010, 107:15898 – 15903. 
V-12 
 
8. Beisel CL, Chen YY, Culler SJ, Hoff KG, Smolke CD: Design of small 
molecule-responsive microRNAs based on structural requirements for 
Drosha processing. Nucleic Acids Res 2011, 39:2981 – 2994. 
9. Beisel CL, Bayer TS, Hoff KG, Smolke CD: Model-guided design of ligand-
regulated RNAi for programmable control of gene expression. Mol Syst Biol 
2008, 4:224. 
10. Gardner TS, Cantor CR, Collins JJ: Construction of a genetic toggle switch in 
Escherichia coli. Nature 2000, 403:339 – 342. 
11. Kramer BP, Viretta AU, Daoud-El-Baba M, Aubel D, Weber W, Fussenegger M: 
An engineered epigenetic transgene switch in mammalian cells. Nat 
Biotechnol 2004, 22:867 – 870. 
12. Stieger K, Belbellaa B, Le Guiner C, Moullier P, Rolling F: In vivo gene 
regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev 2009, 
61:527 – 541. 
13. Kozlova EN, Berens C: Guiding differentiation of stem cells in vivo by 
tetracycline-controlled expression of key transcription factors. Cell 
Transplant 2012. 
14. Wong KK: Recent developments in anti-cancer agents targeting the Ras/Raf/ 
MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009, 4:28 – 35. 
15. Alper H, Fischer C, Nevoigt E, Stephanopoulos G: Tuning genetic control 
through  
promoter engineering. Proc Natl Acad Sci U S A 2005, 102:12678 – 12683. 
V-13 
 
16. Blount BA, Weenink T, Vasylechko S, Ellis T: Rational diversification of a 
promoter providing fine-tuned expression and orthogonal regulation for 
synthetic biology. PLoS One 2012, 7:e33279. 
17. Beisel CL, Smolke CD: Design principles for riboswitch function. PLoS 
Comput Biol 2009, 5:e1000363. 
18. Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: 
RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505 – 
510. 
19. Bowser MT: SELEX: just another separation? Analyst 2005, 130:128 – 130. 
20. Win MN, Klein JS, Smolke CD: Codeine-binding RNA aptamers and rapid 
determination of their binding constants using a direct coupling surface 
plasmon resonance assay. Nucleic Acids Res 2006, 34:5670 – 5682. 
21. Danino T, Mondragon-Palomino O, Tsimring L, Hasty J: A synchronized 
quorum of genetic clocks. Nature 2010, 463:326 – 330. 
22. Tabor JJ, Salis HM, Simpson ZB, Chevalier AA, Levskaya A, Marcotte EM, 
Voigt CA, Ellington AD: A synthetic genetic edge detection program. Cell 
2009, 137:1272 – 1281. 
23. Weber W, Daoud-El Baba M, Fussenegger M: Synthetic ecosystems based on 
airborne inter- and intrakingdom communication. Proc Natl Acad Sci U S A 
2007, 104:10435 – 10440. 
24. Weber W, Fussenegger M: Design of synthetic mammalian quorum-sensing 
systems. Methods Mol Biol 2011, 692:235 – 249. 
V-14 
 
25. Weber W, Schuetz M, Denervaud N, Fussenegger M: A synthetic metabolite-
based mammalian inter-cell signaling system. Mol Biosyst 2009, 5:757 – 763. 
26. Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K: A 
high-efficiency system for the generation and study of human induced 
pluripotent stem cells. Cell Stem Cell 2008, 3:340 – 345. 
27. Kueh HY, Rothenberg EV: Regulatory gene network circuits underlying T cell 
development from multipotent progenitors. Wiley Interdiscip Rev Syst Biol 
Med 2011. 
28. Thomson M, Liu SJ, Zou LN, Smith Z, Meissner A, Ramanathan S: Pluripotency 
factors in embryonic stem cells regulate differentiation into germ layers. Cell 
2011, 145:875 – 889. 
 
 
